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Abstract 
Using the Theory of Self-Determination, the study sought to understand the factors that 
influence HIV treatment adherence among people living with HIV (PLWH).   Fifty-seven 
people completed the self-report questionnaires (Phase I) and 11 took part in face-to-face 
interviews (Phase II).  Results indicated that 42% of the sampled PLWH were not 
completely adherent to their HIV treatment.  While the mediational hypotheses were not 
supported, bivariate correlations pointed to the importance of having an autonomy-
supportive physician, as this variable was associated with better adherence, low 
depression and anxiety, higher social support, and fewer experiences of stigma.  Barriers 
to successful adherence were experiencing side effects.  Phase II findings revealed the 
importance of family support as a motivator for adherence.  Participants also shared 
stories of experienced stigma in hospital settings, but these negative experiences were not 
related to poor adherence.  Interventions should be created to guide physicians to be more 
supportive of patient autonomy. 
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CHAPTER I 
INTRODUCTION 
Significance and Background   
 Medical advances in treatment options have significantly increased life 
expectancy for people living with the Human Immunodeficiency Virus (HIV; Farmer et 
al., 2001).  As a result of these medical advances, people are living longer, healthier, and 
have reported an increase in their quality of life. Unfortunately, the HIV treatments 
known as combination Anti-Retroviral Therapy (cART), are associated with undesirable 
treatment-related side effects, challenging time scheduling and dietary restrictions, which 
contribute to patients' difficulty in adhering to this treatment (Farmer et al., 2001).  In fact, 
the adherence rates are estimated to be as low as 27% (Kennedy, Goggin, & Nollen, 
2004).  Failure to comply with the HIV treatment bears many implications, such as virus 
mutations, higher chances of HIV viral transmission, as well as a financial burden on the 
health care system (Dodds, Colman, Amaratunga, & Wilson, 2000; Molassiotis et al., 
2002).  Research suggests that various demographic (e.g., gender), psychological, and 
socio-economic factors affect HIV treatment adherence (Johnson et al., 2003; Kennedy et 
al., 2004; Parsons, Rosof, & Mustanski, 2008; Roberts & Mann, 2000).  
Few studies have investigated barriers to HIV treatment adherence from a 
Canadian perspective.  In order to address the low adherence rates, and to improve the 
overall health of People Living with HIV (PLWH), further understanding of the unique 
psychosocial and cognitive factors that influence HIV treatment adherence needs to be 
gained.  Using the theoretical model of Self-Determination Theory (SDT), the current 
study empirically examined the motivational basis of HIV treatment adherence.  Of 
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interest, were the following general research questions:  Would perception of having an 
autonomy-supportive physician lead to increased motivation to adhere to the HIV 
medications?  Does social support influence a person's motivation to adhere to their HIV 
treatment regimen?  Furthermore, does HIV-related stigma from health care providers 
have an influence on a person's motivation to adhere to their HIV treatment, and in turn 
does this predict adherence rates?  Lastly, does HIV treatment-related knowledge and 
HIV treatment self-efficacy influence a person's motivation to adhere to their prescribed 
HIV treatment, and in turn does this influence HIV treatment adherence.  In the present 
study, these research questions were examined in a sample of Ontario men and women 
living with HIV. 
Literature Review 
 Prevalence of HIV in Canada.  Acquired Immune Deficiency Syndrome (AIDS) 
is the fourth leading cause of death, globally (USAID, 2008).  In Canada, in 2009, it was 
estimated that approximately 65,000 people were living with HIV and AIDS, a 14% 
increase from 2005 (57,000; Public Health Agency of Canada, 2009).  Women accounted 
for 24% of new infections in Canada (UNAIDS/WHO, 2009).  Among the Caucasian 
population, the most frequently reported mode of HIV transmission is homosexual 
contact (men who have sex with men), and secondly through intravenous drug use 
(38.8% and 34.7%, respectively).  Among the Black population living in Canada, 
heterosexual contact (80.1%) is the most frequently reported mode of HIV transmission.  
Lastly, according to the Public Health Agency of Canada (2003), injection drug users 
continue to be the highest risk group among Aboriginal people, comprising 60.6% of all 
HIV-positive tests for this population between 1998 - 2002.  
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 Etiology of HIV.  In the beginning of the 1980s, when the first AIDS cases were 
recorded, HIV-specific treatments did not exist (Shilts, 1987).  In fact, it took several 
years until scientists and clinicians were able to define and understand the cause of AIDS.  
The majority of the AIDS cases initially identified were young males, with illnesses such 
as skin cancer (Kaposi's sarcoma) or a type of lung infection (Pneumocystic pneumonia) 
that makes breathing difficult (Shilts, 1987).  Accordingly, clinicians would prescribe the 
necessary treatments (i.e., antibiotics, penicillin) to manage these conditions, now known 
as opportunistic infections.  By 1983 and 1984, the virus causing these illnesses was 
identified, and HIV was isolated (Durham & Lashley, 2010).  Since then, scientists have 
proven that HIV causes AIDS.  Today researchers have identified two known general 
strands of HIV: HIV-1 (discovered in 1984) and HIV-2 (discovered in 1986) and both 
strands are transmitted in the same way (Durham & Lashley, 2010).  However, people 
infected with HIV-2 are known to be without symptoms for longer periods compared to 
the HIV-1 type.  Although in the United States a new strain of HIV-2 has been reported, 
HIV-2 is generally only found in West African regions, in contrast to the HIV-1 strand, 
which is found worldwide (Durham & Lashley, 2010).  For the remainder of the paper, 
the term HIV is used to denote both strands.  
 The process by which the HIV virus deteriorates the immune system and leads to 
AIDS is complex.  A simplified version of this process can be described as follows: upon 
entering the human body, the HIV virus vastly multiplies and damages cells in the 
immune system associated with fighting off infections (called T-cells or killer cells), 
causing an infected individual to become easily sick.  The process by which the HIV 
virus invades the human cell is a multistage one, and it begins with the HIV virus 
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entering the CD4 cells.  The CD4 cells are white blood cells with surface receptors called 
CD4.  These cells are important for the regulation of the immune system, as they activate 
killer T-cells (which fight off infections) to produce antibodies. The HIV virus targets 
these CD4 cells.  Clinicians monitor their count because as the number of CD4 cells 
decrease, the HIV-infected person also declines in physical health.  The CD4 cell count 
provides the best marker for disease progression and it is measured as the number of CD4 
cells per one cubic millimeter (cells/m
3
).  A person is said to have AIDS when the CD4 
cell count is less than 200 cells/m
3
, compared to 600 to 1, 200 cells/m
3
 in non-infected 
individuals (Durham & Lashley, 2010).  The second marker of HIV progression and 
treatment initiation is the plasma HIV RNA (viral load).  The HIV viral load is crucial in 
the proliferation of the HIV virus.  Higher viral load units coincide with periods of higher 
chances of HIV transmission (Durham & Lashley, 2010).  The HIV viral load is 
measured in units of HIV RNA copies per milliliter (cp/mL) of blood.  Mellors and his 
colleagues (1996) established a criterion of HIV viral load and AIDS progression, 
showing that the higher the HIV viral load, the closer an individual is to an AIDS 
diagnosis (as cited in Weeks & Alcamo, 2006).  For example, a viral load of 4500 cp/mL 
would mean that the person will likely progress to an AIDS diagnosis in approximately 
ten years.  According to most researchers, HIV viral load of 50 cp/mL is considered an 
undetectable viral load stage, and thus far from progressing to an AIDS diagnosis.  
Prolonged suppression of the viral load, to an undetectable viral load stage, is associated 
with superior immune system and improved health.  Clinicians also use the viral load 
number as an indication of the treatment being ineffective for the patient or poor 
treatment adherence. Clinicians suspect non-adherence (or the HIV medication not 
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working) when the viral load increases from less than 50 cp/mL (undetectable) to 200 or 
more cp/mL (Leppert & Peipert, 2004).  
 Medical treatment of HIV/AIDS.  In treatment of HIV, neither a cure nor 
vaccine is available; however, there are over thirty drug treatments created for people 
diagnosed with HIV/AIDS to manage their health condition (Nundy, 2010).  
Improvement of the physiological health for PLWH began with the introduction of 
Highly Active Antiretroviral Therapy (HAART).  A year later, a new treatment was 
developed called combination Antiretroviral Therapies (cART).  This treatment was more 
effective in treating HIV symptoms and suppressing the proliferation of the virus 
(Durham & Lashley, 2010).  Overall, the HIV therapies suppress the HIV virus, reduce 
mother-to-child (vertical) transmission, and prolong survival (Durham & Lashley, 2010).  
 The HIV drugs are divided into classes and they are used in combination to 
reduce the amount of HIV in the blood (HIV viral load).  Simplifying this complex 
process, the drugs work by blocking certain steps of the HIV proliferation (Durham & 
Lashley, 2010).  There are six "families" of HIV medication and the classes differ at the 
stage of the HIV replication process that they are fighting (Durham & Lashley, 2010).  
For the HIV treatment to be successful, the regimen should preferably contain three 
different classes of medications, where patients are usually required to take multiple 
drugs for each class (Durham & Lashley, 2010).  However, recent advances in medicine 
have designed some medications (e.g., Atriplia) to contain three classes of HIV 
medication in a single pill.   
 The initiation of HIV treatment is mostly based on the CD4 cell counts (Leppert 
& Peipert, 2004).  A criterion most frequently reported is CD4 cell count below 200, or 
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between 200 and 350 cells/m
3
 (Durham & Lashley, 2010).  Others report that treatment 
should begin at higher CD4 cell counts (i.e., > 350 cells/m
3
; Kitahata et al., 2009).  
However, at higher CD4 counts patients may refuse treatment because they may feel 
healthy and starting the medication would seem unnecessary.  Therefore, to achieve the 
best decision regarding the initiation, changing, or termination of an HIV treatment, 
clinicians and patients must work together to arrive at a mutual agreement (Durham & 
Lashley, 2010).  The effectiveness of the HIV treatments is monitored by examining the 
viral loads and the CD4 cell counts.  Although a complete viral suppression is not 
possible, the medications can reduce the HIV viral load to less than 50 HIV viral load 
cp/mL (Durham & Lashley, 2010).  A viral load suppression to less than 50 HIV viral 
load cp/mL is an ideal cell count, referred to as HIV undetectable viral load.  This can be 
achieved 12 to 24 weeks after treatment has began (Durham & Lashley, 2010). 
 Epidemiological data on the benefits of HIV treatments show that in the USA, the 
number of AIDS-related deaths in 2007 was 69% lower than in 1994 (UNAIDS/WHO, 
2009).  In Canada, mortality rates among people living with HIV in the first five years 
after infection are similar to the mortality rates among the HIV-uninfected population 
(UNAIDS/WHO, 2009).  Unfortunately, less promising data suggest that AIDS-related 
deaths have ceased to decline in the past few years.  Failure to decrease AIDS mortality 
has been mainly due to the HIV treatments' inability to work for nearly 50% of patients 
(Halkitis, Shrem, & Zade, 2005).  New drugs have been created, such as the combination 
antiretroviral therapies (cART), but if not taken as prescribed, these drugs will also be 
ineffective.   
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 HIV treatment side effects.  Several studies in the United States have suggested 
that concerns about side effects are the greatest barrier to successful HIV treatment 
adherence (Amico et al., 2007; Gao, Nau, Rosenbluth, Scott, & Woodward, 2000; 
Roberts & Mann, 2000).  The HIV treatment side effects can be highly debilitating and 
lead some people to take time off their treatments (Amico et al., 2007).  HIV treatments 
are associated with short-term and long-term physiological side effects.  Some examples 
of short-term HIV treatment side effects are diarrhea, fatigue, and headaches (Fothergill-
Bourbonnais et al., 2002; Johnson et al., 2007).  The knowledge of the possible side 
effects (i.e., diarrhea, nausea) often leads to social isolation and in turn, diminished 
quality of life, making the HIV-regimens difficult to comply with (Farmer et al., 2001; 
Fothergill-Bourbonnais et al., 2002).  Examples of long-term side effects are 
lipodystrophy (body weight re-distribution), high blood cholesterol, high blood sugar, 
neurological changes leading to delirium, and liver damage (Fothergill-Bourbonnais et al., 
2002; Johnson et al., 2007).  Given these side effects in combination with dietary 
restrictions, it is not surprising that HIV treatment adherence rates are low.  In fact, 30% 
of HIV-positive patients reported missing at least one dose of HIV-medication in the past 
three days (Dunbar-Jacob, Burke, & Puczynski, 1995; as cited in Kennedy et al., 2004).  
Lack of HIV treatment adherence bears many consequences, such as resistance to the 
HIV treatment, vertical transmission (i.e., mother to child HIV transmission), and 
transmitting resistant strains to others (Molassiotis et al., 2002).   
 HIV treatment adherence.  General medical adherence is defined as the extent to 
which patients follow the prescribed regimen corresponding with their medication, 
keeping up with medical appointments, obtaining inoculations, and following medical 
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protocols for changing behaviours, such as dieting, exercising, or cessation of cigarette 
smoking (Molassiotis et al., 2002; WHO, 2003).  Medical non-adherence is failure to 
follow any of the aforementioned factors (Molassiotis et al., 2002; WHO, 2003).  Across 
all chronic illnesses, medical adherence (treatment, diet recommendations, etc) is the 
most modifiable factor that can greatly increase treatment efficacy.   
In research, medical adherence is operationalized in a number of ways, for 
example: as a percentage, a ratio (number of times missed to total doses prescribed), or 
categorically (i.e., good versus poor adherence; WHO, 2003).  Researchers typically 
obtain this information either by using paper-and-pencil questionnaires, through face-to-
face interviews, or electronic monitoring (i.e., pill bottle monitors).  In HIV research, a 
commonly used questionnaire is the Adult Adherence Clinical Trial Group (AACTG), 
administered by an interviewer with a few self-report questions.  This questionnaire 
defines treatment adherence as a percentage, calculated by dividing total number of doses 
missed by the patient, by the total number of doses prescribed, for the past three days.  
Researchers generally agree that a score of 95% or higher indicates successful adherence.  
When HIV treatment adherence falls to less than 90% it is usually associated with a 
significant increase in HIV viral load and is considered non-successful treatment 
adherence (Molassiotis et al., 2002).  An alternative measure for assessing HIV treatment 
adherence is the Center for Adherence Support Evaluation (CASE) Adherence Index 
questionnaire (Mannheimer et al., 2006).  This measure of HIV treatment adherence is 
scored out of 16, based on three Likert-type questions.  A score of 10 is a marker which 
separates successful from poor HIV treatment adherence.  This marker was obtained by 
comparing the CASE Adherence scores to changes in health outcomes (HIV viral loads 
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and CD4 cell counts), every three months for a year (Mannheimer et al., 2006).  The 
CASE Adherence Index is a self-report measure of medication adherence and, like all 
self-report measures, is influenced by social desirability and recall bias, making the 
assessment of HIV treatment adherence complex (Chesney, Morin, & Sherr, 2000).  
Electronic pill bottle monitors (which count each time the pill bottle is opened), blood 
tests, and pharmacy prescription refill history are more reliable measures, but they are 
also more expensive and not easily accessible (Chesney et al., 2000).  Although self-
report measures have their drawbacks, most researchers rely on their use.  Studies show 
that self-reported adherence scores can distinguish between patterns of poor and 
successful treatment adherence (Chesney et al., 2000; Nieuwkerk & Oort, 2005).  
Chesney and colleagues (2000) showed that self-report of missed medication positively 
correlates with HIV viral loads, which is a good physiological indicator of treatment 
effectiveness and disease progression (Durham & Lashley, 2010).  The ubiquity of self-
report measures is evident in the number of studies that have used them when evaluating 
HIV treatment adherence (e.g., Miguez-Burbano, Espinoza, & Lewis, 2008; Kalichman, 
DiMarco, Austin, Luke, & DiFonzo, 2003; Reily & Woo, 2004; Williams, Rodin, Ryan, 
Grolnick, & Deci, 1998).  Several factors have been isolated as influencing HIV 
treatment adherence, and among them are personality characteristics, socioeconomic 
factors, and patient's mental health.  
Patient Characteristics Predicting HIV Treatment Adherence 
 Socio-demographic factors.  Past studies have suggested several psychosocial 
and demographic factors as influencing HIV treatment adherence.  For instance, age, 
gender, ethnicity, and education have been reported to correlate with HIV treatment 
PSYCHOSOCIAL INFLUENCES ON HIV TREATMENT ADHERENCE 10 
 
 
adherence rates (Johnson et al., 2003; Ironson et al., 2005; Kennedy et al., 2004; Roberts 
& Mann, 2000).  Mehta, Moore, and Graham (1997) reported that as age increases, HIV 
medical treatment compliance also increases, with the exception of the elderly (those 
over 75 years of age).  The literature is inconsistent regarding gender differences in HIV 
treatment adherence.  Roberts and Mann (2000) found that women who were not caring 
for children were more likely to adhere to their regimens as compared to men (Roberts & 
Mann, 2000).  On the other hand, Amico and colleagues (2007) found a gender difference 
in HIV treatment adherence rates among their sample of PLWH.  For example, more 
women than men endorsed the following reasons for having missed their HIV medication: 
„didn‟t have the medication with me‟ (53 versus 28%), „was feeling sick‟ (28 versus 
10%), „didn‟t want people to see me taking HIV medication‟ (22 versus 3%) and „was 
taking a break from my HIV medications‟ (22 versus 0%), however, more research is 
needed to undertand why more women felt more physically ill from the medication, 
which resulted in more women taking breaks from their regimen (Amico et al., 2007).   
 Context of location.  An American research team showed that the primary 
predictor of HIV treatment adherence is medical insurance, a fact that is less relevant to 
PLWH in Canada (Mehta, Moore, & Graham, 1997).  In Ontario, patients who have a 
valid Ontario Health Insurance (OHIP), are over the age of 65, and/or are unemployed 
(receiving Ontario Disability Support Program - ODSP) receive drug coverage from the 
Ontario Drug Benefit (ODB) plan.  Typically people who are employed would have an 
employment health care plan and, in addition, can receive further reimbursements from 
the Public Service Health Care Plan (PSHCP).  
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 Factors found to predict treatment adherence also differ for people living in rural 
versus urban settings.  Amico et al. (2007) reported several barriers associated with living 
in rural areas (in the United States).  Not having the medication available was found to be 
the most common reason for failing to take the medication on time (Amico et al., 2007).  
Other reasons reported were not having the medication with them or running out of the 
medication.  In addition, Reif and colleagues (2005) reported that rural areas have 
significantly more barriers that prevent health care access, which in turn influences 
treatment adherence rates.  In their study, HIV/AIDS medical managers from rural and 
urban areas were interviewed (Reif, Golin, & Smith, 2005).  Fifty-eight percent of the 
rural managers identified "lack of transportation services" as the major barrier for patients 
to access their treatment services, while only 30% indicated this to be a "major problem" 
in urban areas (Reif et al., 2005).  In addition, Reif and associates (2005) reported that 
92% of the rural managers reported that HIV-related stigma is also a barrier for health 
care access, compared to 35% of the urban-based HIV/AIDS health care managers.  
Unfortunately, lack of access to health care services also leads to a decline in HIV 
treatment adherence (Reif et al., 2005). 
 Mental health.  Being diagnosed with a chronic health condition like HIV/AIDS 
is a stressful event in one's life (Tucker, Brunam, Sherbourne, Kung, & Gifford, 2003).  
Non-clinical depression, described as daily feelings of hopelessness, denial, and avoidant 
coping, can have a significant negative impact on a person's health outcomes (Ironson et 
al., 2003).  Investigators have shown that daily feelings of despair can be buffered by 
perceived positive social support (Simoni, Frick, & Huang, 2006).  When considering 
clinical depression, in the years prior to an AIDS diagnosis, rates among PLWH have 
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been reported to be as high as 25%, and these rates increase following the development of 
AIDS (Lyketsos et al., 1996).  Some of the negative effects associated with clinical 
depression, or other mental health diagnoses, are poor physical and health outcomes, and 
lower HIV treatment adherence rates (Cook et al., 2004; Mehta et al., 1997).  A study by 
Cook et al. (2004) reported that HIV-positive women who were diagnosed with 
depression experienced faster decline in physiological health and therefore were more 
likely to die sooner.  On the other hand, treating depression has shown to significantly 
increase the probability of HIV treatment adherence (Cook et al., 2006).  Therefore, the 
role of HIV clinicians should be to also address and screen for non-physical symptoms, 
which would address mental health issues and in turn help HIV treatment adherence 
success. 
 Alcohol and drug dependency.  Consistently, alcohol dependence has been 
linked with lack of HIV treatment adherence (Amico, et al., 2007; Kennedy et al., 2004; 
Parsons et al., 2008).  In fact, a study reported that alcohol addiction decreased medical 
compliance by 20% (Parsons et al., 2008).  However, persons regularly consuming 
alcohol were more likely to adhere to HIV regimens of lower complexity versus regimens 
of higher complexity (Parsons et al., 2008).   
Despite the aforementioned psychosocial barriers to successful HIV treatment 
adherence, several studies show that adherence rates could be increased with proper 
screening and a dialogue between the HIV specialist and patient.  A meta-analysis of 20 
studies showed that some of the key factors influencing adherence rates are the patient's 
willingness to start the HIV treatment, patients' psychological distress, complexity of the 
HIV-regimen (dosing frequency and food instructions/timing) - factors that are amenable 
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to change and best understood through a clinician-patient relationship (Ammassari et al., 
2002).   
For patients already on HIV treatment regimens, research shows that when 
patients were given choice over the HIV treatments, their adherence rates were typically 
higher (Williams et al., 1998).  Despite these positive findings, to date, an effective 
intervention to achieve maximum treatment adherence does not exist (Durham & Lashley, 
2010; see Kalichman, Cherry, & Cain, 2005) and a better understanding of factors 
specific to HIV treatment adherence is needed.  The overall aim of the current study was 
to examine HIV treatment adherence rates and the factors associated with successful 
treatment adherence among PLWH in southwestern and central Ontario.  The theory of 
self-determination guided the selection of the following predictors of HIV treatment 
adherence: 1) the degree to which patients perceived they had autonomy over their HIV 
treatments (i.e., autonomy-supportive physicians); 2) patients' perceptions of HIV-related 
stigma from health care providers; 3) degree of HIV treatment knowledge; and lastly 4) 
patient-specific factors, such as perceived level of social support, HIV treatment self-
efficacy, alcohol and drug use, and health locus of control.  These predictors were 
examined in relation to HIV treatment adherence.  
Theoretical Model for HIV Treatment Adherence 
Self-Determination Theory 
 Background on self-determination theory.  The theoretical model that drove the 
research questions in the present study was Self-Determination Theory (SDT), developed 
by Deci and Ryan (1985).  This theory is multidimensional, consisting of cognitive and 
psychosocial predictors of motivation.  SDT suggests that people have an innate 
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predisposition to be self-motivated.  This innate desire can be encouraged or hindered by 
the social environment (Williams, Gagne, Ryan, & Deci, 2002).  Self-motivation has 
been denoted by various names, such as intrinsic motivation, autonomous regulation, and 
integrated or identified motivation.  For consistency in the current study, self-motivation 
is referred to as intrinsic motivation.  In addition to intrinsic motivation, SDT 
distinguishes between several other types of motivations that drive people's behaviour: 
extrinsic motivation (also called controlled motivation), introjected intrinsic, and 
amotivation.  Extrinsic motivation refers to behaviours done in order to attain something 
separate from the activity (i.e., going to the gym to get a reward).  Amotivation is action 
without intent (going to the gym without feeling it was their choice or within their 
control).  However, central to SDT is intrinsic motivation, defined as the motivation to 
engage in an activity because it is enjoyable, challenging or satisfying (going to the gym 
because exercising is pleasant).  Intrinsic motivation is important because people are 
more likely to be persistent at a task when they are engaged because of intrinsic 
motivation, or out of their own volition, rather than for extrinsic reasons (i.e., someone's 
orders; Deci & Ryan, 2002).  In addition, intrinsic motivation can also be partially 
intrinsic (i.e., when one is controlled by anxiety or guilt), also termed introjected 
motivation.  Thus, going to the gym to avoid feeling guilty for disappointing others is an 
example of introjected motivation.  A study by Pelletier and others (2001) highlighted the 
functional difference between introjected motivation and intrinsic motivation. The 
authors showed that introjected motivation positively predicted short-term goals, but in 
turn was negatively associated with long-term goals.  On the other hand, intrinsic 
motivation was positively associated with both short-term and long-term goals (see also 
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Sheldon & Elliot, 1998).  These results indicated the importance of intrinsic motivation, 
rather than only partial intrinsic motivation (or introjected motivation). 
 In the context of treatment adherence, intrinsic motivation is typically assessed 
using the Treatment Self-Regulation Questionnaire (TSRQ; Williams, McGregor, 
Freedman, Zeldman, & Deci, 1996).  This measure has been widely used and research 
has found intrinsic motivation to be predictive of active participation in treatment 
programs, such as alcohol interventions (Ryan & O'Mally, 1995), weight loss programs 
(Williams et al., 1996), physical activity adherence in cancer patients (Wilson, Blanchard, 
Nehl, & Baker, 2005), HIV treatment adherence (Williams et al., 1998), and, in diabetes 
patients, high scores on intrinsic motivation were shown to correlate with better glucose 
level management (Williams, Freedman, & Deci, 1998).  
 The aim of the current study was to apply the Theory of Self-Determination to 
examine several psychosocial factors that could increase intrinsic motivation in PLWH 
and to explore whether intrinsic motivation leads to increased adherence rates to HIV 
treatments.  Given the definition of intrinsic motivation (motivated to accomplish a task 
for the satisfaction of the task itself), it might be difficult to understand how patients 
could ever be intrinsically motivated to adhere to the taxing and arduous HIV treatment 
regimens.  According to Self-Determination Theory, the social environment can foster 
intrinsic motivation, even for unpleasant tasks, when the following three psychological 
needs are satisfied: perceived autonomy (control); perceived relatedness (close emotional 
bond with others or social support); and perceived competence (understanding).  The root 
notion of autonomy is self-rule or self-government, and in the social sciences, the term 
has been used to mean the capacity to govern oneself (Mele, 1995).  The second 
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psychological factor - relatedness - has been defined as feeling connected to others.  This 
need to feel connected and understood by one's social support network is not unique to 
this theory and social support has a vital role that influences motivation, mental health, 
and physical health (for review, see Reis & Patrick, 1996).  Lastly, competence in SDT 
research has mainly been defined as the perceived ability to successfully complete a task.  
Often self-determination researchers operationalize competence as self-efficacy (defined 
as the expectation that a person can successfully perform a task despite the presence of 
adversity).  SDT asserts that satisfying the three psychological needs (autonomy, 
relatedness, and competence) could lead to an increase in intrinsic motivation.  The 
benefits associated with having higher intrinsic motivation are that people are more likely 
to engage in the behaviour if they are self-motivated.  Williams, McGregor, Freedman, 
Zeldman, and Deci (2004) tested the SDT theory in a health care setting.  The authors 
examined whether autonomy (allowing patients choice and control over treatments and 
health-related decisions) and perceived competence (the degree to which patients 
perceive that they can manage daily aspects of diabetes care, such as diet or exercise) 
among diabetes patients would be related to better management of blood sugar.  This 
longitudinal study (baseline, six months and 12 months) tested 159 participants diagnosed 
with Type 2 diabetes, and asked participants to identify whether they perceived they had 
autonomy-supportive health care providers.  The results supported the Theory of Self-
Determination in that the participants who perceived themselves to have autonomy and 
competence were better at managing their blood sugar (glycemic) control.   
Autonomy (Perceived Control)  
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 Autonomy is characterized as perceived control over one's social environment.  
Several researchers in North America argue that most human beings actively try to shape 
and control their environment, as opposed to passively wait for events to occur (e.g., Deci 
& Ryan, 2006; Rothbaum, Weisz, & Snyder, 1982).  In SDT, autonomy (along with 
relatedness and competence), is considered to be a basic psychological need, and failure 
to perceive control can lead to deleterious mental and physiological effects (e.g., Ryan & 
Deci, 2001).  For example, Landsbergis (1988) was interested in evaluating job strain 
among hospital employees.  A total of 289 hospital employees (61% were nurses, while 
the remainder were food service worker, housekeepers, social workers, etc) filled out a 
mail in survey.  Highlighting the importance of autonomy on people's physical and 
mental health, the study found that job strain and burnout were significantly higher in 
jobs with high work demand and low decision making (low autonomy). 
 As previously mentioned, perceived control (autonomy) can be hindered or 
enhanced by the environment (Deci & Ryan, 2006).  Powerful constraints on autonomy 
can be evaluative pressures (e.g., school grades), rewards (e.g., money), controlling 
behaviour (e.g., being told what to do, rather than given a choice), or punishment (Deci & 
Ryan, 2006).  These factors have all been found to undermine autonomy, and in turn, to 
decrease intrinsic motivation.  On the other hand, feedback and opportunity for 
meaningful choice have been found to facilitate intrinsic motivation in people, which is 
illustrated well by Thompson and Wankel (1980).  These researchers recruited 36 women 
recently enrolled in a private health club to investigate the effect of perceived choice on 
the frequency of exercise behaviour.  After they filled out self-report questionnaires that 
assessed the women's preferences for exercise, they were randomly assigned to two 
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groups: a control group and a choice condition.  The latter group was led to believe that 
their activities were selected from their exercise preferences.  The control group was told 
that they were assigned a standardized exercise program.  The results indicated that the 
overall attendance of the choice group was significantly better than the group that was 
assigned an exercise program.  Across both groups, participation declined over the six-
week period; however, the decline was greater for the group that did not have perceived 
choice in their exercise program.  Lastly, upon completion of the exercise program, the 
choice condition group expressed greater intent to continue with the program.  In this 
study, perceived autonomy and choice were associated with higher likelihood of 
committing to the exercise program.  
 The current study examined the importance of autonomy among a sample of 
PLWH from Southwestern and Central Ontario.  In this study, autonomy was assessed as: 
1) HIV-patients' perceived autonomy over their HIV treatments (i.e., if they had 
autonomy-supportive physicians); and 2) Health locus of control (HLOC). 
 Patients' perceived autonomy over their HIV treatment (having an 
autonomy-supportive physician).  The relationship between clinicians and patients is 
one of the most complex relationships, with profound effects for the patients.  It is 
complex because unequal power positions exist between the clinician and the patient, the 
nature of health visits is unpleasant, the issues discussed are extremely important (Ong, 
De Haes, Hoos, & Lammes, 1995).  Ong and colleagues (1995) published a literature 
review on communication between doctors and patients and reported that traditionally the 
clinician-patient relationship was best described as paternalistic, where the doctor 
instructs the patient and makes decisions regarding their treatment.  The benefits 
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associated with avoiding the paternalistic style of communication and encouraging 
clinicians to share more information with their patients has profound effects for patients' 
health outcomes (Miller, Benefield, & Tonigan, 1993) and treatment adherence (Williams 
et al., 1998).  In fact, research showed that patients who are informed of their health 
status have better coping styles and lower anxiety (Molleman et al., 1984).  Molleman 
surveyed 418 cancer patients and found that clinicians could influence their patients' 
coping styles and reduce mental distress, simply by communicating more with their 
patients.  Patients who received more information on their health status, adequate 
attention and understanding had better overall mental health.  According to the authors, 
the patients' coping strategies were likely influenced because providing health related 
information to patients interested in knowing reduced their level of health uncertainty, 
which in turn influenced their coping strategies (Molleman et al., 1984).  
 The advantages associated with clinicians allowing more communication are 
undeniable, but more recently, studies have demonstrated the importance of patients' 
ability to have a say in the type of treatments prescribed to them.  Across treatments 
requiring diverse lifestyle changes, clinicians who allowed patients to have control over 
their prescribed treatments, reported greater treatment adherence rates, more effective and 
long lasting smoking cessation, greater weight loss, better glucose control (in diabetes 
patients), and higher commitment to exercise (see Williams, 2002).  For instance, 
Williams et al. (2002), investigated cigarette smoking cessation rates.  The investigators 
created two interventions, with the only difference being the level of autonomy 
supportiveness the physicians allowed: 1) physicians were autonomy-supportive; or 2) 
physicians were controlling when counseling the patients to quit smoking.  The 
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physician's level of autonomy support was rated from audiotapes. Participants' intrinsic 
motivation to quit cigarette smoking, as well as their perceived competence, was assessed 
using self-report questionnaires.  Structural equation modeling indicated that the 
autonomy supported intervention was rated as fostering more intrinsic motivation, and in 
turn, intrinsic motivation predicted higher smoking cessation rates (Thorndike, Rigotti, 
Stafford, & Singer, 1998).    
 Perceived autonomy and HIV treatment adherence.  Due to the complexity of 
HIV treatments, adequate communications for PLWH with their clinicians is of great 
importance (Durham & Lashley, 2010).  A common reason reported for non-adherence is 
the complexity of the HIV regimens (Corsonello et al., 2009).  Moreover, other 
researchers indicate that the taxing HIV-related side effects also make the regimen 
difficult to adhere to (Amico et al., 2007).  Health care practitioners can help patients by 
communicating with them and tailoring the HIV treatments according to their patients' 
schedule and needs, as much as possible (Durham & Lashley, 2010).  Williams et al. 
(1998) investigated 126 adult outpatients from North Carolina, with multiple diagnoses, 
who were on long-term medication, and had been on a particular drug regimen for at least 
one month.  A clinical psychologist interviewed the participants, assessing each patient's 
levels of intrinsic motivation, their perceptions of having an autonomy-supportive 
physician, and HIV treatment adherence (based on recall and a prospective pill count at 2 
and 14 days).  Analysis revealed that intrinsic motivation significantly accounted for 68% 
of the variance in treatment adherence.  The results demonstrated that having an 
autonomy-supportive physician significantly predicted HIV treatment adherence, and the 
effects of autonomy were mediated through intrinsic motivation.   
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 Findings that support patients‟ need for autonomy over the HIV treatments 
prescribed are important for the implications for interventions to improve treatment 
adherence (Haynes et al., 1996).  However, when creating interventions, it is important to 
keep in mind client's individual differences.  Therefore, an important additional factor in 
assessing need for autonomy is health locus of control.   
 Locus of control.  Locus of Control (LOC) is a belief system that people hold 
regarding the type of control they perceive they have over events in their lives (Rotter, 
1966).  Locus of control emerged from Rotter's (1954) Social Learning Theory, which 
posits that people learn from reinforcements.  Thus, locus of control is a construct 
developed from past reinforcements and is sensitive to social context and past and present 
experiences (Rotter, 1966).  LOC varies along a single continuum ranging from External 
control (forces outside oneself control events in their life, such as luck or God) on one 
end, and Internal control (personal actions control events) on the opposite end of the 
continuum (Rotter, 1966).  Rotter suggested that the basic principle underlying LOC is 
that people create general expectations regarding the extent to which they are able to 
influence future events.  Specifically, if a person has an Internal LOC, then they are likely 
to believe that they can have control over future events.  A person with an Internal LOC 
orientation believes that events in their life occur because of their own behavior.  In 
contrast, people who score high on External LOC are more passive and they believe they 
have less power to cause change, as they perceive that circumstances are caused by things 
outside of their own control, such as luck, or powerful other people (Lynam et al., 2009).  
Internal and External LOC are distinct from intrinsic and extrinsic motivation.  These 
concepts are not synonyms as they stem from different theoretical backgrounds: LOC 
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comes from Rotter's Social Learning Theory (1966) and intrinsic/extrinsic motivation 
comes from causal attribution theory developed by Fritz Heider (1958).  Particularly, 
External LOC differs from extrinsic motivation in that the former is a belief that events 
are not within a person's control, whereas in extrinsic motivation a person may believe 
they have control of events in their life (Internal LOC) but their motivation to engage in 
them is for external reasons (e.g., to get paid).  
 LOC is typically measured using self-report questionnaires, and different scales 
exist, depending on the construct being measured (e.g., learning, health, sports activity, 
etc).  Wallston, Wallston, and DeVellis (1978) extended the concept of LOC to apply it to 
health behaviours as Health Locus of Control (HLOC) and created the Multidimensional 
Health Locus of Control (MHLC), which specifically measures HLOC.  The MHLC is a 
measure that assesses the beliefs that people hold regarding the factors that can control 
their health (External or Internal HLOC).  For instance, the generalized expectancy that a 
person's health depends primarily on his/her behaviour is associated with Internal HLOC.  
The MHLC measure includes extended constructs such as the External HLOC, which 
Rotter (1966) into Powerful others HLOC (e.g., Doctors) and Chance HLOC (e.g., its fate 
if I get sick).  Therefore, the MHLC includes subscales that measure Internal, External, 
Chance, and Powerful Others HLOC.   
 Internal locus of control and health.  Generally, research on HLOC and health 
status shows that an Internal HLOC is associated with better health related outcomes.  
Thus, those who believe that they are able to exercise control over their illness also have 
better psychological and physical management of their health condition (Affleck, Tennen, 
Pfeiffer, & Fifield, 1987; Molinary & Khanna, 1981).  Affleck and colleagues (1987) 
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interviewed and administered questionnaires to 92 patients diagnosed with arthritis to 
study their psychosocial adjustment, illness status, HLOC over treatment of symptoms 
(personal, or internal, versus health care provider), and mood.  Arthritis patients live with 
chronic and painful inflammation of the joints and the disease is characterized by 
unpredictable periods of painful episodes.  The investigators reported that patients who 
perceived greater Internal HLOC as related to management of their disease (i.e., were 
more willing to follow recommended treatment options, etc) expressed greater positive 
mood and adjustment to their illness.  In general, patients exhibiting Internal HLOC have 
more positive health outcomes because they believe that they have an influence over their 
arthritis symptoms, and thus their engagement in health related behaviours is higher.  
 Powerful others and chance locus of control.  Molinari and Khanna (1981) 
undertook a study that examined the relationship between HLOC, depression, and anxiety.  
The authors surveyed 60 male and female university students to examine their attitudes 
towards their HLOC orientation, including their views on Doctors HLOC and chance 
HLOC.  The study found that high scores on powerful others HLOC were positively 
related to anxiety.  High scores on Chance HLOC were related to depression.  In turn, 
both anxiety and depression were found to decrease as students reported higher Internal 
HLOC. 
Relatedness (Social Support) 
 Relatedness concerns the feeling of belonging and connectedness, often defined 
as social support (Deci & Ryan, 1985).  Researchers using Self-Determination Theory, 
suggest that intrinsic motivation would be further supported if individuals feel emotional 
support from others (relatedness; Charbonneau, Barling, & Kelloway, 2001; Ryan, 
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LaGuardia, Solky-Butzel, Chirkov, & Kim, 2005).  In other words, if a person perceives 
that they have high social support, this would increase their intrinsic motivation, and in 
turn increase their commitment to sports training (Tauer & Harackiewicz, 1999) or 
general work productivity (Baard, Decy, & Ryan, 2004), or would ameliorate the 
negative effects of stress among health care providers (Gottfried, 1985; Wilson, 
Blanchard, Nehl, & Baker, 2005).  Research evaluating the effects of relatedness 
consistently shows that regardless of a person's age, ethnicity, or socioeconomic status, 
people appear to function better and report fewer psychological difficulties when they 
experience support, love, and affection from others (Cohen, Sherrod, & Clark, 1986; 
Ryan et al., 1995; Ryan, Stiller, & Lynch, 1994).  A social support network can include 
friends, family members, coaches, subordinates, or managers, and each type has its own 
unique dynamics and benefits (Ryan et al., 2005).  In the current study relatedness was 
defined with the following two factors: 1) perceived social support (from family, friends, 
or intimate partners); and 2) perceived HIV-related stigma from health care providers.  
 Perceived social support (family, friends, or intimate partners).  Socially 
supportive relationships are generally described as help and care that others provide that 
leads to an increase in an individual's level of coping, health benefits, and psychological 
well-being (Ryan et al., 2005).  Researchers have consistently found that people who feel 
more satisfied with their interpersonal relationships are happier and healthier than those 
who feel more dissatisfied with their relationships (Myers, 1992).  The buffering effects 
of social support on mental health have been reported since the 1970s (Zimet, Dahlem, 
Zimet, & Farley, 1988) and recent work continues to support these findings (Chen et al., 
2008).  In youth (9 to 18 years of age) with asthma, Chen et al. (2008) studied social 
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support at the family and peer level as well as asthma severity and symptoms.  Seventy-
eight participants completed self-report questionnaires, were assessed on pulmonary 
functioning (evaluated using an electronic monitor of functional status of the lungs), and 
provided blood samples for a biological evaluation of asthma inflammation and symptom 
severity.  Chen and colleagues (2008) found that lack of perceived family social support 
was related to increased allergic inflammation, which was related to poorer pulmonary 
functioning and increased asthma symptom severity, while peer social support was 
unrelated to asthma outcomes.  More importantly, this study provided evidence for the 
importance of social support for people living with chronic health conditions, and the 
positive effects social support has on physical health functioning.  
 A strong social support network has been shown to have positive effects on the 
mental and physical health of those diagnosed with HIV (Davison, Pennebaker, & 
Dickerson, 2000).  Studies indicate that HIV-positive people who perceive they have 
higher levels of social support experience less physical symptomatology, hopelessness, 
and depression than those with lower levels of support (Mizuno, Purcell, Dawson- Rose, 
Parsons, & the Suids Team, 2003; Serovich, Kimberly, Mosack, & Lewis, 2001).  For 
example, Leserman et al. (1999) examined the effects of stress, depressive symptoms,
 
and 
social support on the progression of HIV among 82 men living in North Carolina.  The 
men were assessed using self-report questionnaires, interviews, and blood samples to 
measure HIV progression (CD4 cell count and HIV viral load) at six-month intervals for 
five and a half years.  When all three variables were entered to predict HIV progression, 
only social support and stress had a significant correlation with the health outcome 
variables.  Specifically, for every severe life stressor, or two moderate stressors 
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(measured as 4-point increase in cumulative average stressful life events), people's risk of 
progressing to an AIDS diagnosis doubled.  In terms of social support, for each 1-point 
decrease in cumulative average of social support,
 
the risk of AIDS increased almost 
three-fold.  This research indicated that those who had lower social support were 
generally three times more likely to develop AIDS than their peers with higher social 
support.  Overall, the researchers demonstrated that stress is a predictor of HIV 
progression and that lack of involvement with friends and family is a significant risk 
factor for developing AIDS.  
 HIV treatment adherence and social support.  Health care providers are needed 
to decide on HIV diagnosis and proper treatments, but when it comes to treatment 
adherence, social relationships may be even more important than physicians (Roberts & 
Mann, 2000).  A qualitative study asked 20 women diagnosed with HIV to keep a 
personal journal for one month.  In the journal, the women were asked to record what 
their lives were like while taking the HIV treatments.  The purpose of the study was to 
identify barriers that women faced in adhering to their HIV treatments.  One of the 
findings that the investigators reported was that if an HIV-positive person has not 
informed family and friends of their HIV status, then their HIV medical adherence 
significantly decreased.  This was true because of the difficulties associated with hiding 
the use of the HIV treatment from people unaware of the person's HIV status.    
 The chronic nature of the HIV/AIDS condition requires continuous social support 
(Reilly &Woo, 2004); individuals who report having a large social support network were 
more likely to disclose their HIV status, engage in more active coping, greater problem 
solving, and less avoidance (Kalichman et al., 2003).  Unfortunately, many individuals 
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living with HIV have been found to experience higher levels of loneliness than the 
general population (Davies, Horton, Williams, Martin, & Stewart, 2009).  The stigma 
associated with an HIV-positive diagnosis may contribute to loneliness and avoidance of 
supportive interactions (Ware, Wyatt, & Tugenberg, 2006).  Davey, Foster, Milton and 
Duncan (2009) researched family support network and its impact on HIV progression.  In 
this study, HIV progression was measured as HIV treatment adherence, with lower HIV 
treatment adherence associated with high HIV-progression among fifty youth recently 
diagnosed youth (ages 14 to 24 years).  The study used retrospective medical review 
charts of participants living with HIV, and indicated that they had poor family support, 
both before and after HIV diagnosis.  Analysis showed that for younger people living 
with HIV, perceived familial social support was an important predictor of acquisition of 
HIV and a risk for poor adherence to HIV treatment.  Although treatment adherence rates 
decline as the AIDS-related illnesses become more severe, social support continues to be 
an important predictor of HIV treatment adherence, mental health, and physiological 
functioning (Bogart et al., 2000; Mehta et al., 1997).  
 Consistent with the SDT model, the proposed study investigated the role of social 
support (with family, friends, and intimate partners) on HIV treatment adherence.  In 
addition, relatedness was also assessed as perceived HIV-related stigma from health care 
providers.  
 Perceived HIV-related stigma in health care settings.  Since the beginning of 
the HIV/AIDS epidemic, some social groups have been stigmatized by the general 
population and even by health care professionals (see Shilts, 1987).  In the first half of the 
1980s, the HIV/AIDS outbreak was associated with public hysteria around the etiology of 
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AIDS and HIV transmission.  Certain groups, such as gay males and intravenous drug 
users, were most associated with the illness (Herek & Glunt, 1988; Shilts, 1987).  The 
lack of knowledge about the etiology of HIV transmission led most people to fear the 
members of these groups and, as a result, to stigmatize and blame them for the epidemic 
(Rintamaki et al., 2006).  Ware and colleagues (2006) illustrated that perceived stigma 
contributes to marginalization and exclusion, driving people into loneliness and isolation.  
Approximately 30 years have passed since the first recorded cases of AIDS in North 
America and researchers continue to identify stigma as one of the most important social 
and psychological issues for people affected by HIV/AIDS (Rintakami, Davis, 
Skripkauskas, Bennett, & Wolf, 2006).  Despite the growing number of media and 
educational campaigns information on HIV transmission, people continue to stigmatize 
PLWH (Cobb & Chabert, 2002).  An extremely disappointing and discouraging fact is 
that similar negative attitudes are found among HIV health care providers as are seen in 
the general population (Cobb & Chabert, 2002).  Canadian researchers, Wagner and 
colleagues (2010) found perceived HIV-stigma to be a barrier for immigrant women 
living with HIV to access fertility care.  They recruited 525 HIV-positive women of 
reproductive age to participate in a paper-and-pencil type survey assessing women's 
desires and intentions to give birth in the future.  HIV-related stigma, anxiety, depression, 
and demographic variables were assessed.  Women born outside of Canada (mainly of 
African descent) reported experiencing judgment and HIV-related stigma by health care 
providers for their intentions to become pregnant. 
 HIV treatment adherence and perceived HIV-related stigma.  Rintamaki and 
colleagues (2006) reported that concern over revealing HIV-status as the most significant 
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predictor of medical compliance.  The study was based in Chicago (and nearby suburbs).  
The authors recruited 204 adults (mean age of 40.1 years) living with HIV to self-report 
their treatment adherence rates and HIV-related stigma concerns (e.g., “I am embarrassed 
to get my medicines from a drug store").  Approximately 20% of patients reported a high 
degree of concern over HIV-related stigma.  Participants who experienced perceived 
HIV-related stigma concerns had higher non-adherence rates, as compared to participants 
with lower perception of stigma.  This study demonstrated the important influence HIV-
related stigma has on treatment adherence among PLWH.  Better efforts to inform 
clinicians of this important barrier may improve patients' quality of life, through 
minimizing non-adherence rates. 
 Other researchers report that perceived stigma has an indirect effect on HIV 
treatment adherence through depression (Dilorio et al., 2007).  DiIorio et al. (2007) 
applied a social cognitive theoretical model in predicting HIV treatment adherence.  In 
their study, some of the social and psychological predictors were self-efficacy 
(confidence in taking the HIV treatment), stigma, depression, social support, and patients' 
satisfaction with health care providers.  Structural equation modeling revealed that the 
best model predicting HIV treatment adherence identified self-efficacy and depression as 
mediators between the predictors (stigma, patients' satisfaction with health care providers, 
and social support) and HIV treatment adherence.  Self-efficacy and depression also 
showed a direct and significant association with treatment adherence.  Although in this 
study perceived HIV-related stigma was not found to be a direct predictor of HIV 
treatment adherence, the effect of perceived stigma was mediated through self-efficacy.  
Specifically, high levels of perceived stigma were associated with lower self-efficacy, 
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which in turn negatively affected HIV treatment adherence rates.  Therefore, despite the 
uncertainty as to whether social stigma has a direct or indirect effect on medical 
adherence, stigma remains an important variable when studying HIV treatment adherence.  
 HIV/AIDS health care providers have a key role in the psychological and physical 
well being of their patients (Cobb & Chabert, 2002).  One of the purposes of the current 
study was to examine if PLWH living in Southwestern and Central Ontario perceived 
HIV-stigma from their health care providers, and the possible effects that this had on HIV 
treatment adherence. 
Competence 
 Most researchers using Self-Determination Theory define competence as 
perceived ability to make change.  Self-determination theory suggests that when 
individuals perceive themselves to be competent, their intrinsic motivation increases.  
Numerous studies have supported this relationship (Williams, McGregor, King, Nelson, 
& Glasgow, 2005).  For example, Bogoien and Halvari (2005) investigated the role of 
competence in physical activity involvement among high school students.  The students 
filled out questionnaires on their involvement in physical activity, their perceived 
competence in sports, and their level of intrinsic motivation.  Statistical analysis showed 
positive relationships among involvement in physical activity, intrinsic motivation, and 
perceived sports competence.  Consistent with Self-Determination Theory, the results 
indicated that intrinsic motivation mediated the relationship between perceived sport 
competence and involvement in physical activity.  In the current study, competence was 
operationalized as HIV treatment self-efficacy and HIV treatment knowledge; both 
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constructs were hypothesized to be important predictors of intrinsic motivation.  In turn, 
intrinsic motivation was hypothesized to influence HIV treatment adherence. 
 Self-efficacy.  Self-efficacy is a concept introduced by Albert Bandura in 1977 
and is described as the expectation that a person can successfully perform a task despite 
the presence of adversity.  Self-efficacy is distinct from Internal HLOC in that the former 
is the ability to continue with an arduous task despite perceived barriers.  On the other 
hand, Internal HLOC is the belief that a person has control over the task, but they may 
have low self-efficacy and give up if an obstacle occurs.  In turn, individuals with 
intrinsic motivation engage in activities because they are satisfying.   
 Applied to health-related behaviour, self-efficacy is defined as the confidence in 
one‟s ability to comply with medical treatments, despite their complexity, the side effects, 
lack of social support, psychological distress, or any additional stressors and barriers 
(Becker & Rosenstock, 1986).  The importance of self-efficacy in predicting treatment 
adherence has been well reported (i.e., Strecher, DeVellis, Becker, & Rosenstock, 1986).  
For example, in diabetes patients higher in self-efficacy for oral care was significantly 
associated with better dental health (Syrjala, Kneckt, & Knuuttila, 2003).  The concept of 
self-efficacy is an important factor in maintaining health behaviours, which extends to 
other chronic illnesses, including HIV/AIDS. 
 HIV treatment adherence and self-efficacy for treatment adherence.  The 
evidence that self-efficacy accounts for some of the HIV treatment adherence rates has 
been well established (Cha, Erlen, Kim, Sereika, & Caruthers, 2008; Johnson et al., 2007).  
For example, Cha et al. (2007) examined the following predictors: perceived social 
support, depressive symptoms, and perceived self-efficacy, in predicting HIV treatment 
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adherence.  The researchers administered self-report questionnaires to 215 people 
between the ages of 19 to 61 and living with HIV.  The authors found that self-efficacy 
mediated the relationship between the predictors (perceived social support and depressive 
symptoms) and HIV treatment adherence (outcome), thus providing evidence for the 
importance of self-efficacy when designing interventions to target HIV treatment 
adherence.  Johnson et al. (2006), who investigated the influence of self-efficacy and 
positive clinician-provider relationship on HIV treatment adherence, reported similar 
results.  The investigators hypothesized that positive clinician-provider relationship and 
HIV treatment adherence would be mediated by self-efficacy.  They administered self-
report questionnaires to 2765 adults living with HIV and residing in the United States.  
The hypothesized model was supported in that self-efficacy was shown to mediate the 
relationship between positive clinician-patient interactions and HIV treatment adherence.  
This relationship was maintained after controlling for age, gender, education, health 
variables (CD4 cell count), depression, and social support.  The importance of these 
findings is the suggestion that improving patients' self-efficacy can lead to better HIV 
treatment adherence.  Focusing on helping clinicians create a positive environment for 
their patients, such as making them feel understood, can lead to increased self-efficacy in 
the patient. 
 Although clinicians may be communicating with patients in a respectful and 
compassionate way, if patients are unable to understand the medical language often 
spoken by clinicians, the benefits of the communication may be lost.  Thus, it is relevant 
to explore the impact of patients' HIV treatment-related knowledge on HIV treatment 
adherence.  
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 HIV Treatment Knowledge and HIV Treatment adherence.  Accurate HIV 
treatment knowledge is needed for PLWH to successfully manage their complex medical 
conditions, and to successfully adhere to their prescribed HIV treatment regimens 
(Balfour et al., 2007).  Recent literature finds support for the association between HIV 
treatment knowledge and better HIV treatment adherence (Balfour et al., 2007; Weiss et 
al., 2003).  Specifically, Weiss and colleagues (2003) found that PLWH who knew the 
importance of adhering to the HIV treatment regimen had higher adherence rates as 
compared to people who were not aware that nearly perfect adherence (>95%) is needed 
for optimal physical health.  In a more recent study by Weiss et al. (2007) the researchers 
reported that among the PLWH in their study, higher HIV treatment-related knowledge, 
as assessed by five open-ended questions (e.g., to provide a definition for viral load) was 
associated with better HIV treatment adherence rates.  However, the majority of the 
published research on HIV treatment knowledge and adherence has been based in the 
United States, and to date less is known about the extent to which HIV treatment 
knowledge is associated with HIV treatment adherence in a Canadian sample of PLWH.  
The present study included HIV treatment knowledge as a predictor of HIV treatment 
adherence.  The measure used for assessing HIV treatment knowledge has been validated 
using a Canadian sample of PLWH. 
 
Present Study 
 The present study consisted of two phases aimed to examine the factors that 
influence HIV treatment adherence among PLWH in Southwestern and Central Ontario.   
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 Phase I used Self-Determination Theory as a framework to understand the 
relationship among several psychosocial factors and HIV treatment adherence.  
Specifically, three main psychological factors (perceived autonomy, relatedness, and 
patient's competence) were predicted to influence intrinsic motivation, which in turn were 
predicted to influence HIV treatment adherence.   
The primary hypotheses were that:  
H1: Intrinsic motivation would mediate the relationship between autonomy and HIV 
treatment adherence.  Specifically, 
H1a: Internal locus of control (Internal HLOC) would be positively related to 
intrinsic motivation.  In turn, intrinsic motivation would be positively related to HIV 
treatment adherence.  
H1b: Chance locus of control (Chance HLOC) would be negatively related to 
intrinsic motivation.  In turn, intrinsic motivation would be positively related to HIV 
treatment adherence.  
H1c: Locus of Control for Doctors (Doctors HLOC) would be negatively related 
to intrinsic motivation.  In turn, intrinsic motivation would be positively related to HIV 
treatment adherence. 
H1d: Other locus of control (Other HLOC) would be negatively related to 
intrinsic motivation.  In turn, intrinsic motivation would be positively related to HIV 
treatment adherence. 
H1e: Perceived autonomy-supportive physician would be positively related to 
intrinsic motivation.  In turn, intrinsic motivation would be positively related to HIV 
treatment adherence.  
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H2: Intrinsic motivation would mediate the relationship between relatedness and HIV 
treatment adherence.  Specifically, 
H2a: Social support would be positively related to intrinsic motivation.  In turn, 
intrinsic motivation would be positively related to HIV treatment adherence. 
H2b: HIV-related stigma in health care settings would be negatively related to 
intrinsic motivation.  In turn, intrinsic motivation would be positively related to HIV 
treatment adherence. 
H3: Intrinsic motivation would mediate the relationship between competence and HIV 
treatment adherence.  Specifically, 
H3a: HIV treatment knowledge would be positively related to intrinsic motivation.  
In turn, intrinsic motivation would be positively related to HIV treatment adherence. 
H3b: HIV treatment self-efficacy would be positively related to intrinsic 
motivation.  In turn, intrinsic motivation would be positively related to HIV treatment 
adherence.  
 Phase II of the present study included semi-structured face-to-face interviews.  
The purpose of the interview component was twofold: 1) to obtain additional information 
on the experiences and factors associated with successful HIV treatment adherence in 
PLWH; 2) to gain a better understanding of the health care related experiences of PLWH; 
and 3) to triangulate the quantitative results with qualitative findings.  The semi-
structured interview questions were predetermined and a protocol was created (Appendix 
A), but the interview protocol was also flexible and it allowed new questions to be 
brought up by the interviewee.  Ultimately, the present study used quantitative (Phase I) 
and qualitative data (Phase II) to interpret the findings. 
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CHAPTER II 
METHOD 
Phase I: Self-report Questionnaires (Quantitative Data) 
Participants   
 Fifty-seven people living with HIV (PLWH) completed the self-report 
questionnaire.  All participants were recruited from AIDS service organizations (ASOs) 
in the Greater Toronto Area.  ASO clients were eligible to participate if they met the 
following three criteria: (1) 18 years or older; (2) have been on HIV medications for more 
than six months
1
; and (3) able to read and write in English.   
Measures 
 Demographics.  Participants completed a demographics questionnaire assessing 
factors such as age, gender, sexual orientation, relationship status, ethnic/racial 
background, religion, educational level, income, housing situation, and two open-ended 
questions (Appendix B). 
 Health variables.  Participants were asked to report their most recent CD4 cell 
count and HIV viral load.   In addition, a list of 15 HIV treatment-related side effects was 
provided and participants were asked to select if any of the side effects applied to them.  
A choice of "other" was also provided.  Participants were also asked to indicate the 
severity of the symptoms, on a scale from 1 (mild) to 7 (severe).   
 Health locus of control (HLOC).  HLOC was assessed using the 
Multidimensional Health Locus of Control scale-form C (MHLC-C).  The entire MHLC-
C is an 18-item self-administered questionnaire.  The items were rated on a 6-point Likert 
 
1 
Fothergill-Bourbonnais et al. (2002) argue that adjustment to the HIV treatment regimens is most difficult 
for patients in the first 3 to 6 months 
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scale, ranging from strongly disagree (1) to strongly agree (6) and it assessed 
participant's beliefs about the general source that influenced their specific health 
condition.  This measure was adapted specifically for HIV/AIDS related research 
(Wallston, Stein, & Smith, 1994).  The MHLC-C contains four dimensions of health 
locus of control: 1) Internal (six items); 2) Chance (six items); 3) Doctors (three items); 
and 4) Other (three items).  The Internal subscale measures an individual's belief that he 
or she is mainly in control of his/her behaviour (e.g., "I am directly responsible for my 
condition getting better or worse").  The Chance subscale measures the extent to which 
one believes that their illness is a matter of fate or luck, for instance "As to my condition, 
what will be, will be".  The Doctors dimension assesses people's beliefs regarding the 
degree of control doctors have over their illness (e.g., "If I see my doctor regularly, I am 
less likely to have problems with my condition").  Lastly, Other is a dimension of HLOC 
that measures an individual's expectations that other relationships, such as friends, 
contribute to their health condition (e.g., "The type of help I receive from other people 
determines how soon my illness improves").  Wallston et al. (1994) reported the internal 
consistency, for each of the four subscales, to range from Cronbach's alpha 
coefficients .85 to .87 (Internal HLOC), from .79 to .82 (Chance HLOC), from .70 to .71 
(Other HLOC), and .71 for Doctors HLOC, with the Internal HLOC and Doctors HLOC 
correlated moderately, r(54) = .51, p < .001, in the present study.  
 HIV treatment adherence.  HIV treatment adherence was measured using the 
Center for Adherence Support Evaluation Adherence Index (CASE Adherence Index; 
Mannheimer et al., 2006).  The CASE Adherence Index consists of three items, with one 
of them being “When was the last time you missed at least one dose of your HIV 
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medications?”; the measure is designed to be quick, simple and easy to administer 
(Mannheimer et al., 2006), and it takes approximately two minutes to complete.  Most 
importantly, the measure has been validated longitudinally against another HIV treatment 
adherence measure, the AACTG three-day self-report (Chesney et al. 2000b), and two 
physiological markers of HIV disease progression - HIV viral load and CD4 cell count.  
Using a sample of 524 PLWH, Mannheimer and colleagues (2006) compared the 
aforementioned measures to the CASE Adherence Index, every three months, for over an 
entire year.  The results indicated that the CASE Adherence Index correlates with the 
AACTG three-day self-report (p = .001), and even higher associations were found with 
the physiological markers (i.e., HIV viral load and CD4 cell count).  The CASE 
Adherence Index is scored out of 16.  Scores that are 10 or below mark poor adherence, 
and scores above 10 indicate good adherence.  This criterion was developed when the 
authors compared the CASE Adherence Index scores to patients' CD4 cell counts 
(Mannheimer et al., 2006).  The results showed that participants who score higher than 10 
on the CASE Adherence Index generally achieved a mean increase of 98 CD4 cell counts 
over 12 months, compared to a 41-cell increase for those who score 10 or lower, and 
these findings were significant (p < .001).  Reliability data for this measure is not yet 
available.  A secondary aim of the proposed study was to establish some of the 
psychometric properties of this scale.   
 HIV Treatment Knowledge.  HIV treatment knowledge about complex 
treatment issues such as adherence, side effects and drug resistance was assessed using 
the HIV Treatment Knowledge Scale.  This is a 21-item true and false questionnaire 
developed by Balfour and colleagues (2007).  An example item from this measure is 
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"When HIV medications work well, the HIV viral load increases".  In previous research, 
this measure has demonstrated high internal consistency, with a reliability coefficient of 
.90 (Balfour et al., 2007).   
 Self-efficacy.  Self-efficacy was measured using the HIV-Adherence Self-Efficacy 
Scale (HIV-ASES), which is a measure of perceived ability to adhere to the HIV 
treatment, despite daily obstacles or side effects from the HIV treatment (Johnson et al., 
2007).  This is a 12-item scale, with a Likert-type response format ranging from 1 
(cannot do it at all) to 10 (certain can do it).  An example item is "How confident are you 
that you can stick to your treatment plan when side effects interfere with daily activities?”  
Higher scores indicate higher adherence self-efficacy.  In previous studies, the HIV-
ASES has demonstrated strong internal consistency (> .90; Johnson et al., 2007).   
 Psychological distress.  The Hospital Anxiety and Depression Scale (HADS; 
Zigmond & Snaith 1983) is a 14-item self-rated questionnaire, used to assess anxious 
(HADS-A) and depressive (HADS-D) symptoms, with seven items for each subscale.  
Both subscales are measured on a 4-point Likert type scale with item scores ranging from 
0 (not at all) to 3 (nearly all the time).  HADS-A and HADS-D scores equal to or higher 
than 11 are considered definite case of high symptoms of anxiety and depression, which 
indicates the need for further diagnostic assessment of these disorders.  Data from this 
measure has high test-retest reliability of r = .74, for up to a six month period (Savard, 
Laberge, Gauthier, Ivers, & Bergeron 1998).  Bjelland, Dahl, Haug and Neckelmann 
(2002) completed a meta-analysis using 15 published studies and indicated that the 
internal consistency for the HADS-A varied from Cronbach‟s alpha coefficient of .68 
to .93 (mean .83), and for the HADS-D from .67 to .90 (mean .82).  The HADS provides 
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a reliable and valid assessment of anxiety and depression for PLWH, due to the low risk 
of conflation with physiological symptoms of HIV disease (Savard et al., 1998). 
 Intrinsic motivation.  Intrinsic motivation was measured using the Treatment 
Self-Regulation Questionnaire (TSRQ), developed by Williams et al. (1996).  This is a 
15-item Likert-type scale with responses ranging from 1 (strongly disagree) to 7 
(strongly agree).  The TRSQ measures people's involvement with health-related 
behaviors because of their own volition, rather than doing so as a response to external 
pressures.  High TSRQ scores represented high internal motivation.  The internal 
consistency for this measure, as reported by  
Levesque et al. (2007), is an alpha of >.78.  An example item is “I want to take 
responsibility for my own health".    
 Autonomy-supportive physicians.  To assess patients‟ perceptions of the degree 
to which their HIV-specialist is autonomy supportive, the Health Care Climate 
Questionnaire (HCCQ) was used (Williams et al., 1996).  Previous research 
demonstrated that the reliability for this scale is a Cronbach's alpha of .96 (Williams et al., 
1996).  This measure assesses the amount of control and choices that patients perceive to 
have over their treatment as 'allowed' from their physicians.  A sample item is "My doctor 
listens to how I would like to do things."   
 HIV-related stigma in health care settings.  Due to the dearth of research 
available on health care-related HIV-stigma, a scale to measure HIV-stigma specific to 
health care settings was created for this study.  Ten questions were developed by the 
author, based on knowledge from the literature on health-care related stigma, to assess 
HIV stigma in health care settings (Appendix C).  These questions were rated on a 5-
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point Likert scale, ranging from strongly disagree (1) to strongly agree (5), and an 
example item is "I have avoided going to dental offices because of their reactions to my 
HIV/AIDS".  For the current study the internal consistency of this scale yielded a 
Cronbach's alpha of 0.86.   
 Perceived social support (family, friends, and intimate partners).  The social 
support scale was adapted from the Social Provisions Scale (SPS; Cutrona & Russell, 
1987).  The SPS scale is an extensive measure of social support assessing six dimensions 
of perceived social support.  For this study two subscales of the SPS were chosen to be 
examined - Attachment and Reliable alliance.  Participants rated perceived attachment 
and the extent to which they can rely on family, friend, or an intimate partner for support 
on 4-point scales using response anchors ranging from strongly disagree (1) to strongly 
agree (4).  The total internal consistency reliability for the Social Provisions scales has 
been demonstrated to be excellent (α = .93; Cutrona & Russell, 1987). 
Procedure 
 Recruitment.  Ethics approval was obtained from the University of Windsor 
Research Ethics Board (REB), conforming to APA, CPA and the Tri-council Policy 
Statement ethical guidelines.  Several AIDS Service Organizations (ASOs) agreed to 
participate in this study by allowing the recruitment of participants from their pool of 
clients.  Specifically, the following ASOs in the Greater Toronto Area participated in the 
recruitment of participants for the self-report questionnaires: AIDS Committee of 
Durham (Oshawa, ON); AIDS Committee of York Region (New Market, ON); LOFT 
Community Services/McEwan Housing & Support Services (Toronto, ON); and Asian 
Community AIDS Services (ACAS; Toronto, ON).  Flyers advertising the study were 
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posted at the aforementioned participating sites.  Please refer to Appendix D for the flyer 
that advertised Phase I of this study.   
 Procedures for the self-report questionnaires.  Clients who noticed the 
advertisements of the study and were interested in participating approached the ASO 
onsite-representative for a questionnaire.  The onsite ASO staff presented an envelope to 
the participant, where directly attached on the envelope was the informed consent form 
(Appendix E).  Once consent was obtained, that is, signed by the participant and returned 
to the onsite staff member, the client completed the questionnaire.  The questionnaire 
took approximately 45 to 50 minutes to be completed.  Private space for filling out the 
questionnaire was provided at the organization, or the participant also had the choice to 
complete it at another location that was convenient for them.  Upon completion, or 
termination, of the questionnaire the participant sealed their questionnaire in the provided 
envelope with no identifiable information and returned the envelope to the ASO onsite 
representatives.  At this time the participants received $20.00 in cash for their 
participation, and were provided with a list of community resources (Appendix F). 
Data Analysis 
 Quantitative analysis.  Prior to the main analysis, for descriptive purposes, 
frequencies of the demographic information were generated and summarized.  Two-tailed 
Pearson product-moment correlations were used to test the influence of the predictor 
variables on the dependent variable (HIV treatment adherence).   
 Mediation analysis was used to test the main hypotheses in Phase I of the present 
study.  Mediation is said to occur when the effect of a predictor (some variable X) on an 
outcome 
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(some variable Y) is explained by a mediator variable, some variable M (see Figure 1; 
Shrout & Bolger, 2002).  A number of techniques are available to test mediation.  For 
example, the Baron and Kenny (1986) four-step approach has been the most influential in 
the past.  This method, however, has received some criticisms.  The main criticism of the 
Baron and Kenny (1986) approach is that the four steps do not test whether the indirect 
effect (refer to Figure 2) is significantly different from zero and whether it is in the 
expected direction (Preacher & Hayes, 2004).   
 
Figure 1. Illustration for Mediation  
 
 a b 
 c 
 
The predictor variable is X, the mediator is M, and Y denotes the outcome variable.   
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Figure 2. Illustration of Indirect effect 
 
 
Indirect effect does not assume the relationship between XY (step a, as part of the 
Baron and Kenny approach to testing mediation).  Some authors (e.g., Shrout & Bolger, 
2002) argue that XY is not necessary, and that the requirement of this step inflates the 
risk of Type II error, for the entire mediation.  This is one of the criticisms for the Baron 
and Kenny (1986) method for mediation analysis.  Shrout and Bolger (2002) explain that 
the XY relationship may not be significant because the effect may be affected by 
another variable (m), or other competing causes (e.g., random uncontrolled factors).  
Shrout and Bolger (2002), therefore, suggest that the association between XY may be 
more powerful when mediation is taken into account.  The present study examines both, 
mediation and indirect effect.   
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 The Sobel test has been considered more accurate; however, the assumption of 
normality cannot be violated (Preacher & Hayes, 2004).  Especially in small sample sizes 
this assumption is frequently violated.  Bootstrapping has been the preferred method 
because it does not require the assumption of normality (Preacher & Hayes, 2004).  In 
addition, the Bootstrapping method can be used with small to moderately small sample 
size; that is 20 to 80 cases (Efron & Tibshirani, 1993).   
 The present study, therefore, used the Bootstrapping method to evaluate the 
mediation hypotheses, outlined on pages 36 to 37 (Preacher & Hayes, 2004).  
Bootstrapping is accomplished by repeatedly re-analyzing a large number of samples 
from the data, sampling with replacement, and computing the indirect effect, in each 
sample; it is recommended that the sampling with replacement is performed 5000 times 
(i.e., bootstrap samples; Preacher & Hayes, 2004).  To use the Bootstrapping test for 
mediation researchers require a syntax created by Preacher and Hayes (2004).  The SPSS 
compatible syntax can be downloaded from the author's website, available at 
http://www.afhayes.com/.   
 The Bootstrapping output, for mediation analyses, produces the indirect effect 
with 95% and 99% lower and upper bound confidence intervals.  A statistically 
significant indirect effect does not have a zero in the confidence interval estimate (95% or 
99%).  This study used confidence intervals of 95% to assess if an indirect effect exists.  
The bootstrap output also includes the relationships among the other variables (e.g., 
XY; XM, etc) as part of the mediation.  Therefore, in the present study, to support 
mediation the following two results were required: 1) a significant relationship between 
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the predictor (X) and the outcome variable (Y); and 2) the Bootstrapping indirect effect 
also needed to be significant; that is no zero within the 95% confidence interval.   
Phase II: Semi-structured Interviews (Qualitative) 
Face-to-face Interviews 
 Narrative accounts of participants' experiences with their HIV treatments and 
their health care-related experiences were obtained through face-to-face semi-structured 
interviews.  The findings from the quantitative analysis were triangulated with results 
obtained from qualitative analysis as further supporting evidence for the predictor 
variables in the proposed model.  There are a number of different theoretical approaches 
to conducting interviews.  Researchers can either have predetermined research questions 
in mind or conduct the interviews with a more exploratory framework.  In the present 
study, the research questions were semi-structured and they reflected the research 
questions assessed by the quantitative data.  The interview protocol, however, also 
allowed new questions to be brought up by the participant. 
Participants 
 Eleven PLWH took part in the face-to-face interviews.  All participants were 
recruited from AIDS service organizations (ASOs) from Windsor (ON) or downtown 
Toronto (ON).  Participants were eligible to participate if they met the following three 
criteria: (1) 18 years or older; (2) have been on HIV medications for more than six 
months; and (3) able to understand and speak English.   
 Recruitment.  For the recruitment of participants, flyers advertising the study 
were posted at the AIDS Committee of Windsor (Windsor, ON) and Fife House (Toronto, 
ON).  AIDS Committee of Windsor (ACW) is a non-for profit organization that provides 
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support, education and outreach services for PLWH or for people at risk for HIV.  Fife 
House provides affordable housing to PLWH in the Greater Toronto Area.  All study 
flyers included the eligibility criteria, the honorarium amount, and the length of the 
interview (Appendix G). 
 Procedures for the face-to-face semi-structured interviews.  Upon ethics 
approval from the University of Windsor, participants were recruited using flyer 
advertisements with a local phone number for potential participants to contact the study 
researcher.  These flyers either were posted throughout the ASOs poster boards (AIDS 
Committee of Windsor), or were distributed in people's mailboxes (Fife House, Toronto).  
Clients who were interested in taking part in the study arranged a date and time for the 
interview by calling the researcher.  The researcher screened every caller to assure that 
the potential participant met the eligibility criteria.  Both participating sites provided the 
researcher with a private interview room.  The semi-structured interviews ranged from 
10.24 to 51.05 minutes in length, averaging at 22.85 minutes.  The session proceeded 
with the participants first completing the consent forms (See Appendices H and I for 
general and audio consent forms).  The interview started with the researcher asking an 
open-ended question about a specific topic, followed by prompting questions when 
necessary to encourage discussion (see Appendix A).  Upon completion, or termination 
of the interview, the participants were provided with $40.00 in cash, and were provided 
with a list of community resources (Appendix F). 
Semi-Structured Interview Protocol 
 In order to correspond with findings from the quantitative analysis, the semi-
structured interview questions were developed based on the variables studied (i.e., 
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Autonomy-supportive health care providers, Health Locus of Control, HIV-related stigma 
in health care settings, social support, HIV treatment self-efficacy, and HIV treatment 
knowledge), as part of Phase 1 of this study.  The interview questions were meant to 
further explore each of the aforementioned constructs, and how they related to HIV 
treatment adherence.  For example, to represent the HIV treatment self-efficacy construct, 
the following question was asked: "Do you feel that you can continue taking the 
medication even when its interfering with your daily activities?”  Please refer to 
Appendix A for the entire interview protocol.  
Qualitative Data Analyses 
The following phases were followed when analyzing the interview data: 
Phase 1: Transcribed the interview data.  In this phase all the audio recorded 
interviews were transcribed verbatim.  
Phase 2: Selected quotes that represent the three constructs as part of the 
Theory of Self-Determination (Deci & Ryan, 1985; Autonomy, Relatedness, and 
Competence): In this phase, quotes were extracted that represented the predictor 
variables examined as part of Phase I of this study.  Specifically, quotes were drawn out 
that best captured the respondents' HIV treatment adherence experiences and one of the 
following constructs: Health Locus of Control, autonomy-supportive physicians, health 
care-related stigma, social support, HIV treatment self-efficacy, and HIV treatment 
knowledge.  This was done manually by re-reading the transcribed interview data and 
highlighting quotes that represented these constructs.   
Phase 3: Reviewed for other major themes.  The purpose of this phase was to 
be aware of other issues that the interviewee found important to share, that needed to be 
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included to fully capture people's experiences with taking their HIV treatment 
medications.   
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CHAPTER III 
RESULTS 
Phase I: Self-report Questionnaires (Quantitative Data) 
 All statistical analyses were performed using PASW Statistics 19.0 (SPSS Inc., 
2010).  The results are presented in the following four subsections: 1) data preparation; 2) 
descriptive analyses of the participants; 3) psychometric properties of the study measures; 
and 4) analyses related to the main hypotheses.   
Data Preparation 
The data were entered once and double-checked by another person to ensure that 
errors were not made when entering the data.  Descriptive statistics were computed to 
verify the ranges for each subscale.   
Expectation-maximization (EM) estimation was conducted to determine if the 
missing variables were missing completely at random (MCAR).  This analysis estimates 
whether the missing values are randomly distributed across all observations, using an 
iterative approach examining the relation between the complete and incomplete data 
(Jamshidian & Bentler, 1999).  If the EM estimation is p < .05, then the missing values 
depend on other values in the database; that is, the missing variables are not randomly 
distributed across all observations.  The EM test statistics indicated that the missing 
variables were missing completely at random, and not systematically, χ2 (367, N = 57) = 
389.69, p = .20, and thus the missing responses in this study did not compromise the data.  
Missing data accounted for less than 5% for all the variables with the exception of the 
followings items: "CD4 cell count and viral load have been explained to me by my 
doctor" (36% missing, n = 21); social support (10% missing, n = 6); "On average, how 
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many doctor prescribed pills do you take daily, excluding vitamins, etc" (9% missing, n = 
5); HIV-related stigma in health care settings (7% missing, n = 4); and Chance HLOC 
(7% missing, n = 4).   
The missing data were handled by substituting the mean score for the scale with 
missing data if at least 80% of the items were answered.  Pair wise deletion was used 
when performing the simple correlation analysis (i.e., Pearson product-moment 
correlations), this method allowed for more data to be retained for the analyses. 
Regarding sample size, according to Efron and Tibshirani (1993) the 
Bootstrapping method for testing simple mediation requires small to moderately small 
sample size, that is 20 to 80 cases.  The current study had an N of 57, and thus the study 
met this requirement.  
The presence of outliers on the dependent variable was assessed using the 
standardized residuals, and values greater than +/- 3 were considered outliers.  The 
analysis did not reveal any outliers.  The Bootstrapping method for testing mediation 
does not assume normality, thus the estimates for skewness and kurtosis were not 
analysed.  Simple correlations among all the predictor variables were examined revealing 
that multicollinearlity assumption was not violated (Stevens, 2000).  Table 1 includes the 
bivariate correlations between all the variables.   
Descriptive Analyses of the Participants 
 The majority (68%, n = 39) of the participants were recruited from AIDS Service 
Organizations (ASOs), such as the AIDS Committee of York Region, organizations that 
offer support services and programs to their clients.  The remaining 32% (n = 18) of the 
participants in Phase I, however, were recruited from McEwan Housing and Support 
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Services, an ASO that provides services to highly vulnerable populations, living with 
HIV/AIDS, who have mental health or substance abuse challenges or both, and are 
homeless or at risk of becoming homeless.  Therefore, the subsample recruited from 
McEwan Housing and Support Services was a unique sample of PLWH because of the 
multiple challenges that they faced.  To ensure that the subsample of people recruited 
from McEwan Housing and Support Services were not different in their level of social 
support, perceived stigma, and HIV treatment adherence, a series of t-tests were 
performed to compare this subsample of participants to the remaining participants 
recruited from ASOs not offering housing services.  The t-test analyses did not 
reveal meaningful differences between the groups on social support from family and 
friends (p = .17), HIV stigma in health care settings (p = .97), and on HIV treatment 
adherence (p = .72).   
 However, as a whole the participants who took part in Phase I were a unique 
subsample of the population living with HIV/AIDS, because at the time of recruitment 
the current sample was in contact with ASOs.  This suggests that the participants in this 
study may have been more self-motivated to obtain the services that they required, as 
opposed to PLWH who were not in contact with ASOs.  Also, it is likely that the people 
in contact with ASOs had higher social support, compared to people who were not 
seeking these support services.  Therefore, the results from the present study should be 
interpreted with caution as this was not a representative sample of PLWH and this has 
implications for limiting the generalizability of the findings.  
 Demographic description of the participants. As part of the self-report 
questionnaire, participants were asked to indicate a number of demographic 
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characteristics.  The sample consisted of 75.4% (n = 43) males and 24.6% (n = 14) 
females.  Twenty-four of the males identified as gay (57.1%), 11 males (26%) identified 
as straight, and the remaining 14% (n = 6) were bisexuals.  Of the female sample 71.4% 
were of heterosexual orientation, 2 (14.3%) were bisexual, and one participant identified 
as a lesbian.  Participants had a mean age of 43.1 years (SD = 9.4).  In terms of ethnicity, 
over one-quarter of the sample (26.3%; n = 15) identified as British, 26.3% (n = 15) were 
of East and Southeast Asian descent, 10.5% (n = 6) participants identified as Canadian, 
and the remaining 3.5% (n = 2) PLWH indicated a biracial ethnic background.  Annual 
income was less than $20,000 for 56.1% (n = 32) of the PLWH in this sample, and 63.2% 
(n = 36) of the participants indicated that they were on government assistance (i.e., 
Ontario Disability Support Program).   
 The majority of the PLWH (73.7%, n = 42) self-reported an undetectable HIV 
viral load.  The average CD4 cell count was 366.30 cells/m
3
 (SD = 336.26); thus, this 
sample of participants were above the CD4 200 cells/m
3 
cut off for an AIDS diagnosis.  
Please refer to Table 2 for additional demographic and medical characteristics of this 
study sample.  
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Table 1 
Summary of Intercorrelations for all the Predictor Variables (continuous variables) 
 1 2 3 4 5 6 7 8 9 10 11 
1. HCCQ  1           
MHLC-C:            
 2. Internal HLC .16 1          
 3. Chance HLC .10 .46
** 
1         
 4. Doctors HLC .34
** 
.51
** 
.08 1        
 5. Others HLC .17 .35
** 
.67
** 
.26 1       
6. Health care-related stigma -.57
** 
-.13 .09 -.13 -.09 1      
7. Social Support .36
* 
-.10 -.28 .13 -.13 -.43
** 
1     
8. HIV Treatment Knowledge Scale .02 -.11 -.31
* 
-.09 -.24 -.19 .21 1    
9. HIV-ASES  .43
** 
.02
 
-.34
* 
.34
* 
-.17 -.14 .29
* 
.08 1   
10. HADS-D -.46
** 
-.26 .04 -.35
** 
.17 .36
** 
-.54
* 
-.03 -.34
* 
1  
11. HADS-A -.27
* 
-.10 .15 -.07 .22 .39
* 
-.53
** 
-.07 -.14 .65
** 
1 
Note. 
*
Correlation is significant at the 0.05 level (2-tailed), p < 0.05; 
** 
Correlation is significant at the 0.01 level (2-tailed).  p < 0.01; HCCQ = Health 
Care Climate Questionnaire (assessing autonomy-supportive physicians); MHLC-C = Multidimensional Health Locus of Control scale-form C; HLC = 
Health Locus of Control; HIV-ASES = HIV-Adherence Self-Efficacy Scale; HADS-D = Hospital Anxiety Depression Scale - Depression subscale; 
HADS-A = Hospital Anxiety Depression Scale - Anxiety subscale.  
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HIV treatment adherence.  With regard to HIV treatment adherence, on average 
the participants were successful at adhering with their prescribed HIV treatment regimen.  
Specifically, the average score on the CASE Adherence Index was 11.98 (SD = 2.78); 
scores higher than 10 indicated good adherence.  The most frequent CASE Adherence 
Index score was 15.0, and four participants (7.0%) indicated 100% adherence (a score of 
16).  Despite these promising results, however, two-fifths of the sample, 40.4% (n = 23), 
were classified as having poor HIV treatment adherence (CASE Adherence Index ≤ 10).  
Table 3 summarizes the demographic and medical characteristics of the sample of people 
considered non-adherent (CASE Adherence Index ≤ 10) and adherent to their prescribed 
HIV treatment regimen (CASE Adherence Index ≥11).  Age was significantly different 
between the two groups, in that the less adherent group was younger, as compared to the 
more adherent group. 
Forty-four percent of the sample was taking 1 to 5 medically prescribed pills per 
day, excluding vitamins and other supplements.  The participants were also asked 
whether they were involved in the decision to begin their HIV treatment, and 32.1% (n = 
18) of the participants indicated yes.   
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Table 2 
Demographic and Medical Characteristics of Study Participants (N = 57) 
Characteristic frequency (%) M (SD) 
Age   43.1 (9.5) 
Gender:    
 Females 14 24.6  
 Males 43 75.4  
Sexual Orientation:    
 Straight/heterosexual 21 36.8  
 Gay 24 42.1  
 Lesbian 1 1.8  
 Bisexual 8 14.0  
City:    
 Toronto 34 59.6  
 Oshawa 8 14.0  
 Other 15 26.3  
Ethnic Background:    
 British 15 26.3  
 East/Southeast Asian 11 19.3  
 African/African-Caribbean 5 8.9  
 Aboriginal 4 7.0  
 Other 18 35.2  
Born in Canada 30 52.6  
PSYCHOSOCIAL INFLUENCES ON HIV TREATMENT ADHERENCE 57 
 
 
Table 2 continued - Demographic and Medical Characteristics of Study Participants 
(N = 57) 
 Has a romantic partner 27 48.2  
Employment status:    
 Full/Part time work 17 29.8  
 ODSP 36 63.2  
 CPP 9 15.8  
 Other 10 17.6  
Yearly Income:    
 < 20, 000 32 59.3  
 20, 000-40, 000 9 16.7  
 > 40, 000 7 13.1  
Education level:    
 High School or less 18 31.6  
 College or more 37 64.9  
Medical Variables:    
 HIV viral load < 50 (Undetectable)  42 82.4  
 CD4 count cells/m
3
   366.3 (336.2) 
 Number of side effects   8.5 (5.1) 
 Number of daily intake of pills
 
  2.9 (1.7) 
Alcohol use (per day)   1.7 (1.6) 
IDU (times use per month)   1.3 (1.3) 
Cannabis (times use per month)   2.1 (1.9) 
Note.  ODSP = Ontario Disability Support Program; CPP = Canadian Pension Plan; IDU = Injection Drug 
Use 
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Table 3 
Descriptive Information of Study Participants Identified as adherent and non-adherent to 
their prescribed HIV treatment regimens  
 HIV treatment adherence  
 Yes (n = 32)  No (n = 25)  
Variables n (%)  n (%) p-values 
Age, M (SD) 45.77 (7.54)  39.82 (10.54) .02 
Gender:    .47 
 Male 25 (78)  18 (72)  
 Female 7 (22)  7 (28)  
Ethnic Background:    .35 
 African 2 (6)  1 (4)  
 Caribbean 2 (6)  1 (4)  
 French-Canadian 4 (12)  2 (8)  
 Aboriginal/Other 3 (9)  1 (4)  
Birth Place:    .27 
 Inside Canada 15 (50)  15 (60)  
 Outside Canada 15 (50)  9 (38)  
In a relationship  16 (50)  11 (46)  
Education:    .26 
Less than High School 2 (6.3)  7 (28)  
High school or higher 29 (91)  18 (72)  
Income:  .44 
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Table 3 continued - Descriptive Information of Study Participants Identified as  
adherent and non-adherent to their prescribed HIV treatment regimens 
<20, 000 16 (52)  16 (70)  
20, 000-40, 000  6 (19)  3 (13)  
>40, 000 4 (13)  3 (13)  
Full-time/Part-time 10 (31)  6 (24) .67 
On government assistance 20 (62)  16 (64) .59 
Medical variables:     
 CD4 count cells/m
3
, M (SD) 352.34 (279.8)  384.16 (402.7) .48 
 Undetectable viral load 25 (83)  17 (81) .87 
 # of side effects, M (SD) 9.2 (5.3)  7.6 (4.9) .37 
Note. Significance test for frequency variables were conducted using chi-square analysis; t-test was 
conducted for continuous predictors; Yes = good HIV treatment adherence (CASE Adherence Index ≥ 11); 
No = poor HIV treatment adherence (CASE Adherence Index ≤ 10). 
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Side effects due to the HIV medications.  Participants were asked to indicate if 
they had experienced any HIV treatment-related side effects, and if yes, they were asked 
to indicate the severity of those symptoms (out of 7).  The most common side effect, as 
indicated by 82.5% of the participants (n = 47), was weakness, and the average severity 
of this side effect was 4.24 (SD = 1.99).  The most severe side effect (M = 4.63, SD = 
1.73) was trouble falling asleep, and 63.2% (n = 36) of the participants indicated that they 
had trouble falling asleep.  Table 4 lists all the identified HIV treatment-related side 
effects, their average severity level as indicated by the participants, and the relationship 
between the indicated side effects and HIV treatment adherence (CASE Adherence 
Index).  Headache severity was significantly correlated with HIV treatment adherence, in 
that the higher the severity of this HIV treatment-related side effect (i.e., headache) the 
greater the reduction in HIV-treatment adherence.   
Twenty-one participants (37.5%) indicated that their HIV treatment side effects 
were stopping them from doing their everyday activities.  Despite this high percentage 
according to the HIV-ASES scale, based on a measure of HIV treatment self-efficacy (i.e., 
perceived ability to be able to adhere to the HIV treatment despite obstacles), the 
participants' HIV treatment self-efficacy was very high.  The average score on the HIV-
ASES was 90.53 (SD = 24.55), and the scale ranged from 0 to 120, which indicated that 
the participants had high HIV treatment self-efficacy to adhere to their prescribed HIV 
treatments.  
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Table 4  
Side effects due to the HIV treatment, sorted by the most common to the least commonly 
reported side effect, correlated with HIV treatment adherence 
HIV treatment side effect n % M severity SD r 
Weakness (fatigue) 47 82.5 4.24 1.99 -.07 
Body Fat Changes 41 71.9 3.85 2.22 -.03 
Decreased Memory 40 70.2 3.44 2.06 -.10 
Night Sweats 38 66.7 3.57 2.18 -.30 
Trouble Falling Asleep 36 63.2 4.63 1.73 -.02 
Headaches 35 61.4 3.34 1.88 -.37
* 
Bodily Pain 35 61.4 4.47 2.18 .04 
Feeling Sad 33 57.9 3.37 2.11 -.21 
Diarrhea 31 54.4 3.52 1.77 -.09 
Dizziness 29 50.9 3.48 2.11 -.25 
Weight loss 29 50.9 3.14 1.98 -.24 
Sexual dysfunction 24 42.1 3.96 2.25 -.17 
Rash 24 42.1 2.50 1.64 .32 
Vomiting 20 35.1 3.10 2.31 -.32 
Fever  17 29.8 2.29 1.57 -.25 
Other:      
 Wasting disease 1 0.5 7 - - 
 Neuropathy 1 0.5 - - - 
Note. 
*
Correlation is significant at the 0.05 level (2-tailed), p < 0.05 
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Psychometric Properties of the Study Measures 
 Reliability Analyses.  Cronbach's Alpha was calculated on the nine main variable 
measures: the CASE Adherence Index (Mannheimer et al., 2006), the Health Care 
Climate Questionnaire (HCCQ; Williams et al., 1996), Internal Health Locus of Control 
(HLC), Chance HLC, Doctors HLC, and Others HLC subscales as part of the 
Multidimensional Health Locus of Control Scale (MHLC), the Treatment Self-Regulation 
Questionnaire (TSRQ; Williams et al., 1996), the HIV Treatment Knowledge Scale 
(Balfour et al., 2007), the HIV-Adherence Self-Efficacy Scale (HIV-ASES; Johnson et al., 
2007); the Hospital Anxiety and Depression Scale (HADS; Zigmond & Snaith, 1985); 
social support, and health care-related HIV stigma.  The results are summarized in Table 
5.  All self-report measures showed adequate ( > .7) to excellent ( > .9) internal 
consistency, with the exception of the CASE Adherence Index, HIV-treatment 
knowledge, Doctor, and Other HLOC.  The latter four measures had very low internal 
consistency, ranging from .32 to .58; these measures consisted of only three items, which 
was likely to have contributed to their low internal consistency.  Measures with low 
internal consistency can decrease the likelihood of finding a statistical difference, and 
thus increasing the risk of Type II error.  All the scales, however, were retained for the 
statistical analysis.  
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Table 5 
Reliability of the Study Measures  
Measure   N M SD Possible 
Range 
Actual 
Range 
# of 
items 
 
CASE Adherence Index Questionnaire 55 11.98 2.78 3-16 6-16 3 .52 
MHLC - C:        
 Internal HLC 55 20.90 6.60 6-36 6-36 6 .79 
 Chance HLC 53 16.34 6.37 6-36 6-31 6 .75 
 Doctor HLC 56 14.34 3.14 3-18 8-18 3 .58 
 Other HLC 56 10.12 3.11 3-18 3-16 3 .32 
HCCQ 57 86.06 21.76 15-105 15-105 15 .94 
Social Support 51 25.04 4.71 8-32 10-32 8 .80 
Health care-related stigma 53 28.52 9.80 10-50 10-50 10 .86 
HIV-ASES 54 90.53 24.55 0-120 21-120 12 .91 
HIV Treatment Knowledge Scale 55 18.48 2.31 0-21 8-21 21 .46 
TSRQ 52 66.88 16.18 15-105 15-102 15 .83 
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Table 5 continued - Reliability of the Study Measures  
HADS:        
 HADS-A 55 8.47 4.04 0-21 2-17 7 .68 
 HADS-D 55 6.79 5.48 0-21 0-20 7 .87 
Note.  = Internal consistency, Alpha coefficient; HLC = Health Locus of Control; MHC-C = Multidimensional Health Locus of Control Scale; HCCQ 
= Health Care Climate Questionnaire; HIV-ASES = HIV-Adherence Self-Efficacy Scale; TSRQ = Treatment Self-Regulation Questionnaire; HADS = 
Hospital Anxiety and Depression Scale; HADS-A = Hospital Anxiety and Depression Scale - Anxiety subscale; HADS-D = Hospital Anxiety and 
Depression Scale - Depression subscale.  
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Correlational Analyses 
 Relationships between the predictor and demographic variables and HIV 
treatment adherence.  Two-tailed Pearson product-moment correlations were used to 
examine the relationship among the demographic variables, medical characteristics, the 
predictor variables (MHLC, HCCQ, Health care-related Stigma, Social Support, HIV 
Treatment Knowledge Scale, and HIV-ASES), and HIV treatment adherence (CASE 
Adherence Index; Table 6).  Age was positively correlated with HIV treatment adherence, 
r(51) = .31, p = .02; that is, the older sample of PLWH in this study had better adherence 
rates.  Perceived autonomy-supportive health care provider (HCCQ) was marginally 
associated with HIV treatment adherence, r(53) = .26, p = .05.  People who perceived 
that they had autonomy-supportive physicians had higher HIV treatment adherence 
scores.  Interestingly, people who perceived that their doctor had high influence on their 
health (i.e., high on Doctors HLOC) also had high scores on the CASE Adherence Index 
(HIV treatment adherence), r(53) = .31, p = .02.  Lastly, a medium effect was found 
between HIV treatment self-efficacy (HIV-ASES) and HIV treatment adherence, r(52) 
= .40, p = .003, which indicated that as a person's efficacy to adhere to the HIV-treatment 
increased, their adherence to the HIV treatment also increased.  
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Table 6  
Pearson Correlations between HIV treatment Adherence and Demographics, Medical 
characteristics, and the Predictor Variables 
Characteristics R p-value n 
Age .31
* 
.02
 
53 
Gender .16 .24 55 
Education level .18 .09 55 
In a relationship  .07 .60 55 
Employment status:    
 Full/Part time working 11 .43 55 
 On government assistance -.07 .59 55 
Alcohol and Substance Use:    
 Alcohol consumption (daily) .05 .74 54 
 IDU use (monthly) .07 .59 55 
 Cannabis use (monthly) -.25 .06 55 
Medical Characteristics:    
 Undetectable Viral load -10 .47 50 
 CD4 count cell count -.06 .65 55 
 Daily medication intake -.07 .64 51 
 Number of side effects .12 .40 55 
 Side effects interfere with daily activities .23 .09 55 
I was involved in the decision to begin the 
HIV treatment 
-.02 .90 57 
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Table 6 continued - Pearson Correlations between HIV treatment Adherence and 
Demographics, Medical characteristics, and the Predictor Variables 
HIV medications are necessary .12 .38 54 
TSRQ (intrinsic motivation) .12 .38 51 
HCCQ (autonomy-supportive physician) .26
* 
.05
 
55 
MHLC-C:   
 Internal HLC .22 .11 54 
 Chance HLC -.05 .73 52 
 Doctors HLC .31
* 
.02
 
55 
 Others HLC .05 .72 55 
Social Support .09 .53 50 
Health care-related stigma -.11 .42 52 
HIV Treatment Knowledge Scale -.13 .36 54 
HIV-ASES (HIV treatment self-efficacy) .40
** 
.003
 
54 
HADS-A  .02 .86 54 
HADS-D -.14 .15 54 
Note. 
*
Correlation is significant at the 0.05 level (2-tailed),  p < 0.05; 
** 
Correlation is significant at the 0.01 
level (2-tailed). p < 0.01; TSRQ = Treatment Self-Regulation Questionnaire; HCCQ = Health Care Climate 
Questionnaire; MHLC-C = Multidimensional Health Locus of Control scale-form C; HLC = Health Locus 
of Control; HIV-ASES = HIV-Adherence Self-Efficacy Scale; HADS-A = Hospital Anxiety Depression 
Scale - Anxiety subscale; HADS-D = Hospital Anxiety Depression Scale - Depression subscale. 
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 Relationships among the predictor variables only.  An examination of Table 1 
revealed several significant relationships amongst the predictor variables.  Specifically, 
HCCQ (autonomy-supportive physician) was positively correlated with Doctors HLOC, 
r(54) = .34, p < .01, and HIV-ASES (HIV treatment self-efficacy), r(52) = .43, p < .01.  
That is, participants who perceived having an autonomy-supportive physician also 
believed that their physician had a lot of control over their health, but they also had high 
HIV treatment self-efficacy to take their HIV treatment despite obstacles.  Furthermore, 
the HCCQ was negatively correlated with the following variables: health care-related 
stigma, r(51) = .44, p < .01, depression symptoms, r(53) = -.46, p < .01, and anxiety 
symptoms, r(53) = -.27, p < .05; indicating that people who perceived having an 
autonomy-supportive physician also perceived less HIV-related stigma in health care 
settings, had lower depressive symptoms, and lower anxiety.   
 Internal HLOC was positively correlated with the other MHLC-C subscales; 
specifically, it was significantly and positively associated with Chance HLOC, r(51) 
= .46, p < .01, Doctors HLOC, r(53) = .51, p < .01, and others HLOC, r(53) = .35, p < .01.   
 Chance HLOC was negatively correlated with HIV treatment knowledge, r(49) = 
-.31, p < .05 and HIV treatment self-efficacy, r(49) = -.34, p < .05.  This indicated that 
people who scored high on Chance HLOC, that is, those who believed that aspects 
outside of their control influenced their health, had lower HIV-related treatment 
knowledge and lower self-efficacy to adhere to the HIV-treatment.  Chance HLOC and 
Other HLOC were highly and positively correlated with each other, r(51) = .67, p < .01.   
 Doctors HLOC scale was positively associated with HIV-ASES (HIV treatment 
self-efficacy), r(52) = .34, p < .05, and negatively correlated with symptoms of 
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depression, r(53) = -.35, p < .01; meaning that participants who believed that their 
physicians had control of their health, also had higher HIV treatment self-efficacy, and 
lower depression scores.  
 HIV-related stigma in health care settings was negatively associated with 
perceived social support, r(48) = -.43, p < .01; that is, greater HIV-related stigma 
measure was associated with lower perceived social support.  Health care-related stigma 
was positively associated with depression, r(49) = .36, p < .05, and anxiety r(49) = .39, p 
< .05.   
 Social support was positively correlated with HIV-ASES, r(47) = .29, p < .05, 
suggesting that perceptions of high social support were associated with high self-efficacy 
to adhere to the HIV treatment despite difficulties with the treatment.  Low scores on 
social support, on the other hand, were associated with higher levels of depression, r(48) 
= -.54, p < .05, and anxiety, r(48) = -.53, p < .01.   
 Symptoms of depression negatively correlated with the HIV-ASES scale (HIV 
treatment self-efficacy), r(51) = -.34, p < .05, suggesting that people who had higher 
depressive symptoms were more likely to have low HIV treatment self-efficacy scores.  
Lastly, symptoms of anxiety (HADS-A) and depression (HADS-D) were highly and 
positively correlated, r(53) = .62, p < .01, suggesting that these conditions tended to be 
co-morbid in this sample of PLWH.  
Analyses Related to the Main Hypotheses 
 Hypotheses 1a to 1e stated that intrinsic motivation (TSRQ) would mediate 
the relationship between autonomy (Internal, Chance, Doctors, and Others HLOC, 
and HCCQ) and HIV treatment adherence (CASE Adherence Index).  Figures 3 to 7 
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illustrate these mediations.  The unstandardized regression coefficients (B) were used in 
the interpretation of the results.  For HIV treatment adherence and autonomy, significant 
mediators did not emerge.     
The mediating effect of intrinsic motivation on the relationship between Internal 
HLOC and HIV treatment adherence was not supported, as the estimate of the indirect 
effect was not significant, B = .01, 95% CI [-0.01, 0.05], and the relationship between 
Internal HLOC and CASE Adherence Index was also not significant, B = .06, p = .24.  
The remaining paths indicated that Internal HLOC did not have an effect on intrinsic 
motivation, B = .47, p = .13.  Lastly, intrinsic motivation was not associated with HIV 
treatment adherence scores, after controlling for Internal HLOC, B = .02, p = .43, as 
shown in Figure 3. 
 
Figure 3. The mediating effect of Intrinsic motivation on the relationship between 
Internal HLOC and HIV treatment adherence. 
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The unstandardized regression coefficients are illustrated.  This mediation was not 
supported.  
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The mediating effect of intrinsic motivation on the relationship between Chance 
HLOC and HIV treatment adherence is illustrated in Figure 4.  This mediation was not 
supported, as the relationship between Chance HLOC and CASE Adherence Index was 
not significant, B = -.02, p = .67, and the estimate of the indirect effect was also not 
significant, B = .01, 95% CI [-0.02, 0.04].  The remaining paths indicated that Chance 
HLOC did not have an effect on intrinsic motivation, B = .46, p = .14.  Lastly, intrinsic 
motivation was not related to HIV treatment adherence scores, even after controlling for 
Chance HLOC, B = -.03, p = .59.   
 
Figure 4. The mediating effect of intrinsic motivation on the relationship between Chance 
HLOC and HIV treatment adherence 
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The unstandardized regression coefficients are illustrated.  This mediation was not 
supported. 
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The mediating effect of intrinsic motivation on the relationship between Doctors 
HLOC and HIV treatment adherence was not supported (see Figure 5).  The relationship 
between Doctors HLOC and CASE Adherence Index was not significant, B = .17, p = .16 
and, the estimate of the indirect effect was also not significant, B = .02, 95% CI [-0.05, 
0.13].  The remaining paths indicated that Doctor HLOC had a significant effect on 
intrinsic motivation, B = 1.14, p = .03.  Lastly, intrinsic motivation was not associated 
with HIV treatment adherence scores, even after controlling for Doctors HLOC, B = .01, 
p = .63.   
 
Figure 5. The mediating effect of intrinsic motivation on the relationship between 
Doctors HLOC and HIV treatment adherence 
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The unstandardized regression coefficients are illustrated.  This mediation was not 
supported. 
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The mediating effect of intrinsic motivation on the relationship between Others 
HLOC and HIV treatment adherence was also not supported.  Others HLOC was not 
significantly associated with HIV treatment adherence, B = -.01, p = .96.  In addition, the 
bootstrapping results indicated a non-significant estimate of the indirect effect, B = .05, 
95% CI [-0.05, 0.17].  However, Others HLOC and intrinsic motivation were 
significantly associated, B = 1.74, p = .001.  Lastly, intrinsic motivation was not related 
to HIV treatment adherence scores, even after accounting for Others HLOC, B = .03, p 
= .34.  Figure 6 illustrates this mediation analysis. 
 
Figure 6. The mediating effect of intrinsic motivation on the relationship between Others 
HLC and HIV treatment adherence 
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The unstandardized regression coefficients are illustrated.  This mediation was not 
supported.  
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The relationship between HCCQ and HIV treatment adherence was not significant, 
B = .01, p = .35, and the estimate of the indirect effect was also not significant, B = .005, 
95% CI [-0.01, 0.01], indicating that intrinsic motivation did not have a mediating effect 
on the relationship between HCCQ and HIV treatment adherence.  HCCQ was also not 
significantly associated with intrinsic motivation, B = .02, p = .83.  Lastly, intrinsic 
motivation was not associated with HIV treatment adherence scores, even after 
controlling for HCCQ, B = .02, p = .40.  Refer to Figure 7 for this mediation.  
 
Figure 7. The mediating effect of intrinsic motivation on the relationship between HCCQ 
and HIV treatment 
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The unstandardized regression coefficients are illustrated.  This mediation was not 
supported.  
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Hypotheses 2a and 2b stated that intrinsic motivation (TSRQ) would mediate the 
relationship between relatedness (health care-related stigma and social support) and 
HIV treatment adherence (CASE Adherence Index).  Figures 8 and 9 illustrate these 
mediations.  The unstandardized regression coefficients (B) were used in the 
interpretation of the results.  For HIV treatment adherence and relatedness significant 
mediators did not emerge.     
The mediating effect of intrinsic motivation on the relationship between health 
care-related stigma and HIV treatment adherence was not supported (see Figure 8).  
Specifically, the estimate of the indirect effect was not statistically significant, B = -.01, 
95% CI [-.03, .01], and the relationship between health care-related stigma and CASE 
Adherence Index was also not supported, B = -.02, p = .68.  Health care-related stigma 
was also not related to intrinsic motivation, B = -.23, p = .30.  Even after controlling for 
health care-related stigma, intrinsic motivation was not associated with HIV treatment 
adherence, B = .02, p = .34.   
Figure 8. The mediating effect of intrinsic motivation on the relationship between Health 
Care-related Stigma and HIV treatment adherence (CASE Adherence Index). 
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The unstandardized regression coefficients are illustrated.  This mediation was not 
supported.  
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Figure 9 illustrates the mediating effect of intrinsic motivation on the relationship 
between social support and HIV treatment adherence.  This mediation was not supported.  
The estimate of the indirect effect was not significant B = -.02, 95% CI [-0.06, 0.02], and 
the relationship between social support and HIV treatment adherence was also not 
significant, B = .03, p = .69.  Intrinsic motivation was not associated with HIV treatment 
adherence scores, even after controlling for social support, B = .03, p = .30.  The 
remaining paths indicated that social support did not have an effect on intrinsic 
motivation, B = -.10, p = .82.   
 
Figure 9. The mediating effect of intrinsic motivation on the relationship between Social 
Support and HIV treatment adherence (CASE Adherence Index). 
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The unstandardized regression coefficients are illustrated.  This mediation was not 
supported.  
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Hypotheses 3a and 3b stated that intrinsic motivation would mediate the 
relationship between competence (HIV treatment knowledge and HIV-treatment 
self-efficacy) and HIV treatment adherence.  Figures 10 and 11 illustrate these 
mediations.  The unstandardized regression coefficients (B) were used in the 
interpretation of the findings.  For HIV treatment adherence and competence, significant 
mediators did not emerge.     
 The mediating effect of intrinsic motivation on the relationship between HIV 
treatment knowledge and HIV treatment adherence was not supported, as the estimate of 
the indirect effect was not significant B = -.02, 95% CI [-0.10, 0.05].  The relationship 
between HIV treatment knowledge and CASE Adherence Index was also not significant, 
B = -.24, p = .23.  The remaining paths indicated that HIV treatment knowledge did not 
have an effect on intrinsic motivation, B = -.78, p = .47.  Lastly, intrinsic motivation was 
not associated with high HIV treatment adherence scores, even after controlling for HIV 
treatment knowledge, B = .02, p = .43.  Refer to Figure 10. 
 
Figure 10. The mediating effect of intrinsic motivation on the relationship between HIV 
treatment knowledge and HIV-treatment adherence 
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The unstandardized regression coefficients are illustrated.  This mediation was not 
supported.  
The mediating effect of intrinsic motivation on the relationship between HIV 
treatment self-efficacy and HIV treatment adherence was also not supported because the 
estimate of the indirect effect was not significant B = .01, 95% CI [-0.01, 0.01].  This 
mediation is illustrated in Figure 11.  HIV treatment self-efficacy, however, was 
statistically significant with HIV treatment adherence, B = .02, p = .02.  The remaining 
paths of this model were not significant.  Specifically, HIV treatment self-efficacy was 
not related to intrinsic motivation, B = .11, p = .18,and even after controlling for HIV 
treatment self-efficacy, intrinsic motivation was not associated with HIV treatment 
adherence scores, B = .02, p = .50.   
   
Figure 11. The mediating effect of intrinsic motivation on the relationship between HIV 
treatment self-efficacy and HIV treatment adherence 
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The unstandardized regression coefficients are illustrated.  This mediation was not 
supported.  
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Ancillary Analyses: HIV Treatment Self-efficacy  
 The objective of the ancillary analyses was to gain a more comprehensive 
understanding of the relationship between HIV treatment self-efficacy and HIV treatment 
adherence.  In the Pearson product-moment correlations, HIV treatment self-efficacy was 
significantly and positively correlated with HIV treatment adherence; therefore, in an aim 
to further understand this relationship, several ancillary mediation analyses were tested.  
Particularly, HIV treatment self-efficacy was predicted to be a mediator between the 
predictor variables, tested as part of the main hypothesis, and HIV treatment adherence.  
The results indicated only one indirect effect:  Chance HLOC significantly predicted HIV 
treatment self-efficacy, B = -1.29, p = .01, and in turn HIV treatment self-efficacy was 
significantly associated with HIV treatment adherence, even after controlling for Chance 
HLOC, B = .05, p < .001, and this indirect effect was statistically significant, B = -.07, 
95% CI [-0.15, -0.01].  That is, people who perceived that others had control over their 
health, had low HIV treatment self-efficacy; however, high scores on the self-efficacy 
scale was associated with better HIV treatment adherence rates, see Figure 12. 
 
Figure 12. An indirect effect between Chance HLC and HIV treatment adherence, 
through HIV treatment self-efficacy. 
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The unstandardized regression (B) coefficients are illustrated.  This indirect effect was 
supported.  
Chance LOC HIV treatment 
self-efficacy 
HIV treatment 
adherence 
PSYCHOSOCIAL INFLUENCES ON HIV TREATMENT ADHERENCE                 80 
 
Phase II: Semi-structured Interviews (Qualitative Data) 
 Each interview was audio recorded and transcribed.  The transcriptions were read 
and quotes were extracted that best supported the constructs investigated throughout the 
present study, that is autonomy (autonomy-supportive physicians and health locus of 
control), relatedness (social support and stigma), and competence (HIV treatment 
knowledge and HIV treatment self-efficacy).  Ellipsis (…) indicated pauses in the 
participants' responses.  
Descriptive Information of the Participants  
 Eleven participants were interviewed for the second phase of this study.  Seven 
males and 4 females participated in the face-to-face semi-structured interviews.  Three of 
the participants (2 males and 1 female) were recruited from AIDS Committee of Windsor 
(Windsor, ON), and the remaining 8 participants (5 males, 3 females) were clients of Fife 
House Inc. (Toronto, ON).  Fife House offers short and long-term housing and it is likely 
that without the support of this organization, the clients of Fife House would be at risk for 
being homeless.  The majority of the participants interviewed were clients of Fife House 
and they were a unique subpopulation of PLWH because they required housing, as 
compared to the clients recruited from AIDS Committee of Windsor and PLWH who 
may not require housing services.  Applying the current findings to other populations of 
PLWH should be done with caution, as this sample is not representative of the general 
population of PLWH.  This is important to note because clients of organizations that offer 
housing are likely living on their own, as most housing services provide single rooms 
which exclude families and even couples.  Therefore, it is possible that the participants 
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recruited from Fife House differed in their social support system as compared to 
participants not living in such housing organizations, for example.    
 Demographic description of participants. Participants ranged in age from 30 to 
59 years (M = 37.9, SD = 7.7).  Average time since HIV diagnosis for this group was 13.9 
years (SD = 6.8), and on average, the participants had been on HIV treatment for 10.9 
years (SD = 8.3).   
The HIV Treatment Regimen 
 Two out of the 11 PLWH interviewed indicated that they sometimes forgot to 
take their HIV treatment; therefore, Phase II found18% non-adherence rate among this 
sample of PLWH.  Interviewees were asked to indicate how many HIV-related pills per 
day they had to take.  On average, people indicated that they take 2 pills per day (SD = 
1.09), once a day.  Everyone, with the exception of one person, expressed that their HIV 
treatment regimen was very easy.  The one individual, who found his HIV treatment to be 
complex and difficult, said the following:  
 They [the HIV treatment regimen] are really cumbersome to take actually, and it 
 takes a lot of organization because I have to take it a certain time - always, and 
 one of the ARVs [Antiretrovirals] that I take is [sic] - has to be refrigerated - so I 
 can't put it in a blister pack that would make it simpler. (Male, on HIV treatment 
 for 13 years) 
 
This individual indicated that he has to take the HIV treatment four times per day and 
because the drug needs to be refrigerated, he is bound to be near his home.   
 Therefore, with the exclusion of one male participant, as a whole, the sample of 
PLWH in this study expressed that they did not have complicated HIV treatment 
regimens.  Two female participants conveyed throughout the interview that their HIV 
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treatment schedule had gotten much simpler, as compared to the treatment that they had 
to take in the initial years of their HIV diagnoses, 20 and 13 years ago.   
 Importance of adhering to the HIV-treatment regimen.  Knowing the 
importance of adhering to the HIV treatment schedule was clearly acknowledged by all 
of the participants who took part in these interviews.  Specifically, participants' were 
asked, "Do you think it's important to adhere to your HIV-treatment regimen?", and 
100% (11 out 11) people indicated that it is very important to adhere to the prescribed 
regimen.  Therefore, everyone agreed that adhering to the prescribed HIV treatment was 
important for his or her health and for the effectiveness of the HIV treatment.  One 
participant had the following to say, "Yes it is very, very important [to adhere to the HIV 
treatment] because I am already resistant to one set of meds, so in order to make sure that 
I don‟t build new resistance [sic]."  (Male, on HIV treatment for 13 years).   
 Difficulties adhering to HIV treatment regimen.  Participants were then asked 
if they found adhering to the HIV treatment to be difficult.  Three out of the 11 
interviewed (27%), all males, expressed that it was difficult for them to adhere to their 
HIV treatment regimen.  On average these three individuals had been on HIV treatment 
for 7 years (SD = 6.56).  One of the respondents found it hard because of their 
complicated HIV treatment regimen.   
 The second interviewee found the regimen difficult to take because he would 
forget to take his medication.  Specifically, he said, "I have difficulties remembering to 
take my meds daily. Like when I am supposed to take them, it's like yesterday I forgot, 
today I took them".  When this participant was further prompted he said, "it's just 
sometimes I look at them, and I am like I don‟t want to take them."  (Male, on HIV 
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treatment for 10 years).  It was unclear, therefore, whether this male participant did not 
want to take them, or he did not take them because he simply forgot about his HIV 
treatment schedule.  He was asked if he was experiencing any side effects and he shared 
that he was not.   
 The third respondent expressed difficulties with adhering to his HIV treatment 
regimen because of other medical conditions that he also had.  Specifically, he stated that 
he had drug addiction issues and that he had severe depression.  As a result, he found that 
these two conditions interfered with his prescribed HIV treatment schedule.  This 
respondent had the following to say: 
 I have had some other issues - health wise [he later stated these health issues are 
 drug addiction and depression] that have interfered with the meds … missed 
 couple of doses… I was always told that if you missed a day or two it's not good 
 because it compromised the immune system.  So I would stop after missing a 
 couple of days for you know 4 months and then I would go see him [the family 
 physician] and tell him.  (Male, on HIV treatment for 8 years).  
 
 As the interview progressed, this participant shared that because of his drug 
addiction he would sometimes leave the house for days to join friends and do drugs, 
without taking the HIV treatment with him.  Furthermore, he also partially attributed his 
difficulties with the HIV treatment to the severe depression that he had been experiencing 
for the past few years.  When this respondent was asked whether he felt that his drug 
addiction and depression influenced his HIV treatment adherence, he firmly agreed, and 
stated that: 
 If I run out of them [the HIV treatment medication] I am usually too depressed to 
 go get  them from the pharmacy ... The depression really pulled me into some 
 weird places  because I am an intelligent man, and I know what I need to do 
 [related to staying healthy and taking the HIV medication], but I was pretty 
 immobilized from it [the depression]. 
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This respondent was aware that it is dangerous for his health to miss doses of his HIV 
treatment.  This participant clearly identified that his drug addiction and depression were 
barriers to his successful HIV treatment adherence.  He articulated throughout the 
interview that he had repeatedly requested that his family physician, who was also his 
HIV specialist, refer him to a psychiatrist.  The respondent said that his physician would 
not refer him unless he sorted out his addiction issues.  This point is later revisited during 
a more comprehensive discussion on quality of health care.    
 Therefore, from the three male interviewees it can be noted that a demanding and 
complex HIV treatment regimen, forgetting the HIV treatment and co-morbid health 
conditions could all make the HIV treatment regimen more difficult to comply with.  
However, for the respondent with the difficult HIV treatment plan, despite the complex 
regimen, he felt that the regimen did not influence his HIV treatment adherence in a 
negative way.  For the respondent who had difficulties remembering to take his HIV 
medications on time, it seemed that this difficulty contributed to lack of HIV treatment 
adherence.  Lastly, the participant who indicated that his drug addictions and depression 
made his HIV treatment difficult, also indicated that this was a contributing factor for his 
poor HIV treatment adherence.    
 HIV treatment related side effects.  When participants were asked whether they 
were experiencing any HIV treatment side effects, 36% (2 males and 2 females) of the 
respondents indicated that they had side effects as a result of the HIV treatment.  One 
participant had the following to say, "Some mornings I'll wake up and I'll throw up, I 
can't eat. Like I have no appetite … I can go for days without feeling hungry." (Female, 
on HIV treatment for 8 years).   
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People indicated a number of other side effects, such as parts of the body swelling, losing 
fat in some parts of the body, heart palpitations, nausea, exhaustion, and diarrhea.   
People's Perceptions of Autonomy 
 Health locus of control.  At the beginning of each interview, participants were 
asked whether they thought they had control over their health.  This question was asked 
to better understand the extent to which participants believed that they could exercise 
control over their health.  Eighty percent of the people (8 out of the 10 people) said that 
they perceived that they had control over their physical health.  One person did not fully 
understand the question, even after they were provided with prompts and explanations of 
health locus of control.  The remaining two individuals (1 male and 1 female) trusted that 
they had some control over their health, but suggested that their health also depended on 
their physician, and/or HIV specialist.  For example,  
 I can say that I am in control of my health, because it's my responsibility to take 
 the medication it's my responsibility to report to the doctor when I am sick, 
 but I don‟t have the control and knowledge on what to take because that is 
 determined by the professionals. (Female, on HIV treatment for 5 years).  
  
This individual further explained that if she was a physician then she would have a lot 
more control over her health, but because she did not have the medical knowledge, she 
was limited in her ability to be in full control of her physical health.  
 Autonomy-supportive physician.  Participants were asked if it was important for 
them to have a doctor who encouraged them to ask questions related to their health, and if 
it was important for them to be involved, that is to have some control over their HIV 
treatment.  Ten respondents (91%) said that having a doctor who encouraged them to ask 
question was very important to them.  One male participant until recently did not express 
interest in having a doctor who would encourage him to be more active towards his 
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health.  However, since 2 months prior, he had started to become more interested in his 
health and wished to be more involved with decisions regarding his treatment, and health 
in general.  He stated the following, "No and I never really have [wanted his doctor to 
encourage him to ask questions].  So I almost trust what he says … Although, that has 
sort of changed recently.  I've been a little more interested to see what is happening."  
(Male, on HIV treatment for 8 years).   
 When this individual was prompted with the following question: Given that you 
started to be more interested, does your doctor make the time to answer your questions?  
This male respondent answered, "No I find him very surface, he is misdiagnosed many 
times, or he is taken the time  [took a long time] to actually diagnose something, elements 
of something, which sounds  like its should've been pretty obvious to me, I feel a little 
neglected sometimes - yes."  Unfortunately, this response was echoed by 3 more people 
(27%).  That is, these respondents also indicated that they did not have an autonomy-
supportive physician.  Two of these participants stated that they did not spend enough 
time with their physicians, even when they had scheduled an appointment in advance.  
For example, "I would like that [to spend more time with my doctor] but the doctor that I 
have is pretty busy and has a lot of clients, so I do feel little pressed even when I have an 
appointment with him". (Male, on HIV treatment for 13 years).  
 The third respondent stated that he did not have a physician who encouraged him 
to ask questions, but he was also not interested in having such a relationship with his 
practitioner.  This respondent expressed that he had complete trust in his physician's 
decision concerning his health.  
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 When these individuals were asked if they thought that their physicians' busy 
schedules influenced their ability to properly take their HIV medication, they indicated 
that it was not related - If they had questions, they would ask them anyway.   
Accounts Related to Relatedness (Social Support and Experienced Health Care-
related Stigma). 
 Participants were asked questions pertaining to their level of perceived social 
support from family members and friends.  In addition, participants were also asked if 
they perceived that the health care system was free of HIV-related stigma, and whether 
health care providers were non-judgmental and helpful.   
 Social support.  Due to time constraint two people were not asked whether they 
had the support of family members and friends.  In addition, one man indicated that he 
has lived on the streets for the past 15 years, and he did not give a clear answer of the 
extent to which he felt that he had the support of family or friends.  From the eight 
remaining people who answered this question, 4 respondents (3 female and 1 male) stated 
that they did not have the support from any family member.  For instance, one responded 
shared that,  
 Actually, my parents have both passed away.  Since I found out I told my brother 
 and my family right away, that I was HIV.  My brother never spoke to me from 
 that day on. And I tried and until today he will not speak to me. I don‟t know 
 where he is, what he is doing, and I don‟t try anymore.  (Female, on HIV 
 treatment for 20 years) 
 
 Another participant shared that, "not too much of family because I have been 
away from my family for quite a while." (Male, on HIV treatment for 3 years).   
 The remaining 4 individuals (1 female and 3 males) indicated that they had social 
support only from some family members.  When asked if having the support of family 
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members helped with regularly taking the HIV treatment, some indicated that it did help.  
For example, one male participant shared the following: 
 She knows [his fiancé] how important it is, you know what I mean. She doesn‟t 
 want me to see me get sick.  I think about it, and I know you don‟t want me to get 
 sick, so I am going to take my meds.  (Male, on HIV treatment for 10 years)    
This respondent shared that his fiancé was an effective motivator for him to take his 
medication daily.  In addition, his fiancé often reminded him to take his pills, because he 
indicated that he was forgetful.  
 All eight individuals identified that they had some social support either from 
friends, or from peer support networks (e.g., Hepatitis C co-infected group).  Although 
everyone expressed that they had a support network, generally it had not been easy to 
disclose their HIV-status to friends.  One female participant shared her deep feelings 
about some of the hurt that she experienced from friends, because of her HIV diagnosis.  
She said,  
 You know, who would want this? You know I am still human, I am still me, there 
 is still more to me than I am HIV+, that‟s just something that happened, you know.  
 I am still smart, I am still funny, I am out going I am a good person to talk to, 
 I am a good listener, there is so many qualities to me but it's just that when 
 people hear HIV, next to my [sic], that's just the first thing that come up, and 
 they forget the [sic], and is tough [started crying].  I have lost so many friends 
 because I have tried to be honest with them, and it's  tough, it's tough, I am still the 
 same person, I didn‟t ask for this.  This choice was made for me, you know 
 who would want this? I am sorry [crying].  (Female, on HIV treatment for 6 
 years). 
 
 Although not everyone shared the same experiences, it was clear from the 
interviews that people had been disappointed, hurt, and lost friendships because of their 
HIV status.  
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 HIV-stigma in health care settings.  Participants were asked the following 2 
questions pertaining to health care-related stigma: 1) "Have you experienced any HIV-
related stigma, or discrimination, from your family physician, or HIV specialist?” and 2) 
"Have you experienced any HIV-related stigma, or discrimination, from any other health 
care provider (i.e., doctors in a hospital, nurses, dentists, any health care-related 
provider)?" 
 Perceived stigma from family physicians, or HIV specialists, did not emerge.  
That is, everyone (n = 11) was able to agree that they had never experienced stigma nor 
discrimination from their general practitioner, and/or their HIV specialist.  For instance, 
one female participant shared the following, "I adore my general practitioner … my 
general practitioner is very, very nice and treats me you know as I wasn‟t HIV-positive."  
(Female, on HIV treatment for 5 years) 
 A clear distinction should be made, however: although stigma was not specifically 
reported, this was not indicative that everyone was completely happy with the services 
that they received from their family physician, or from their HIV specialists.  Some 
people found their HIV-specialist, or family physician to be non-helpful or arrogant.  For 
instance, "I adore my GP, and I think my HIV specialist is a pompous jackass, but that's a 
whole another story.  He thinks he knows it all".  (Female, on HIV treatment for 6 years) 
Overall, however, people indicated that their family physicians, or HIV specialist, were 
very supportive, helpful, and non-judgmental towards them. 
 Regarding perceptions of stigma in health care settings, 6 of the respondents (1 
female and 5 males) had very strong reactions against hospital staff, particularly nurses, 
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and one psychiatrist.  A male participant who had a negative experience with a 
psychiatrist shared this:  
 I also have psychological problems, so basically I was … I met the doctor there 
 and she was a relatively new doctor there and the experience that I had …  she 
 wasn‟t aware that I was HIV+ because I'm also paranoid-schizophrenic and that‟s 
 why she was seeing me, she was seeing me for mental but she and I shook hands 
 and sat down and then when I told her that I was HIV+ she looked afraid and ran 
 out of the room, and ran to the bathroom - I guess to wash her hands.  But it was 
 the way that she reacted to that information that really, really made me feel down 
 on myself.  (Male, on HIV treatment for 13 years). 
 
 Another respondent was staying at a downtown Toronto hospital because he 
required a surgery to repair damaged veins in his arm, because of injection drug use.  The 
nurses at the hospital made him feel unworthy, and he had the following to share, "I was 
treated [in the hospital] like dirt actually.  Just a junkie anyway sort of thing.  It was 
really kind of weird, weird thing because it's not what I am anyway."  On the positive 
side, however, he had the following to say, "The doctor [his surgeon] was great 
though … He was really good.  The other ones were afraid to touch me and it was weird."  
During the interview, this man was asked to describe a particular experience that he had 
during his 5-day stay at the hospital, and he shared the following,   
 You know, I don‟t know if they meant to but I remember when I was in there … 
 and my IV kept blocking and this big Middle Eastern nurse would come and 
 say 'it's too bad', and really pound it [the IV needle], it really was to say that‟s 
 what you get, but it was extremely painful and she really wouldn‟t care. I was 
 trying to make excuses why it has been this way … maybe I should stop and why 
 they have not been really helpful" (male,  on HIV treatment for 8 years).   
 
This respondent was not only emotionally hurt by being treated like a 'junkie' but also he 
was physically hurt because of the insensitive health care provision.  He has tried to bring 
a meaning to these negative experiences, by repeatedly stating that he was not sure why 
he has been treated this way. 
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On a similar note, another person had the following to say,  
 They wouldn‟t do nothing for me. I would say, excuse me can I get a glass of 
 water, they would say 'get it yourself'.  I would say 'excuse me', they would 
 say 'shut up, leave me alone'. No they wouldn‟t do nothing for me.  So I would 
 just take off on them all the time.  (Male, on HIV-treatment for 20 years) 
 
The respondents brought up other instances related to lack of sensitive health care 
provision, and another male participant shared the following,  
 Well… With some doctors or nurses, or whatever the thing is that they associate 
 you with being a junkie or homosexual.  You know they, so, they often think that 
 he is going to go and get high, so why should we treat him.  Not all of them but 
 that‟s how I think anyways. You know.  (Male, on HIV treatment for more than 
 25 years). 
 
This respondent also shared that in the 1980s, before people knew what the HIV virus 
was, it was understandable for people to have been afraid.  However, his disappointment 
with the health care system stemmed from the fact that today we know a lot more about 
the HIV virus and there is no excuse for people to be rude, judgmental, and 
discriminatory.   
 An instance of discrimination and lack of health care provision was shared by 
another male participant.  This person was admitted to a downtown Toronto hospital 
because he needed abdominal surgery.  He shared that he did not receive proper care at 
the hospital, because he was not given his HIV medication.  Typically, surgical 
procedures suppress the immune system (Newsholme, 2001), making it easier to get an 
infection, or have other complications; thus, it is crucial for PLWH not to miss their HIV 
treatment during such medical procedures.  Therefore, because of the importance of this 
issue he was deeply disturbed by the lack of actions to supply his medication, on the part 
of the health care providers.  He said,  
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 They [the nurses] gave me my medication for one day, and then the next day they 
 said 'we ran out, we only have 1 pill', so 1 out of the three, because it is 
 combination therapy that is necessary and it's not just one - but they gave me one 
 pill. … I don‟t know what was in the mind of the doctor, or whoever was in 
 control of that, but it really hurt me a lot because I was in a vulnerable position 
 anyway.  Because I don‟t have any family here and basically I didn‟t have 
 anybody to visit me, to overlook anything, so I was at the mercy of the doctors 
 and the nurses.  So basically I felt very vulnerable and I recovered  very quickly 
 from the exploratory surgery just to leave.  (Male, on HIV treatment for 13 years) 
 
 Another perspective on health care-related stigma was brought in by a female 
participant, raising an issue related to lack of sensitivity and ignorance among some of 
the hospital staff.  She said, 
 I think nurses need a sensitivity training where people with HIV are concerned.  
 For example, when I was pregnant, I needed to go to an OBGYN triage 
 because I thought I was going into labour prematurely, and the nurse there looked 
 at my chart and said 'How dare I bring a child into this world?', being that I am 
 HIV+.  And I looked at her and said 'how dare you to work in this department, 
 and not know that you have better chances of going and sleeping with 
 somebody and stand and contract HIV, than I do giving it to my child.  Did you 
 know that there's a 0.02% chance of transmission, from a mother to a child, 
 during labour and only during labour?  (Female, on HIV treatment for 8 years) 
 
This participant slightly understated the risk of HIV vertical transmission (i.e., mother to 
a child transmission).  In the literature the approximate risk for mother to child 
transmission (MTC) is reported to be less than 2% and this percentage is true if the 
mother started treatment in the early stages of her pregnancy, and it also depends on the 
mother's health at the time of her pregnancy (Cooper et al., 2002).  This participant was 
also incorrect to say that mother-to-child transmission can only occur during labour.  In 
fact, the HIV virus can be transmitted to the baby during pregnancy and breastfeeding as 
well.  Nevertheless, this was an important quote as it captured the negative health care 
related experiences that this woman has had because of her pregnancy.  She continued the 
conversation by sharing the following,  
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 So they make you feel like you are nothing, like you are worthless, they 
 stigmatize you like in front of you.  Like you know, hey [a lab technician would 
 say to another lab technician] 'can you give me those AIDS gloves' [meaning 
 double gloves], I don‟t need everyone to know that I am HIV+, I am very private 
 and I would like to keep it that way. 
 
 On the other hand, some participants indicated a better outlook on the health care 
system.  Five respondents did not have anything negative to comment about concerning 
their experiences with hospital staff or any other health care provider.  Out of these 5 
participants, 2 respondents (1 male and 1 female) do not go to hospitals because they are 
unhappy with the long wait times, and thus they prefer to wait until their family physician, 
or HIV specialist can attend them.  One participant had health care-related stigma 
experiences as a result of his mental health disorder, but never as a result of his HIV 
status.  Lastly, it was very encouraging to hear that the fifth female respondent, who had 
been living with HIV for 13 years, had never had a negative experience with hospital 
health care staff, dentists, nor pharmacists.  Specifically, she had the following to say, 
"I've never experienced that yet … thank God.  But I am hoping that they don‟t do that 
kind of thing." (Female, on HIV treatment for 7 months) 
 HIV-related stigma, unfortunately, exists but it was very encouraging to hear that 
of the 9 people who attended hospitals (out of the 11 interviewed), 3 of these participants 
had never experienced stigma or discrimination in health care settings.  The 6 
respondents who had experienced stigma were further asked if these negative experiences 
stopped them from going to the hospital and obtaining health care, or if they felt that the 
lack of health services had an influence on their HIV treatment regimen.  The general 
response was that it did not affect them.  For instance,  
 To be honest … I am prepared.  It doesn‟t dissuade me from going to the hospital.  
 All the stigma is basically other people's problem … not my problem, so I just let 
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 it pass over my head and focus on the, what I want in the moment.  (Male, on HIV 
 treatment for 13 years) 
 
 Despite the considerable anecdotal evidence of HIV-related stigma in health care 
settings, it was encouraging to hear that some of the participants were not compromising 
their health by avoiding health care services, in order to avoid the stigma and 
discrimination that evidently exists.  
Themes Related to Competence 
 The questions on competence were concerned with factors that may influence 
HIV treatment adherence, such as general knowledge related to the HIV treatment and 
perceived ability to be able to adhere to the HIV treatment despite obstacles. 
 HIV treatment Knowledge.  Specifically, the following question was asked in an 
attempt to gauge the participants' knowledge of how their HIV treatment works: "When 
your viral load is undetectable do you stop using your HIV medications?"  Two people 
were not asked this question because the interview was approaching one hour in length.  
From the 9 people asked, 8people firmly disagreed with the question, and indicated that 
they would not take a break from their HIV treatment based on their HIV viral load.  One 
interviewee said,  
 No. Yeah I am undetectable right now with the HIV and I am undetectable with 
 the Hep C, so as long as I keep taking the meds - I'll probably live for a long 
 time.  More than what I would've if I didn‟t start this treatment.  (Male, on  HIV 
 treatment for 3 years) 
 
Lastly, the one respondent who did not firmly disagree with the questions said, "Well it's 
up to my doctor" (female, on HIV treatment for 7 months) 
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 Based on the responses to the HIV treatment knowledge question, majority of the 
respondents were aware that HIV treatment medication breaks do not depend on their 
health status. 
 Self-efficacy to adhere to the HIV treatment.  Participants were also asked to 
share whether they perceived themselves to be able to adhere to their HIV treatment 
schedule even if it was interfering with their daily activities.  The majority of the 
participants indicated that they did not allow their daily activities to interfere with their 
HIV treatment regimen.  All of the participants (11 out of 11) interviewed stated that they 
took their pills despite their daily schedule.  Out of the 11, 8 said that their treatment did 
not interfere with their schedule at all, because they take the pills first thing in the 
morning.  Conversely, 3 participants (out of the 11), indicated that the treatment did 
interfere with their daily schedule, but that they took the medication anyway.  
Specifically, one male participant shared, "They interfere with my daily schedule, 
because there have been times when the pills feel almost like a hot flash. And you just 
want to puke, especially when you get too stressed  out, and there is a lot stress.  (Male, 
on HIV treatment for 3 years) 
 A male and a female respondent also said that the medication side effects 
interfered with their daily schedule.  For the male participant, however, his health was a 
priority and he indicated that he was adherent to his treatment schedule in order to stay 
healthy, because his CD4 cell count was very low.  The female participant, on the other 
hand, indicated that her children were a priority, above all her other daily activities, and 
in order to stay healthy for her children she adhered to her prescribed HIV treatment 
regimen.   
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Additional Themes that Emerged 
 Treating co-morbidities.  Although participants were not asked whether they had 
additional medical diagnoses, a few indicated multiple medical health conditions, in 
addition to their HIV-positive status.  Specifically, 1 male participant felt that it was 
important for him to share that he had been diagnosed with Hepatitis C and depression, 1 
male participant indicated Hepatitis C, and lastly another male participant shared that he 
had rapid-cycling bipolar.   
 When the participant diagnosed with Hepatitis C was asked if he received proper 
care for his co-existing conditions, he said,  
 It‟s a whole team of doctors constantly monitoring.  They constantly [sic] … if 
 you are open to them and you are showing that you want to be involved with your 
 health care they are going to be just as receptive and just as caring.  (Male, on 
 HIV treatment for 3 years) 
 
It was very encouraging to hear that some people were getting the required treatment that 
they needed and deserved. 
 Conversely, the male participant diagnosed with Hepatitis C and depression, 
shared that his health care treatment had been very negative.  This individual shared the 
following,  
 It took him [his physician] 3-4 months with the blood work to figure out that I 
 have Hep C first of all.  And the treatment actually causes - the Interferon 
 injection that I have to do once a week causes severe depression and he knew I 
 was susceptible.  And even after I was treated and you know went to and I  cried 
 in my bed … I only did 3 months out of a 9 month treatment that was proposed 
 for me.  (Male, on HIV treatment for 8 years) 
 
This participant continued the conversation and said the following: 
 This was 2 years ago. I was in my bed curled up crying for the next 3 months 
 before I went to the doctor and I said 'I guess I gotta [sic] get back on, I messed 
 up, I couldn‟t do it'.  And he goes [his physician] and he even said 'maybe we 
 should've put you on depression pills before you started since Interferon [the 
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 Hepatitis C treatment] causes  severe depression'.  So he missed a lot of things 
 along the way like he is not really … I am just like a number almost.  It just really 
 odd and you know the thing with Hepatitis C is that your liver enzymes are huge, 
 and mine were 3 times in a row and they went back to normal and they went huge 
 again.  So he couldn‟t figure out that it was my body trying to fight it - apparently 
 20% of the people that contract it don‟t really know because you can actually 
 fight it yourself … like why wouldn't you tell me this before. Whether I wanted to 
 or not [to hear about medical related issues] … stuff like that.  The depression 
 pills he should've know that for sure.  Since 2001 I've been on depression pills 
 really.  (Male, on HIV treatment for 8 years) 
 
Unfortunately, this person's Hepatitis C diagnosis took a long time to be identified.  The 
treatment for the Hepatitis C had long-term and very damaging effects on this person.  
For example, this participant cried for days from the severe depression and without the 
support of any health care providers.   
 For the male participant diagnosed with rapid cycling bipolar, he indicated that he 
had also been diagnosed with a series of other physical health conditions because of 
being severely physically abused by his former partner.  This person had knee and hip 
replacement surgery, and also as a result of the assault both of his ankles were shattered.  
This individual took 18 pills in the morning, 10 in the afternoon, and 14 at bedtime and 
only 2 pills were for his HIV.  When he was asked if he is receiving proper care for his 
medical conditions, he stated the following: 
 Yes … Yeah I don‟t have a regular psychologist [maybe he meant psychiatrist] 
 that I  see, but I do have one that I have been dealing with for the last 5 years, 
 through my family doctor.  And he has no room to take patients on a permanent 
 basis but if it comes to a point where we need to adjust my medication, or I am in 
 a crisis stage, he will take me on and see me for 3 months or 6 months, once 
 or twice a week if I need it.  (Male, on HIV treatment for 3 years) 
 
 Therefore, of the 3 individuals who shared that they had additional medical 
diagnoses, only 1 individual seemed to be receiving comprehensive health care for his co-
infection (Hepatitis C and HIV).  The individual diagnosed with rapid cycling bipolar 
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was receiving care; however, in order to receive care his mental health state had to 
become critical.  Lastly, it was evident that the third respondent was in need of mental 
health services, and needed a treatment support program to help with overcoming his 
drug addiction.  At the time of the interview, this individual was still not receiving the 
care that he required for his multiple health conditions.   
 Coping with HIV.  Three participants alluded to their HIV-related coping 
strategies.  Specifically, 2 female participants and 1 male shared a similar theme of 
coping with HIV by ignoring their HIV positive status.  One female participant shared the 
following, "Half of the time I don‟t think that I am HIV, so I don‟t play on the fact that I 
am sick, that I have AIDS or HIV, to me it‟s the same thing - I don‟t know why they 
break it down."  (Female, on HIV treatment for 20 years).   
Similarly, another female participant  said, 
  I like to think it [the HIV virus] as flu that will not go away.  It's easier mentally 
 for me  to find a way of accepting it, because I tested positive at 17 after my first 
 sexual  encounter.  So just to carry that burden for 8 years, I finally had to come to 
 a realization hey this is not a bad dream this is reality.  (Female, on HIV 
 medication for 6 years) 
 
The male participant shared that, "There was a sort of the denial thing for the longest time 
so if I leave them at home … it's hard to say.  There were few issues but I really did need 
a psychiatrist and I still think that I do."  (Male, on HIV medication for 7 years)  
 Avoiding the HIV diagnosis, and renaming it to mean "just a bad flu that won't go 
away", or choosing to forget that they have an HIV diagnosis was one coping related 
strategy that emerged from some of the interviews.   
 Other individuals indicated that they were very private about their HIV status; that 
is, they did not disclose their diagnosis to many people.  Perhaps as a way to avoid 
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rejection and cope with the HIV-positive diagnosis, these individuals chose not to talk 
about their HIV-status with other people, or only share their health condition with a few 
selected individuals.  Thus, it seemed that for the people interviewed in the current study, 
these two personal coping strategies (denying the diagnosis or being very private) were 
ways to cope with the disease and perhaps avoid HIV-related stigma by not disclosing 
their HIV-status to everyone.    
 In summary, the responses from the interviews elucidated the experiences of 
people living with HIV and their HIV treatment regimens.  The interviews support the 
idea that multiple psychosocial factors can influence HIV treatment adherence rates.  All 
of the individuals indicated that it was important to have an autonomy-supportive 
physician, one who encouraged their patients to ask questions, and took actions to better 
their health.  However, the anecdotal evidence showed that over one third of the 
individuals did not have such optimal health care.  Furthermore, health care providers 
(especially as part of large hospitals) were sometimes judgmental, discriminatory and 
unhelpful towards patients diagnosed with HIV.  People also indicated that a number of 
HIV treatment side effects could sometimes interfere with their daily activities.  Other 
challenges that were indicated, that made the HIV treatment more difficult to adhere to, 
were additional medical diagnoses, such as depression.  However, despite these multiple 
challenges faced by these participants, the majority indicated that they were adherent to 
their prescribed HIV treatment regimen.  Some participants found means to overcome 
these difficulties by focusing on the importance of their health, that is keeping their CD4 
cell count high and their HIV-viral load low.  A few people indicated that their health 
was a number one priority because their loved ones (romantic partners or children) gave 
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them the strength to persevere with the side effects, and to continue taking their HIV 
medication.  The findings from these semi-structured face-to-face interviews highlighted 
the importance of autonomy, HIV treatment self-efficacy, social support, medical health 
co-morbidities, and HIV treatment side effects, as important variables that help to 
understand the complexities associated with HIV treatment adherence. 
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CHAPTER IV 
DISCUSSION 
Consistent adherence to HIV treatment regimens is necessary to achieve the 
maximum benefit of the medication and to reduce the risk of HIV resistance to the 
medication (Catz, Kelly, Bogart, Benotsch, & McAuliffe, 2000).  The present study 
sought to understand psychological and social factors that influence HIV treatment 
adherence in a sample of people living with HIV (PLWH); Self-Determination Theory 
(SDT; Deci & Ryan, 1985) guided this study.  Specifically, the aim of the study was to 
examine the relationship between autonomy (autonomy-supportive physicians and health 
locus of control), relatedness (perceived social support and HIV-related stigma in health 
care settings), and competence (HIV treatment knowledge and HIV treatment self-
efficacy) and HIV treatment adherence.   
The study had two phases: Phase I used self-report questionnaires to assess 
predictors of HIV treatment adherence, and Phase II used face-to-face semi-structured 
interviews to gain in-depth understating of people's experiences taking and adhering to 
the HIV treatment regimen.  The quantitative and the qualitative data uniquely 
contributed to revealing aspects about people's experiences with their HIV treatment 
regimens.   
Summary of Findings 
 In Phase I, none of the main hypothesized mediating relationships were supported.  
Mediation analyses did not find support for autonomy, one of the three main constructs of 
Self-Determination Theory (SDT).  Biviarate correlational analysis, however, showed 
that Doctors HLOC and having an autonomy-supportive physician (HCCQ) were related 
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to higher HIV treatment adherence.  Phase II supported the important role of the primary 
health care physician; specifically, respondents reported that their physician was a source 
of knowledge and power to prescribe the HIV medication.   
 The second construct as part of SDT - relatedness - was also not statistically 
related to HIV treatment adherence, as assessed by the hypothesized mediations.  In 
Phase II, anecdotal evidence indicated that for the participants who had the support of 
family members, their loved ones were an important motivator related to HIV treatment 
adherence.  Unfortunately, half of the people interviewed in Phase II indicated that they 
did not have contact with any family members.  In Phase I and II, HIV-related stigma in 
health care settings was not associated with HIV treatment adherence.   
 Lastly, the third construct as part of SDT - competence - was also not associated 
with HIV treatment adherence, as assessed by the hypothesized mediations.  However, 
simple Pearson product moment correlations showed that HIV treatment self-efficacy 
was significantly related to HIV treatment adherence.   
Therefore, in summary, Phase I results revealed several significant bivariate 
correlations.  Specifically, it was found that older age, having autonomy-supportive 
physicians (HCCQ), high Health Locus of Control for Doctors (i.e., Doctors HLOC) and 
high HIV treatment self-efficacy (HIV-ASES), were all associated with successful HIV 
treatment adherence.  On the other hand, HIV treatment side effects, specifically 
headache, were found to be a barrier to successful adherence.  Lastly, post-hoc analysis 
revealed that HIV treatment self-efficacy mediated the relationship between Chance 
HLOC and HIV treatment adherence.   
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In Phase II, participants shared their perceived challenges associated with taking 
the HIV medications.  The most frequent response associated with making the HIV 
treatment difficult to adhere to was the side effects (e.g., vomiting, diarrhea, weakness, 
body fat redistribution, etc).  Co-morbidities also surfaced as an additional challenge; for 
example, people diagnosed with depression and HIV, or other mental health conditions, 
indicated some difficulties with successfully taking their HIV medication.  Lack of 
consistent and proper health care provision additionally complicates these co-morbidities.  
Conversely, some of the buffers identified in Phase II were the support of a family 
member, and a strong desire to be healthy.  Finally, it was found that ignoring the illness, 
and keeping the diagnosis as private as possible were common coping strategies 
associated with HIV in the present study.   
Rate of HIV Treatment Adherence 
Based on the CASE Adherence Index results, in Phase I, two-fifths of the sample 
(41.8%) was classified as having poor HIV treatment adherence (CASE Adherence Index 
≤ 10).  The high prevalence of poor HIV treatment adherence in this sample of PLWH is 
consistent with other research (e.g., Gordillo et al., 1999).  For example, Gordillo and 
colleagues (1999) found that 42% of the mixed-gendered sample of PLWH in their study 
self-reported being non-adherent.  In general, however, the published findings on HIV 
treatment adherence rates vary widely.  This is mostly because of the multiple ways in 
which HIV treatment adherence can be measured.  Most often authors report adherence 
as a dichotomous variable, which has a cut-off value of 95% (< 95% is non-adherence).  
Ninety-five percent is often used because it is considered an optimal cut-off criterion for 
immune functioning; that is, people who are adherent less than 95% of the time have 
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worse physiological outcomes (Paterson et al., 2000).  Based on this criterion, estimates 
of non-adherence are between 24.2% (Barclay et al., 2007) and 43% (Wenger et al., 
1999).  Moreover, using a digital monitoring pill count, the HIV treatment adherence 
rates become even more variable, ranging from 25.3% (Paterson et al., 2000) to 62% 
(Bangsberg et al., 2000).  Therefore, although the rates for HIV treatment adherence vary 
in the published literature, the 42% non-adherence rate found in the present study was 
similar to the self-reported rates found in the general literature.   
The Sample of PLWH in the Present Study 
 The sample of PLWH who took part in Phase I and II of the present study were 
predominantly males (73.5%), and 57% of the males identified as gay/homosexual.  
These percentages represent the overall prevalence of males with HIV in Canada.  As of 
2009, approximately 76% of all HIV cases were males, and the majority identified as 
gay/homosexual (60%).  In terms of ethnicity, however, the sample of PLWH in this 
study was less diverse, as compared to the Canadian HIV-positive population.  In Phase, I 
the majority of the participants (32%) indicated British/Irish, or Mediterranean descent, 
19% were of Southeast Asian descent, 7% were of South Asian background, and 11% 
were of African or African-Caribbean descent, and small minorities (7%) of participants 
were of Aboriginal background; lastly, the remaining participants (15%) indicated other 
or "don‟t know".  The ethnic distribution of PLWH in Canada is more diverse, as 
compared to the present study, with recent data showing that 44% of PLWH are White, 
33% Aboriginal, and 12% Black PLWH (PHAC, 2009).  In terms of age, the mean age of 
participants was 43, and people ranged from 24 to 64 years of age.  According to the 
Public Health Agency of Canada, the highest proportion of HIV case reports is among 
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people between the ages of 30 to 49 years of age (PHAC, 2009).  An interesting finding 
from Phase I of the present study was that older age was significantly associated with 
better HIV treatment adherence; this finding is consistent with other published research 
(Barclay et al., 2007; Kennedy et al., 2004; Paterson et al, 2000).  Barclay and colleagues 
(2007) found that older adults (>50 years of age) were two times more likely to be 
adherent, as compared to younger participants.   
 Therefore, in terms of the age, gender, and sexual orientation the demographic 
distribution of the participants in the present study resembles the demographic 
characteristics of PLWH in Canada.  The ethnic breakdown of the study participants, 
however, was less representative of the ethnic distribution of PLWH in Canada.   
 It is very important to note, however, that the participants in this study were 
exclusively recruited through AIDS Service Organizations (ASOs), which indicates that 
PLWH not in contact with such service organizations were not included in the present 
study.  Therefore, the sample of PLWH in this study represented  a unique subpopulation 
of PLWH because they were connected with support services (e.g., ASOs), they were 
literate (Phase I), or were able to understand and speak English (Phase II), and were 
likely eager to participate because they noticed the posted flyers advertising the study and 
were interested in taking part in this research.  Also, the social and psychological needs 
of people attending ASOs might be different from the PLWH not in touch with service 
organizations, and caution should be used when interpreting the findings, in that they 
should not be generalized to all PLWH.   
 Furthermore, the subsample of PLWH who participated in Phase I and II also 
differed.  Specifically, the PLWH who participated in Phase II were primarily recruited 
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from Fife House (64% of the participants), an organization that provides short and long 
term housing services to people without current homes, and without this organization the 
people would likely be at risk for being homeless, as compared to the majority of the 
participants in Phase I, who had their own homes.  Typically, housing services for PLWH 
consist of single rooms and usually families or mothers with children are not housed at 
these organizations.  This is likely why the majority of the participants in Phase II were 
males.  In Phase I, only 31% of the participants were recruited from an organization that 
offers housing services (McKewan Housing and Support Services).  Therefore, in 
contrast to Phase II, the majority of the participants in Phase I were probably living in 
their own homes or with family members, or friends.  These differences were relevant 
because the findings from Phase I and II were triangulated.  That is, caution was 
exercised when the findings from Phase I and II were compared, as the degree of overlap 
between some of the variables (e.g., social support) may have been questionable.  Overall, 
the results from the present study are not intended to be generalized to PLWH beyond 
this study, especially to other ethnic and racial groups of PLWH not identified in the 
present sample.   
The HIV Treatment Regimen: Complexity and Side Effects  
 According to some previous findings, one of the key reasons for poor HIV 
treatment adherence results from the complexity of the regimen; that is, too many pills, 
dosing frequency, or food restrictions (Ammassari et al., 2002; Corsonello et al., 2009).  
The present study did not support these findings.  In Phase I, specifically, Pearson 
product-moment correlational analyses did not find an association between number of 
pills a person needs to consume every day and HIV treatment adherence.  There are 
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several possible reasons that may ultimately help to explain the lack of association 
between HIV treatment requirements and adherence.  In Phase I, the majority of the 
participants identified that their HIV treatment regimen did not involve taking multiple 
pills each day.  The overwhelming majority (91%) of the participants from Phase II 
confirmed that they had very simple HIV regimens, consisting of approximately 2 pills 
per day, and twice a day intake.  As a result of this little variability in the number of pills 
that PLWH had to consume, it was unlikely to find a meaningful statistical association 
between the HIV treatment regimen and other variables.  Therefore, it is possible that the 
sample of PLWH in this study, had simpler HIV treatment regimens, as compared to the 
PLWH in other published research.  In fact, several of the participants who have been 
HIV-positive for more than 15 years indicated that in the initial years of the HIV 
epidemic, the treatments were onerous, but now they were much simpler.  Therefore, it 
could be that HIV treatment complexity and HIV treatment adherence are related but 
because this sample of PLWH had very simple regimens, this relationship may not have 
been accurately assessed.   
Instead of treatment complexity, what was found to be associated with making the 
HIV treatment difficult was the resulting HIV treatment side effects.  Specifically, in 
Phase II, approximately half of the participants identified HIV treatment side effects to be 
very burdensome.  However, when the participants were further prompted to share if they 
thought that their treatment related side effects interfered with their HIV treatment 
adherence, everyone firmly disagreed.  All of the participants indicated that they never 
missed their HIV treatment despite the difficult side effects.  Some of the side effects 
identified by participants in Phase II were diarrhea, vomiting, loss of energy, body fat 
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redistribution, heart palpitations, nausea, and parts of the body swelling.  In Phase I, 
statistical analysis found that headache symptom severity was significantly associated 
with poor HIV treatment adherence, while the remaining HIV treatment side effects were 
not associated with adherence.  In addition, 82% of the participants identified weakness 
(fatigue) as the most common side effect.  Therefore, it seems that both groups (Phase I 
and II) were experiencing HIV treatment side effects, but only for the participants in 
Phase I did these side effects significantly interfere with their treatment adherence.  Phase 
II participants indicated that the side effects made the HIV treatment difficult but these 
experiences did not interfere with the regimen. 
 It was unclear why the HIV treatment side effects were more burdensome for 
participants in Phase I, as compared to Phase II.  Perhaps because the participants in 
Phase II did not report headache-related side effects, they were able to adhere to the 
treatment despite the other symptoms reported.  In addition, social desirability bias may 
have influenced the interviewees' responses; that is, the participants may not have been 
comfortable admitting that they were not fully adherent.   
 In summary, the number of pills that PLWH had to take each day was not found 
to be associated with poor HIV treatment adherence, but the sample of PLWH in this 
study tended to have fairly simple treatment regimens.  However, Phase I found support 
for an association between HIV treatment side effects and non-adherence.  Phase II did 
not support the aforementioned results, but the participants in Phase II mentioned that 
some of the side effects made the HIV treatment regimen more burdensome.   
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The Main Mediational Findings 
 The main meditational hypotheses as part of Phase I of the present study were not 
statistically supported.  Possibly a larger sample size would have resulted in significant 
results.  
Autonomy 
 In the literature, autonomy is typically operationalized as people's perceived 
control over their environment.  In the present study, autonomy was examined in the 
context of people's perceived ability to have control over their health.  In assessing 
autonomy, participants were asked to indicate if they felt that they had open 
communication with their physician (i.e., autonomy-supportive physician), where they 
could exercise some control over their health.  Autonomy was further defined as people's 
perceived ability to influence their health, usually referred to as health locus of control.  
None of the hypotheses related to autonomy was supported. 
 Autonomy-supportive physician (HCCQ).  It was predicted that an autonomy-
supportive physician would be associated with higher motivation to adhere to the HIV 
treatment, and as a result, this would be associated with better adherence rates.  This 
mediation was not supported.  Other researchers, however, have found support for this 
relationship (Williams et al., 1998).  Two reasons could be associated with these 
contradictory findings.  Firstly, Williams and colleagues (1998) had a larger sample size; 
specifically, 126 PLWH participated in their study.  Secondly, Williams and colleagues' 
(1998) study used two different methods of calculating adherence rates: self-report and 
prospective pill count at two different time points.  Together, these two different methods 
of assessing HIV treatment adherence represent a less unbiased estimation of the 
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adherence rates, as compared to the self-report method used in the present study.  In 
Phase I, adherence rates were self-reported and participants may have been reluctant to 
indicate the frequency of their actual missed doses of the HIV treatment.  The adherence 
rates found in Phase I and in the Williams and colleagues' (1998) study, therefore, may 
not be comparable because of the different measures utilized to assess adherence.  If the 
present study had used a digit monitoring pill count, for example, a more unbiased 
method of measuring adherence rates, then perhaps autonomy could have emerged as a 
predictor of adherence in this sample of PLWH.  Therefore, in contrast to the previous 
literature, the mediation analysis did not find support for the relationship among 
autonomy-supportive physician, intrinsic motivation, and increased HIV treatment 
adherence.  
 Pearson product-moment correlations, however, found some support for the 
relation between having an autonomy-supportive physician and HIV treatment adherence.  
That is, people who had autonomy-supportive physicians had higher adherence rates.  
This finding is not unique to the present study (e.g., Schneider, Kaplan, Greenfield, Li, & 
Wilson, 2004).  For example, in a mixed gendered sample of 554 PLWH from the United 
States, researchers found that individuals who perceived that they had more autonomy-
supportive physicians had better HIV treatment adherence rates (Schneider et al., 2004).  
This finding could have important implications for developing interventions aimed to 
improve adherence rates.  Adherence rates among PLWH are generally not high 
(Bangsberg et al., 2000; Gordillo, Amo, Soriano, & Gonzalez-Lahoz, 1999); thus, when 
research identifies variables that are associated with better adherence, and these factors 
are modifiable, then health care providers should adopt them in an effort to help their 
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patients (Bangsberg et al., 2000).  Communication patterns between physicians and 
patients are modifiable; that is, it is possible for clinicians to become more patient-
centered and thus autonomous in their practice (Moral, Alamo, Jurado, & de Torres, 
2001), and there is evidence that these training programs can have long-term outcomes 
(Bowman, Goldberg, Millar, Gask, & McGrath, 1992).  Schneider and colleagues (2004), 
however, pointed out that research is needed to better understand if improved physician-
patient communication style through training programs is associated with improved HIV 
treatment adherence.  This could be a future extension and direction of this research. 
 Pearson product-moment correlations further found some support for the relation 
between having an autonomy-supportive physician and less psychological distress as 
reported by the patient.  Specifically, high perceptions of having an autonomy-supportive 
physician were correlated with lower anxiety and depression symptoms.  These findings 
are congruent with the general literature.  For example, in cancer research, better 
communication style and more autonomy allows the physician to reduce the patient's 
mental distress (Molleman et al., 1984).  Unfortunately, research on autonomy-supportive 
health care providers and mental health among PLWH is not yet available.  This is the 
first study to find an association between having an autonomy-supportive physician and 
lower anxiety and depression symptoms.  Future research should further examine these 
relationships.     
 Autonomy-supportive physician was also statistically correlated with HIV-related 
stigma in health care settings.  Specifically, Phase I indicated that patients who perceived 
that they had an autonomy-supportive physician showed decreased level of HIV-related 
stigma and discrimination in health care settings.  The present study was the first to find 
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an association between HIV-related stigma in health care settings and having an 
autonomy-supportive physician.  The findings from Phase II were in support of this 
association.  The interviewees who indicated that they had an autonomy-supportive 
physician indicated fewer instances of perceived stigma from health care settings.  One 
explanation that helped to elucidate this relationship was that the patients who had a good 
relationship with their physician might have visited hospitals considerably less.  
Participants from Phase II generally identified that hospitals (negative stigma-related 
experiences from dentists were not mentioned) were associated with higher HIV-related 
stigma and discrimination, as compared to primary health care settings.  Other 
researchers have also supported this view.  In the United Kingdom, for example, almost 
half (49.6%) of the participants sampled identified that they had experienced stigma from 
a health care worker including their dentist, as compared to only 17.4% of people who 
reported HIV-related experiences of stigma in primary health care settings (Elford, 
Ibrahim, Bukutu, & Anderson, 2008).  Research suggests that lower levels of education 
may be associated with discriminatory attitudes toward PLWH (Elford et al., 2008).  
Moreover, health care providers who are familiar with the appropriate medical 
procedures when treating patients with infectious diseases are likely less to discriminate 
(Li et al., 2007).  Therefore, one reason for the higher prevalence of HIV-related stigma 
in health care settings may be because the hospital staff varied in their education levels 
and in their preparedness to work with patients who have HIV/AIDS (Li et al., 2007).  
Research suggest that providing HIV/AIDS training increases health care practitioners‟ 
knowledge about HIV/AIDS and improves their attitudes toward PLWH (Wu et al., 
2002).  Primary health care settings, therefore, which specialize in HIV care, have likely 
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acquired the necessary knowledge, skills, and awareness on how to treat PLWH, and thus 
a combination of these factors may result in lower HIV-related stigma and 
discrimination.     
Simple Pearson product-moment correlations further revealed that an autonomy-
supportive physician was also positively associated with Doctors health locus of control 
(Doctors HLOC).  That is, participants who perceived that their physician had control 
over their health (Doctors HLOC) also perceived themselves to have more autonomy 
from that physician.  This is a positive finding, as it indicated that the patient and the 
physician shared responsibility over the health of the patient.  This finding is also 
consistent with the literature, which suggests that over 80% of PLWH desire to have a 
balanced and shared responsibility for their health (Deber, Kraetschmer, Urowitz, & 
Sharpe, 2007).  A large meta-analysis study showed that the need for shared decision 
making is true across patients of most medical conditions, such as in cardiac patients 
(66%), HIV (81%), and 44% breast cancer patients (Deber et al., 2007).  Findings from 
Phase II supported this desire for shared responsibility.  In Phase II, all of the participants 
indicated that having an autonomy supportive physician was very important for them.  
Specifically, a common theme that emerged was that they would prefer that their 
physician listen to them more.  This may be because of the nature of the HIV condition, 
which continues to be a stigmatizing health condition.  PLWH may have a limited 
number of people with whom they can discuss their health concerns, and for many, the 
family physician or HIV specialist may be that key person.  In fact, Pearson correlations 
revealed that people who have support from their physicians perceived a stronger social 
support system.   
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Unfortunately, although everyone desired a little more autonomy from their 
physician, it was found that one third of the respondents reported that they did not have 
an autonomy-supportive physician.  When the participants, as part of Phase II, were 
asked if they thought that the lack of autonomy was a barrier to successful HIV treatment 
adherence, the majority of the respondents indicated that it was not.  When further 
prompted, most participants indicated that if they had a question regarding their treatment 
or health, they would ask their doctor directly.  It was encouraging to hear that 
participants did not allow themselves to be at the mercy of their physician, and that they 
took a proactive stance towards their health by asking questions.  This is not unique to the 
participants of this study; in fact, research shows that 94% of HIV-positive patients ask 
their health care providers questions related to their treatment and health (Catz, Kelly, 
Bogart, Benotsch, & McAuliffe, 2000).  Catz and colleagues (2000) identified this to be a 
frequently endorsed strategy used to self-promote adherence.   
In sum, Phase I bivariate correlations indicated that having an autonomy-
supportive physician was a very important and significant variable associated with high 
HIV treatment adherence, low depression and anxiety symptoms, higher perceptions of 
social support, and fewer experiences of stigma.  These results are of great importance as 
they highlight the vital role physicians have on people's ability to successfully adhere to 
their prescribed HIV treatment regimens.  Phase II findings demonstrated that autonomy 
is important but not necessary for successful HIV treatment adherence.  
 Health locus of control (HLOC).  In Phase I, it was predicted that health locus 
of control (each subset of HLOC: Internal, Chance, Doctors, and Others) would be 
associated with intrinsic motivation (TSRQ), which in turn would be associated with HIV 
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treatment adherence.  Each of the four hypotheses, testing the subscales of HLOC was 
not supported.   
 Internal HLOC.  It was predicted that Internal HLOC would be associated with 
higher motivation to adhere to the HIV treatment, and as a result, with better adherence 
rates.  This mediation was not supported and the results were in contrast to the findings 
reported by Affleck and colleagues (1987).  One reason for the lack of supporting 
evidence for Internal HLOC may have been that the sample of PLWH in this study may 
not have felt that their health was entirely in their control.  Instead, the participants may 
have placed more emphasis on other factors, perhaps more contextual circumstances.  For 
example, in the literature, contextual factors found to impact adherence rates are lack of 
stable housing (Johnson, Catz, Remien, Rotheram-Borus, Morin, Charlebois, et al., 2003) 
or access to health care services (Johnson et al., 2006).  Specifically for women, a large 
number of people that live in the same home and parenting stress are some gender 
specific factors found to influence HIV treatment adherence (Mellins, Kang, Leu, 
Havens, & Chesney, 2003).  Unfortunately, Phase I was not designed to identify 
contextual factors associated with HIV treatment adherence, and it remained unclear what 
(if any) social circumstances may have been associated with adherence.  This could be a 
direction for further research.   
 In Phase II, a few respondents supported the idea that contextual factors, outside 
of their control, can influence their HIV treatment adherence.  For instance, two people 
indicated that the HIV medication that they took depended on their Ontario Disability 
Support Program (ODSP).  Not all drugs are covered by the ODSP, and sometimes 
people need to switch medication in order to match this social service plan, or the 
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alternative would be to pay for the medication.  One individual skipped a few weeks of 
medication because her ODSP coverage plan switched once she became a permanent 
resident (from a refugee status).  The drugs that she was eligible to take, under the new 
ODSP plan, caused her many side effects, and she preferred to be without the treatment.  
Fortunately, this participant was able to resolve her situation; however, for many, 
especially with language barriers, challenging government policy may be outside of their 
control.  Another individual indicated that his drug dependency and depression were 
associated with poor HIV treatment adherence.  This finding is also consistent with the 
literature (Yun, Maravi, Kobayashi, Barton, & Davidson, 2005).   
 In summary, in Phase II, the interviewees generally indicated that they had some 
control over their health; however, they also found that there were other factors, outside 
of their control, that could make treatment adherence very difficult.  Physicians treating 
HIV-positive patients need to be aware of the various social circumstances that can 
influence adherence.  These physicians should also know and refer their patients to 
community resources where people can go for help.    
 In Phase I, bivariate correlations also revealed an unexpected pattern of 
association between Internal HLOC and the remaining sub-scales as part of the Health 
Locus of Control measure (Chance, Doctors, and Others).  That is, people who perceived 
to have high Internal HLOC also perceived Chance, Doctors, and Other events to have 
some control over their health.  This indicates that the PLWH in this sample had a more 
balanced view of the factors that influenced their health; that is, the participants viewed 
that things inside their control (Internal HLOC), outside (Chance HLOC), their physician 
(Doctors HLOC), and others factors (Others HLOC) combined to influence their health.  
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Phase II data indicated that the respondents mainly considered themselves and their 
doctor to be the two main factors in control of their health.  
 In sum, Internal HLOC was not significantly associated with HIV treatment 
adherence.  In Phase II, however, participants identified government insurance plans and 
co-morbidities as factors outside of their control that may prevent successful HIV 
treatment adherence in this sample of PLWH.   
 Doctors HLOC.  It was predicted that Doctors HLOC would be associated with 
high adherence rates, through intrinsic motivation as a mediator.  Although this mediation 
was not supported, bivariate analysis revealed that Doctors HLOC was significantly 
associated with fewer symptoms of depression and higher HIV treatment self-efficacy.   
 Phase II indicated several examples of anecdotal evidence of the importance of 
Doctors HLOC.  The sample of PLWH in Phase II indicated that their primary physician 
was an integral part of their HIV care, because they were the source of knowledge, 
support, and power to prescribe the HIV treatment.  However, less is known in the 
literature about Doctors HLOC and HIV treatment adherence.  Future research should 
further explore this construct and especially its relevance to patients' mental health.   
 Therefore, in the present study, Doctors HLOC proved to be an important variable, 
associated with lower depression scores, and higher HIV treatment self-efficacy, but this 
factor was not directly associated with HIV treatment adherence.   
Chance HLOC.  It was predicted that Chance HLOC (i.e., the idea that factors 
outside of a person's control can influence health) would be associated with lower 
motivation to adhere to the HIV treatment, and as a result, would predict worse adherence 
rates.  This mediation was not supported.  In the literature, less is known about Chance 
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HLOC and its influence on HIV treatment adherence.  Furthermore, this is the first study 
to demonstrate a bivariate association between Chance HLOC and less knowledge about 
the HIV treatment (as assessed by the HIV treatment Knowledge Scale).  Also bivariate 
analyses showed that participants high on Chance HLOC had lower HIV treatment self 
efficacy; in other words, these participants were less able to adhere to the HIV treatment 
when obstacles arose, as compared to individuals who believed that their health was 
influenced by factors other than chance.   
 In Phase II, the respondents did not comment on Chance HLOC as a factor that 
influenced their physical health.  It should be noted, however, that participants were not 
asked about their perceptions of Chance HLOC, specifically, but rather a general 
questions was posed, asking what they perceived to be influencing their health.  Their 
responses to this question related to either Internal HLOC or Doctors HLOC. 
 In summary, although Chance HLOC was associated with less HIV treatment 
knowledge and less HIV treatment self-efficacy, this variable was not directly associated 
with HIV treatment adherence.   
 Others HLOC.  It was predicted that Others HLOC would be associated with 
lower motivation to adhere to the HIV treatment, and as a result, with worse adherence 
rates.  This mediation was not supported.  In Phase II of this study, Others HLOC did not 
emerge as a relevant variable associated with HIV treatment adherence.  Less is known in 
the literature about this variable and HIV treatment adherence.  Future studies should aim 
to better understand the influence Other HLOC may have on HIV treatment adherence 
rates. 
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 Taken together, results from the data obtained from Phase I and II revealed 
interesting findings related to health locus of control and HIV treatment adherence.  
Specifically, in Phase I, with the exception of Doctors HLOC, the remaining subscales of 
health locus of control were not associated with HIV treatment adherence.  The findings 
from Phase II, however, indicated a slightly more clear distinction of the factors that 
influence HIV treatment adherence; specifically, drug addictions and mental health 
diagnoses seemed to be barriers to successful adherence.   
Relatedness 
 From a Self-Determination Theory perspective, relatedness is linked to a person's 
feelings of belongingness and connectedness.  In the present study, therefore, relatedness 
was defined as perceived social support from friends and family, as well as perceived 
HIV-related stigma and discrimination from health care providers.  In Phase I, the 
mediational hypotheses pertaining to relatedness were not supported. 
 Social support.  It was predicted that social support would be associated with 
higher motivation to adhere to the HIV treatment, and as a result, would lead to better 
adherence rates.  In Phase I, this mediation was not supported.  It is not clear why in 
Phase I, social support was not a significant predictor of HIV treatment adherence, when 
the literature shows clear evidence for this association (Johnson et al., 2003; Roberts & 
Mann, 2000).  Perhaps this sample of PLWH preferred to be more private about their 
diagnosis.  Unfortunately, the present study did not assess for this possibility.  Future 
studies might be strengthened by including an item concerning privacy about one‟s HIV 
status as part of the battery of questionnaires, or as part of an interview protocol. 
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 The interviews from Phase II, however, offered more insight into the role of 
social support on people's experiences with their HIV treatment adherence.  Two 
participants reported that their family members (romantic partners, or children) were a 
motivation for them to take their HIV treatment regularly.  Specifically, one of the female 
participants indicated that her two young children and husband were her personal 
motivation to take the medication every day, despite the side effects that it caused.  
Qualitative research supports these findings (Remien, Hirky, Johnson, Weinhardt, 
Whittier, & Minh Le, 2003).  Remien and colleagues (2003), found that among their 
sample of PLWH, children (especially for women), were a strong motivator for people to 
adhere to their HIV treatment regimens.  In the present study (Phase II), one participant 
indicated that he sometimes forgot to take his medication on time, but that his fiancé was 
a very important motivator, and most importantly she also reminded him to stick to the 
prescribed treatment.  The literature suggests that 63% of people indicate forgetfulness as 
a barrier to successful treatment adherence (Catz et al., 2000).  Therefore, it was 
encouraging to see that family members can be a protective factor against non-adherence.   
 From the data on social support, we can conclude that based on the interviews 
from Phase II, social support was an important construct that helped PLWH to adhere to 
their prescribed treatment.  The support of a loved one was a motivator to take the HIV 
treatment medication and stay healthy.  In Phase I, however, social support did not 
emerge as a significant predictor of HIV-treatment adherence.  More research is needed 
to understand these inconsistent findings.    
 HIV-related stigma in health care settings.  It was predicted that perceived 
HIV-related stigma in health care settings would be associated with low motivation to 
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adhere to the HIV treatment, and as a result, this would be associated with poor 
adherence rates.  In Phase I, this mediation was not supported, and this is in contrast to 
other published research  
(Rintamaki et al., 2006).  Rintamaki and colleagues (2006) found that in a mixed 
gendered sample of PLWH, living in the United States, high perceptions of HIV-related 
social stigma were significantly associated with poor HIV treatment adherence.  These 
researchers defined HIV-related social stigma using three items specifically related to 
concerns with the HIV treatment and public opinions.  For example, one of the items was 
“I am embarrassed to get my medicines from a drug store”.  A possible reason for why 
the present study failed to support the Rintamaki and colleagues (2006) study, may be as 
a result of how HIV treatment adherence was defined in the earlier study, as compared to 
the present study.  Rintamaki et al. (2006) reported adherence as a dichotomous variable, 
which placed people into categories of 100% adherent or not adherent, if less than 100%.  
Although the researchers were not the first ones to measure HIV treatment adherence in 
this way (e.g., Gonzalez et al., 2004), this method was in sharp contrast to the continuous 
scale used for the analysis of HIV treatment adherence in Phase I of the present study; 
thus, the results may not be comparable.  One problem with dichotomization of people 
into completely adherent (100% adherence rates), or not (<100%) categories, is that the 
result are less generalizable, as most PLWH are not actually 100% adherent.  In addition, 
the present study may have been influenced by social desirability, and as a result, the 
respondents may not have been as accurate with their estimates of non-adherence.  An 
extension of this study should use a more unbiased method of measuring adherence.  This 
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will aid in better understanding of the role of HIV-related stigma on HIV treatment 
adherence rates.   
 Phase II further offered some insight into people's HIV stigma-related experiences 
and HIV treatment adherence.  Close to half of the participants (54%) indicated that they 
had received less than adequate health care provision (from health care professionals, 
other than their family physician).  Generally, the interviewees‟ dissatisfaction was 
related to the lack of ability to obtain service (e.g., obtaining a glass of water), perceived 
lack of communication with staff, and judgmental health care providers (e.g., judging the 
decision of an HIV-positive woman to become pregnant).  When participants were asked, 
however, whether they thought that these negative experiences influenced their HIV 
treatment regimen, the majority of the respondents indicated that it did not affect them.  
Therefore, despite the negative attitudes that they had experienced, the participants 
indicated that they usually asked the questions that needed to be clarified.   
In summary, Phase I did not find supporting evidence for relatedness (that is 
social support and HIV-related stigma in health care settings) and HIV treatment 
adherence.  On the other hand, Phase II showed that social support from family members 
was a positive influence on treatment adherence.  Furthermore, Phase II indicated that 
people generally experienced HIV stigma, but that these negative experiences did not 
affect their adherence rates.  All together, there is support for relatedness as an important 
factor that influenced adherence rates; however, evidence for this only comes from the 
findings obtained from Phase II of the present study. 
Competence 
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 From the self-determination theory perspective, competence is defined as 
perceived ability to make a change.  In the present study, competence was defined as the 
perceived ability to adhere to the HIV treatment regimen despite difficulties.  
Competence was also defined as HIV treatment related knowledge.  The mediational 
hypotheses pertaining to competence were not supported.   
HIV treatment knowledge.  In Phase I, the prediction was that low HIV 
treatment knowledge would be associated with lower intrinsic motivation and in turn 
poor HIV treatment adherence rates; this association was not supported.  This hypothesis 
was based on past research that suggests that low HIV treatment knowledge is associated 
with low HIV treatment adherence rates (Balfour et al., 2007; Veinot et al., 2006; Weiss 
et al., 2003).  A few reasons may have contributed to failing to support this hypothesis.  
One possibility is that the education level of the participants in the present study might be 
higher, as compared to the participants in other published studies.  For example, in the 
present study, only 15.8% of the participants had less than high school education, as 
compared to 45.7% people who had less than a high school education in the study 
conducted by Weiss and colleagues (2003).  Another reason for the inconsistent findings 
between HIV treatment knowledge and HIV treatment adherence may have been a result 
of the way HIV treatment knowledge was measured.  Phase I used a validated measure 
for HIV treatment knowledge (HIV Treatment Knowledge Scale; Balfour et al., 2007).  
This is a recently developed and validated 21-item measure created by a Canadian team 
of researchers.  Other studies (e.g., Kalichman et al., 2000) used a fourteen-item 
questionnaire to assess HIV treatment knowledge.  These questions were created for the 
purpose of their study, and it is unclear if the questions were appropriately created; that is, 
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they may have been too easy or too difficult.  It is recommended that future research 
assessing HIV treatment knowledge use validated measures to ensure that the questions 
assessing these constructs are of the appropriate level.  In sum, the findings from Phase I 
did not find support for a relationship between low HIV treatment knowledge and poor 
HIV treatment adherence, and to date, the literature findings on this subject are very 
inconsistent.   
The participants in Phase II of this study were aware of the importance of 
adhering to the HIV treatment.  They indicated that missing medication builds HIV 
resistance.  For the individuals concerned about their health, knowing this information 
seemed to be a motivator to adhere to their prescribed medication.   
In general, the results of the present study added to the inconsistent findings 
reported in the literature on the relationship between HIV treatment knowledge and HIV 
treatment adherence.  Statistical analysis, as part of Phase I, indicated that these two 
variables were not related.  In Phase II, however, there was some anecdotal evidence that 
a person's motivation to adhere to the prescribed treatment may be influenced by their 
knowledge of the importance of medication adherence.   
HIV treatment self-efficacy.  In Phase I, it was predicted that HIV treatment 
self-efficacy would be associated with high intrinsic motivation, and in turn with better 
adherence rates.  There is substantial evidence to suggest that treatment self-efficacy 
accounts for some of the variance in adherence rates (Cha et al., 2008; Johnson et al., 
2007).  In the present study, this prediction was not supported.  Correlational analysis, 
however, revealed a strong relationship between HIV treatment self-efficacy (HIV-ASES) 
and HIV treatment adherence.  It was also found that treatment self-efficacy mediated the 
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relationship between Chance HLOC and HIV treatment adherence, suggesting that 
people who have high self-efficacy can adhere better to their treatment, despite the fact 
that they attributed Chance to control their health.  These findings have implications for 
improving HIV treatment adherence, such that fostering self-efficacy may lead to better 
medication adherence (Cha et al., 2008; Johnson et al., 2007).  Some research suggests 
that self-efficacy can be increased with the support of family and friends (Van Servellen 
& Lombardi, 2005).  Future research should focus on identifying other factors that may 
be associated with an increase in HIV treatment self-efficacy for PLWH.   
In summary, competence was an important variable that influenced HIV-
treatment adherence.  Specifically, Phase I showed that HIV treatment self-efficacy had a 
significant impact on people‟s adherence rates, but HIV treatment knowledge did not.  
Future research should focus on creating intervention programs that aim to increase 
people's self-efficacy, as this in turn may improve adherence rates. 
Additional findings 
HIV-related coping.  In Phase II, several people indicated that they preferred to 
forget about their HIV-status, and they would rather think of HIV „as a flu that won‟t go 
away‟ or just avoid thinking about the disease all together.  These reports of choosing to 
forget about the disease are consistent with other findings (Catz et al., 2000).  
Specifically, Catz and colleagues (2000) found that the item “Treatment reminds me that 
I am HIV-positive” as being the most frequently endorsed barrier to HIV treatment 
adherence.  The current study was not designed to assess if 'not thinking about the virus' 
or 'denying the diagnosis' would influence the HIV treatment adherence rates.  However, 
according to past research, not accepting the HIV diagnosis affects HIV treatment 
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adherence, and future research should focus on developing interventions that focus on 
helping PLWH to accept their diagnosis.  
Co-morbidity.  In Phase II, participants also indicated that there was lack of 
mental health care provision for people diagnosed with HIV and a mental health 
condition (e.g., depression or drug dependency).  For example, it was found that people 
who had mental health conditions, in addition to their HIV diagnosis, did not obtain the 
necessary services that they required; these people did not have access to a mental health 
professional, or if they did, it was only in emergencies.  Therefore, based on the findings 
from Phase II, more mental health services are needed for PLWH.  In order to improve 
their quality of life and eliminate some of the barriers to successful HIV treatment 
adherence, interventions aimed to address mental health issues are needed.   
Strengths and Limitations 
Strengths 
 Although none of the hypothesized mediations were supported, this study was 
able to provide a number of important insights about the psychosocial and demographic 
factors that influence HIV treatment adherence.  Specifically, Phase I (correlational 
analysis) found that younger age, lack of autonomy-supportive physicians, headache as 
side effects, and low HIV treatment self-efficacy were associated with poor HIV 
treatment adherence.  The results of this study add to the literature by providing a more 
comprehensive understanding of people's experiences taking and adhering to their 
prescribed HIV treatment regimens.   
 Secondly, this is one of the first studies to examine HIV-related stigma in 
Canadian health care settings and its impact on HIV treatment adherence.  Fortunately, 
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through Phase I, it was found that only some people experienced HIV-related stigma.  
Conversely, the findings as part of Phase II indicated that more than half of the people 
had numerous negative experiences with health care providers (in hospital settings only), 
but these experiences were not related to adherence rates.  Although HIV-related stigma 
in health care settings was not related to adherence rates, the importance of knowing 
more about the quality of health care provision for PLWH was evident from the present 
study. 
 Another strength of this study was that, except for the measure assessing HIV-
stigma in health care settings, all other measures used in Phase I were validated and have 
previously been used with HIV positive populations.  The HIV-related stigma scale was 
created for the purpose of the present study because, to date, a measure assessing this 
variable has not been created. 
In addition, the present study employed a mixed methods research design.  Thus, 
the findings were triangulated using self-report questionnaire data as well as anecdotal 
accounts obtained through semi-structured interview data.  
Limitations 
Despite the important findings and strengths of the present study, this study also 
had a number of limitations, which are outlined below.  The use of self-report adherence 
data has been questioned because of recall and social desirability bias (Johnson, Chesney, 
Goldstein, et al., 2006; Johnson, Dilworth, Taylor, & Neilands, 2011).  Currently, there 
are no acceptable criteria for measuring HIV treatment adherence (Johnson et al., 2006).  
However, future research replicating this study should utilize several techniques when 
measuring adherence (e.g., Johnson et al., 2006).  For example, in addition to patient self-
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report, researchers can use electronic pill bottle monitoring (e.g., Medication Event 
Monitoring System; see Paterson, Swindells, Mohr, Brester, Vergis, & Squier, 2000), 
blood testing (i.e., plasma drug testing), or monitor pharmacy refill patterns.   
In addition, no hypothesized mediations were supported.  It is likely that the study 
in Phase I required a larger sample size to detect any significant relationships.  The small 
sample size also precluded the testing of the entire model.  That is, a larger sample would 
have allowed for the use of a more powerful statistical analysis, which would include all 
the variables simultaneously based on the theoretical grounds of Self-Determination 
Theory.  As a result of the small sample size, only independent pieces of the theory were 
examined, rather than the whole model.   
Some of the measures, including the measure for HIV treatment adherence (the 
dependent variable), had low alpha reliabilities, which decreased the power to detect any 
significant differences.  It is also possible that not enough information was obtained to 
account for other possible relationships.  For instance, when assessing autonomy-
supportive physicians, the dynamic relationship between the physician and the patient 
could have been influenced by additional variables, such as the physician's gender or 
ethnicity (Hall, Roter, & Katz, 1988; Street, 2002).  These additional variables were not 
assessed in the present study.  Future research should narrow its focus and obtain a more 
comprehensive and in-depth understanding of the factors that may influence autonomy-
supportive physician-patient communication, and use measures that yield higher alpha 
reliabilities.  Lastly, it is also reasonable to assume that the components of Self-
Determination Theory that were tested may not  apply to the unique subpopulation of 
PLWH who participated in this study - primarily white gay men with access to AIDS 
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Service Organizations (ASOs).  Future studies using more diverse samples of PLWH will 
be needed to assess the applicability of SDT to PLWH.   
Moreover, although the educational level of respondents in Phase I was high, the 
questionnaire was limited to participants who could only read and write in English.  
Therefore, the potential experiences of PLWH with low literacy in English were not 
obtained.  Phase II, however, was not limited to people with English literacy, but it did 
require people to be able to speak and understand English.  Furthermore, all the 
participants in the present study were only recruited from ASOs, which means that 
PLWH not in contact with ASOs did not have the chance to participate in this study.  The 
sample of PLWH who were in contact with ASOs were likely more motivated to obtain 
help, more involved with their community, and it was more likely that they spoke English, 
as compared to PLWH who did not seek the services of such community organizations.  
Therefore, the findings in the present study are not intended to be generalized to all 
PLWH.  Also, the subsamples of participants who took part in Phase I and II likely 
differed in some characteristics, because a majority of Phase II participants were without 
stable homes and required the housing services of an organization, whereas the majority 
of Phase I participants were not at risk for being homeless.  Therefore, the results from 
Phase I and II may not have been entirely comparable.   
The findings presented in this study were based on cross-sectional data.  For this 
reason, conclusions about causality among the relationships tested could not be reached.  
The present study relied on a large number of Pearson-product moment correlations; 
therefore, one has to be cautious of Type I error.  It may be necessary to employ 
longitudinal research to posit any causal relationships among the variables tested in the 
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present study and HIV treatment adherence.  Furthermore, in Phase II, the respondents 
who took part in the face-to-face interviews may have been influenced by social 
desirability bias; that is, the tendency for the respondent to be influenced by the 
researcher (Nederhof, 1985).  This may explain the fact that only 18% (2 out of 11) said 
that they sometimes forgot to take their medication; this was in sharp contrast to the 
adherence rates found through the self-report questionnaires (42% non-adherent).  One 
way to account for social desirability bias, and not depend on self-report questionnaires, 
is the use of computer programs like the ACASI (Audio Computer Assisted Self 
Interview).  ACASI has been successfully used in research that requires participants to 
respond to sensitive questions; for example, research on sexual risk taking frequently 
employs the use of ACASI (e.g., Ghanem, Hutton, Zenilman, Zimba, & Erbelding, 2004). 
Conclusions and Future Directions 
Despite these limitations, the present study shed additional light on the factors 
associated with HIV treatment adherence.  Some very important relationships were noted, 
and one of particular importance was the role of the health care providers on people's 
HIV treatment adherence rates.  Future efforts should be made to create interventions 
aimed to promote a patient-practitioner alliance where the physician allows the patient to 
have some control (autonomy) over their treatment management, as this may result in 
better adherence rates and better physical health for PLWH.  Moreover, physicians 
should be aware that some of the HIV treatment-related side effects are significant 
barriers to successful adherence.  Physicians treating PLWH should spend the time to 
discuss with their patients the potential treatment-related side effects and techniques for 
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managing them, as this could improve the quality of life, treatment options, and increase 
adherence rates in their patients.   
Furthermore, the participants in Phase II reported anecdotal evidence of stigma 
and discrimination in health care settings against PLWH.  These findings could be used 
to inform the design of programs and interventions to reduce HIV-related stigma in 
health care settings as their primary goal, and elements of these efforts should be to 
inform patients of the importance of HIV treatment adherence.  Improving the quality of 
health care provision in hospitals may improve the health of PLWH, and most 
importantly, the patients will receive the sensitive health care that they need and deserve.  
Lastly, a patient-specific recommendation would be to increase people's HIV 
treatment self-efficacy.  This could be done by creating safe social support networks for 
PLWH to be able to share their concerns, experiences, and find reassurance.  Social 
support and having the encouragement of a loved one can be powerful motivators for 
PLWH to adhere to their treatment and increase their HIV treatment self-efficacy.  
Increasing patients‟ perceived ability to adhere to the HIV treatment despite obstacles 
should be an important aspect of any interventions aimed to improve medical adherence.   
Many PLWH successful adhere to their prescribed HIV treatments; however, for 
the people that require some assistance, sensitive HIV care, social support, and available 
health services to assist clients to adhere to their HIV treatments could all improve the 
health of people living with HIV in Canada.   
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APPENDIX A 
Interview Protocol:  People's experiences with their HIV-treatments and health care 
related experiences 
 
A. Autonomy as related to HIV-treatment adherence  
 
1. Who or what do you think its responsible for your health? (if the interviewee is 
uncertain how to answer this question - I will given an example) and say: "For example, 
do you think you have control over your health? Do you think that by taking your HIV 
medication you can improve your health? or is your health out of your control? 
 
2. Do you have an HIV Specialist or a Family Doctor? 
 
3. How important was it for you to have an HIV Specialist/Family Doctor who 
encourages you to ask questions? 
 
4. How important was it for you to be asked to be involved in the decision to start the 
medication?  
 
Follow up question 
- were you asked?  
- Do you think these experiences influence your motivation to take your 
medication? 
 
Follow up question 
 - Do you feel that you are thoroughly explained and involved with your HIV-
 treatment when you visit your doctor's office?  
 - Do you think this would influence your motivation to take your HIV 
 medications? 
5. Are you experiencing a lot of side effects from your HIV medication? 
 
B. Competence 
 
1. Do you think it is important to adhere to your HIV-treatment? 
 
 - do you think this would influence your motivation to take your HIV medications? 
 
2. How difficult/easy is it for you to take your medications?  
 
3. Do you feel that you can continue taking the medication even when it is interfering 
with your daily activities? (Self-efficacy)  
 
4. Have you ever had difficulties accessing health information?  
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 - Is there someone/organization that you can go to for help with health related 
 paper work? 
 
5. When your viral load is undetectable, do you stop using your medications? 
 
C. Relatedness 
 
1. What have been some your experiences with health care professionals? 
 
Follow up questions: 
 - How did that make you feel? 
 - Have you found yourself avoiding the doctor's office because of these previous 
 experiences? 
 - Do you think that these experiences influence your motivation to take your HIV 
medication? 
 
2. Do you think it is important to have a big support of family and friends?  
 
Follow up question:  
 - Do you feel that you have the support of family and friends? 
 - how about an intimate partner? 
 Do you think their support influences your motivation to take your medication? 
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APPENDIX B 
Demographics Questionnaire  
Below are some basic questions about YOU. Please DO NOT attach your 
name to this or any sheet.  Remember that all your answers are confidential 
and you cannot be identified by any of the pieces of information you provide 
in this questionnaire package 
 
Today' Date           month/year 
1. Age (in years) 
2. How do you describe your gender?: 
□ Female  
□ Male  
□ Female-to-Male transgender)    
□ Male-to-Female transgender 
□ Two-spirited 
□ Inter-sexed 
□ Other (please specify)  
□ Don‟t know 
□ Refused 
 
3. What is your sexual orientation? 
 Straight or heterosexual 
 Gay 
 Lesbian 
 Bisexual 
 Not sure or questioning 
 Other (please specify) 
□ Don‟t know 
□ Refused 
 
4. In what city do you live now? 
 
5. What is your belief system? Please check all that apply to you: 
□ Catholic 
□ Protestant 
□ Christian (if not Catholic or Protestant) 
□ Jewish 
□ Muslim 
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□ Hindu 
□ Sikh 
□ Buddhist 
□ Eastern Orthodox 
□ African Traditional 
□ Aboriginal Traditional 
□ New Age  
□ Wicca  
□ Paganism  
□ Agnostic 
□ None/Atheist 
□ Other (please specify)  
□ Don‟t know 
□ Refused 
 
The following questions ask about your Ethnicity: 
 
6. In what country were you born? 
7. How long have you lived in Canada? (in years) 
(if you were born in Canada - write "BORN IN CANADA" - do not leave blank) 
 
8. Ethnic Background: What ethnicity do you identify with? Please check all that apply: 
 
  African (e.g., Nigeria, Ghana, Ethiopia) 
  African-Caribbean (i.e., from the Caribbean and of Black/African descent) 
  Indo-Caribbean (i.e., from the Caribbean and of South Asian descent) 
  Other Caribbean (i.e., from the Caribbean and of other ethnic descent) 
  South Asian (e.g., India, Pakistan, Bangladesh, Sri Lanka) 
  East Asian (e.g., Hong Kong, China, Vietnam, Korea, Philippines) 
  Middle Eastern or North African (e.g., Iran, Israel, Egypt, Morocco) 
  White – British and/or Irish background (e.g., England, Scotland, Wales, 
Ireland) 
  Italian 
  Portuguese 
  Greek 
  Russian 
  Eastern European (e.g., Ukraine, Romania) 
  White – Other  
  Hispanic / Latino/a 
  Aboriginal  
  Biracial (please tell us) 
  Other (please tell us) ____________________ 
   Don‟t know 
   Refused 
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9. What are the sources of your personal income? Please check all that apply to you: 
□ Full time work 
□ Part time work 
□ Self-employed 
□ Disability Pension (ODSP) 
□ Old age Pension 
□ Worker's Compensation 
□ Employment Insurance 
□ Ontario works 
□ CPP 
□ Student loan 
□ Volunteering 
□ Other (please specify)  
□ Don‟t know 
□ Refused 
 
10. Are you in a romantic and/or sexual relationship/s (including marriage), either with a 
single partner or multiple partners? 
□ Yes 
□ No 
IF YES, How long have you been in this relationship? (in months) 
11. Are you in a romantic and/or sexual relationship/s with multiple partners? 
□ Yes 
□ No 
IF YES, How long have you been in this relationship? (in months) 
12. Education 
□ Elementary school: Grades 1 to 8 - (6 to 14 years old) 
□ Less than high school (14 to 18+ years old) 
□ Completed high school  
□ some college or university (18 years of age and older) 
□ College or university 
□ Graduate school  
□ Doctoral Degree (Medical Degree or Ph.D) 
□ Post-doctorate  
□ Don‟t know 
□ Refused 
 
13. Your Income (your yearly income): check one 
 
□ $ 0-19,999 
□ $ 20, 000-29, 999 
□ $ 30, 000-39, 999 
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□ $ 40, 000-49, 999 
□ $ 50, 000-59, 999 
□ $ 60, 000-69, 999 
□ $ 70, 000-79, 999 
□ $ 80, 000-100, 000 
□ $ 120, 000 or more 
□ Don't know 
□ Refused 
    
 
 
 
 
 
 
 
 
14. Was it your choice to begin the HIV-treatment? 
□ yes 
□ no 
 
 
15. Was it your choice to begin the HIV-treatment? 
 
□ YES      
□ NO  
□ Refused to answer 
□ Don't know 
 
 
16. Did you and your doctor decide to begin the HIV-treatment? 
 
□ YES      
□ NO  
□ Refused to answer 
□ Don't know 
 
17. Did you feel the need to begin the HIV-treatment? 
 
□ YES      
□ NO  
□ Refused to answer 
□ Don't know 
 
 
 
Here are some basic questions about your medical history. 
Please do not attach your name. Remember, all of your answers 
are confidential and you cannot be identified by any information 
you provide in this package. 
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Open-ended questions: 
1. Do you find that you receive enough information regarding your HIV medications 
from your HIV Specialist or family doctor? Please Explain. 
 
2. Have you ever had difficult time taking your medications as prescribed? 
□ Yes 
□ No 
IF YES, what do you think are some reasons for that difficulty? 
 
3. Have you ever felt stigmatized by the actions of a health care professionals (doctors, 
dentists, nurses, dental technicians, etc? 
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APPENDIX C 
 
HIV-related Stigma in Health Care Settings 
 
  
 
 
 
1. It is easier to avoid the hospital than worry about telling them/ or they finding out 
that I have HIV 
1 
Strongly 
Disagree 
2 
Disagree 
3 
Neither agree 
nor disagree 
4 
Agree 
5 
Strongly 
agree 
6 
Don‟t know 
7 
Refused 
To 
answer 
2. It is easier to avoid the doctor's office (General practitioner or walking in clinic) 
than worry about telling them/ or they finding out that I have HIV 
1 
Strongly 
Disagree 
2 
Disagree 
3 
Neither agree 
nor disagree 
4 
Agree 
5 
Strongly 
agree 
6 
Don‟t know 
7 
Refused 
To 
answer 
 
3. I am hurt by how some health professionals (i.e., doctors, nurses, dental 
technicians) react to learning that I have HIV/AIDS  
1 
Strongly 
disagree 
2 
Disagree 
3 
Neither 
agree nor 
disagree 
4 
Agree 
5 
Strongly 
agree 
6 
Don‟t 
know 
7 
Refused 
to answer 
4. I have avoided going to dental offices because of their reactions to my 
HIV/AIDS.  
1 
Strongly 
disagree 
2 
Disagree 
3 
Neither 
agree nor 
disagree 
4 
Agree 
5 
Strongly 
agree 
6 
Don‟t 
know 
7 
Refused 
to answer 
5. Some of the health care professionals attitudes about HIV/AIDS make me feel 
worse about myself.  
1 
Strongly 
disagree 
2 
Disagree 
3 
Neither 
agree nor 
disagree 
4 
Agree 
5 
Strongly 
agree 
6 
Don‟t 
know 
7 
Refused 
to answer 
Stigma: This questionnaire contains items that are related to your 
visits with any health care professional.  
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6. I have received rolling eyes and glances from health care professionals as a 
result of my HIV/AIDS health condition 
1 
Strongly 
disagree 
2 
Disagree 
3 
Neither 
agree nor 
disagree 
4 
Agree 
5 
Strongly 
agree 
6 
Don‟t 
know 
7 
Refused 
to answer 
7. In hospitals people with HIV/AIDS are treated like outcasts.  
1 
Strongly 
disagree 
2 
Disagree 
3 
Neither 
agree nor 
disagree 
4 
Agree 
5 
Strongly 
agree 
6 
Don‟t 
know 
7 
Refused 
to answer 
   8. I have never been mistreated by any health care professionals, as a result of my 
HIV      status. 
1 
Strongly 
Disagree 
2 
Disagree 
3 
Neither 
agree nor 
disagree 
4 
Agree 
5 
Strongly 
agree 
6 
Don‟t know 
7 
Refused 
to answer 
9. I wish HIV clinics had more privacy in the waiting rooms 
1 
Strongly 
disagree 
2 
Disagree 
3 
Neither 
agree nor 
disagree 
4 
Agree 
5 
Strongly 
agree 
6 
Don‟t know 
7 
Refused 
to answer 
10. I feel like hospitals as not discreet with my HIV/AIDS condition. There is a 
lack of privacy 
1 
Strongly 
disagree 
2 
Disagree 
3 
Neither 
agree nor 
disagree 
4 
Agree 
5 
Strongly 
agree 
6 
Don‟t know 
7 
Refused 
to answer 
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APPENDIX D 
 
Flyer Advertising Phase I of this Study 
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APPENDIX E 
 
 
 
CONSENT TO PARTICIPATE IN A SELF-ADMINISTERED SURVEY STUDY 
 
 
Title of Study: Patient Perceptions of Factors that Influence HIV Treatment. 
 
You are asked to participate in a research study conducted by Elena Ivanova, B.A. (M.A. 
candidate) under the supervision of Dr. Kathryn Lafreniere (faculty supervisor), from the 
Department of Psychology at the University of Windsor. The results of this study will be 
used to contribute to the requirements of the M.A. thesis of the first investigator. The 
study is in part supported by research funding from the Canadian Institutes of Health 
Research. 
 
If you have any questions or concerns about the research, please feel to contact: 
 
Elena Ivanova            Dr. Kathryn Lafreniere 
ivanova@uwindsor.ca   or               Daytime phone: 519-253-3000   
        ex.2233 
             lafren1@uwindsor.ca 
 
PURPOSE OF THE STUDY 
 
The purpose of this study is to explore your experiences with your HIV treatment 
adherence. Specifically, the study will examine your experiences with taking HIV 
medication. The results of this study are expected to contribute to a better understanding 
of how to make HIV-treatments easier for the people who need them.   
 
PROCEDURES 
 
You will be asked to the following things: 
There is only one component to this study, which asks you to fill out a questionnaire 
packet. The survey is expected to take approximately 60 minutes. We will not contact 
you for follow-up sessions or subsequent studies. 
 
POTENTIAL RISKS AND DISCOMFORTS 
 
Given the potentially sensitive nature of the topic under investigation, it is possible that 
you will experience some discomfort during filling out the surveys. You may choose to 
withdraw from the study or take a break at any point. You will be provided with contact 
information and resources to HIV/AIDS health care specialist/providers.   
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POTENTIAL BENEFITS TO SUBJECTS AND/OR TO SOCIETY 
 
Participants will gain useful knowledge about themselves through filling out the questionnaires as 
some of the questions will make them reflect on some of the factors influencing their health, as 
well as on some of the factors influencing their HIV-treatment adherence. Directly asking 
participants such questions may lead them to become more aware of their own attitudes towards 
their health and towards medication adherence. 
 
PAYMENT FOR PARTICIPATION 
 
Upon completion, or termination, of the questionnaire you will be given $20 (in cash) for 
your participation.  
 
CONFIDENTIALITY 
 
Any information that is obtained in connection with this study and that can be identified 
with you will remain confidential and will be disclosed only with your permission. Your 
name will not be associated with the questionnaire, or your demographic information. 
Please DO NOT put your name anywhere. The questionnaires will be stored by the 
primary investigator; the files will be retained for 6 years following publication of the 
study. After 6 years, the physical files will be shredded. Information will not be provided 
to a third party for any reason.  
 
 
PARTICIPATION AND WITHDRAWAL 
 
You can choose whether to be in this study or not.  If you volunteer to be in this study, 
you may withdraw at any time without consequences of any kind.  You may also refuse 
to answer any questions you do not want to answer and still remain in the study. The 
investigator may withdraw you from this research if circumstances arise which warrant 
doing so. You also have the option to destroy the questionnaires at any time prior to 
completion of the research project. 
 
 
FEEDBACK OF THE RESULTS OF THIS STUDY TO THE SUBJECTS 
 
Research findings will be available in a pamphlet form and posted at the participating AIDS 
Service Organizations (ASOs). Please inquire onsite staff members at the ASO to direct you to 
the pamphlet, which will be available after October 2011.  Also, in fall 2011 a summary of the 
results will be posted at  http://www.uwindsor.ca/reb/study-results, and participants can find the 
study by searching for the study title " Psychosocial Influences on HIV Treatment Adherence: 
Utility of the Theory of Self-Determination".    
 
Date when results are available: _October 2011_________________ 
 
SUBSEQUENT USE OF DATA 
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This data may be used in subsequent studies. 
RIGHTS OF RESEARCH SUBJECTS 
 
You may withdraw your consent at any time and discontinue participation without 
penalty. If you have questions regarding your rights as a research subject, contact: 
Research Ethics Coordinator, University of Windsor, Windsor, Ontario N9B 3P4; 
Telephone: 519-253-3000, ext. 3948; e-mail:  ethics@uwindsor.ca 
 
SIGNATURE OF RESEARCH SUBJECT/LEGAL REPRESENTATIVE 
 
I understand the information provided for the study Patient Perceptions of Factors that 
Influence HIV Treatment as described herein.  My questions have been answered to my 
satisfaction, and I agree to participate in this study.  I have been given a copy of this form. 
 
 
______________________________________ 
Initials of Participant  
 
 
______________________________________  _________________ 
Signature of Participant        Date 
 
 
 
SIGNATURE OF INVESTIGATOR 
 
These are the terms under which I will conduct research. 
 
 
_____________________________________  ____________________ 
Elena Ivanova        Date 
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APPENDIX F 
 
Information Sheet: Community Resources 
 
Post-study Resources  
 
If you have any complains about the study please contact:  
 
Dr. Kathryn Lafreniere  
(519) 253-3000 ext. 2233 
lafren1@uwindsor.ca 
 
If your concerns were not addressed then please contact the University of 
Windsor ethics director: 
 
Dr. Pierre Boulos 
(519) 253-3000 Ext: 3767 
boulos@uwindsor.ca 
 
Health Care Information 
 
The Maple Leaf Medical Clinic: Community and HIV Care 
 
Need a Doctor? Then visit the Maple Leaf Medical Clinic: 
http://mapleleafmedical.com/index.php 
 
"Having both an Internist with HIV and Hepatitis specialization and an Infectious 
Diseases specialist “in-house” enhances patients‟ ability to receive thorough and opinion-
leading consultations in a seamless fashion" 
 
70 Carlton St., Toronto, ON,  M5B 1L6 
Telephone: 416-465-0856 ext 2  
Fax: 416-465-8344 
 
Social Place 
 
Long Yang Club – Social Club for gay people of Asian and non-Asian ancestry 
 
Telephone: Dial 416-925-9872 (416-925-XTRA) 
e-mail address - toronto@longyangclub.org 
website: http://www.longyangclub.org/toronto/about.php 
 
Throughout the years their events have included: barbecues, bike rides, bowling, Dim 
Sum, disco nights, discussion groups, hiking, karaoke, picnics, pool, potluck dinners, 
skating. "We are trying to create an environment for singles and couples who are looking 
for an alternative social outlet to the bar scene.”  
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Legal Protection and Advice 
To contact federal (Canadian government) agencies responsible for 
protecting human rights or privacy 
Canadian Human Rights Commission: www.chrc-ccdp.ca  
1-800-999-6899 • TTY 1-888-643-3304 
 
HIV & AIDS Legal Clinic (Ontario): www.halco.org  
416-340-7790 or 1-888-705-8889 TTY 416-922-2352 or 1-866-513-9883 
 
HIV-related information 
 
Canadian AIDS Treatment Information Exchange (CATIE) 
 
Knowing helps... 1-800-263-1638 or visit them at http://www.catie.ca/eng/home.shtml 
 
Part of CATIE's mission statement is to:  
 
Support and connect people with HIV, other individuals, and organizations to develop, 
synthesize, share and apply HIV knowledge. 
 
Additional Contacts: 
 
AIDS Sexual Health Info. Line-1-800-267-7432 
Africans in Partnership against AIDS-416-924-5256 
African and Caribbean Council on HIV/AIDS in Ontario-416-977-9955 
Bereaved Families of Ontario-1-800-236-6364 
Canadian Aboriginal AIDS Network-1888-285-2226 
Canadian AIDS Society-1-800-668-2437 
Central Toronto Community Health Centres-416-703-8482 
Ontario Disability Support Plan: (Toronto) - 416-314-5700 
Ontario Drug Benefits- 1-866-811-9893 
Voices of Positive Women- 1800-263-0961 
Women’s Health in Women’s Hands- 416-593-7655 
Alliance for South Asian AIDS Prevention- 416-599-2727 
Anishnawbe Health Toronto- 416-360-0486  
Asian Community AIDS Services - 416- 963-4300 
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Barrett House- 416-869-3619 
Maggie’s-The Toronto Prostitutes’ Community Service Project- 416-964-0150 
Miriam Child & Family Support Services- 905-681-7157 
Ontario HIV Treatment Network (OHTN) - 416-642-6486 
Peel HIV/AIDS Network- 905-362-2025 
Queen West Community Health Centre- 416-703-8482 
Regent Park Community Health Centre- 416-364-2261 
Rexdale Community Health Centre-416-744-0066 
Warden Woods Community Centre- 416-694-1138 
South Riverdale Community Health Centre- 416-461-1925 
Toronto Prostitutes’ Community Service- 416-964-0150 
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APPENDIX G 
 
Flyer Advertising Phase II of this Study 
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APPENDIX H 
 
 
  
 
CONSENT TO PARTICIPATE IN A FACE TO FACE INTERVIEW 
 
 
Title of Study: Patient Perceptions of Factors that Influence HIV Treatment. 
 
You are asked to participate in a research study conducted by Elena Ivanova, B.A. (M.A. 
candidate) under the supervision of Dr. Kathryn Lafreniere (faculty supervisor), from the 
Department of Psychology at the University of Windsor. The results of this study will be 
used to contribute to the requirements of the M.A. thesis of the first investigator. The 
study is in part supported by research funding from the Canadian Institutes of Health 
Research. 
 
If you have any questions or concerns about the research, please feel to contact: 
 
Elena Ivanova            Dr. Kathryn Lafreniere 
ivanova@uwindsor.ca   or               Daytime phone: 519-253-3000   
        ex.2233 
             lafren1@uwindsor.ca 
 
PURPOSE OF THE STUDY 
 
The purpose of this study is to explore your experiences with your HIV treatment 
adherence. Specifically, the study will examine your experiences with taking HIV 
medication. The results of this study are expected to contribute to a better understanding 
of how to make HIV-treatments easier for the people who need them.   
 
PROCEDURES 
 
You will be asked to the following things: 
There is only one component to this study, which asks you to participate in a face-to-face 
interview. The interview is expected to take approximately 35 to 40 minutes. We will not 
contact you for follow-up sessions or any subsequent studies. 
 
POTENTIAL RISKS AND DISCOMFORTS 
 
Given the potentially sensitive nature of the topic under investigation, it is possible that 
you will experience some discomfort during the interview. You may choose to withdraw 
from the study, and you may choose not to answer particular questions and can take a 
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break at any point. You will be provided with contact information and resources to 
HIV/AIDS health care specialists/providers.   
 
POTENTIAL BENEFITS TO SUBJECTS AND/OR TO SOCIETY 
 
Participants will gain useful knowledge about themselves through filling out the questionnaires as 
some of the questions will make them reflect on some of the factors influencing their health, as 
well as on some of the factors influencing their HIV-treatment adherence.  Directly asking 
participants such questions may lead them to become more aware of their own attitudes towards 
their health and towards medication adherence.  Also, this being a face-to-face interview, 
participants will have an avenue for having their voice heard and the opportunity to raise relevant 
concerns related to their health care experiences. 
 
There are potential benefits to the scientific and medical community as well as society.   
 
 
PAYMENT FOR PARTICIPATION 
 
Upon completion, or termination, of the questionnaire you will be given $40 (in cash) for 
your participation.  
 
CONFIDENTIALITY 
 
Any information that is obtained in connection with this study and that can be identified 
with you will remain confidential and will be disclosed only with your permission. Your 
name will not be associated with the interview. Please DO NOT use your real name 
during the interview. The audio tape will be destroyed as soon as the data is recorded on 
paper. Information that identifies you will not be provided to a third party for any reason.  
 
 
PARTICIPATION AND WITHDRAWAL 
 
You can choose whether to be in this study or not.  If you volunteer to be in this study, 
you may withdraw at any time without consequences of any kind.  You may also refuse 
to answer any questions you do not want to answer and still remain in the interview. The 
investigator may withdraw you from this research if circumstances arise which warrant 
doing so. You also have the option to delete the audio recording at any time prior to 
completion of the interview. 
 
 
FEEDBACK OF THE RESULTS OF THIS STUDY TO THE SUBJECTS 
 
Research findings will be available in a pamphlet form and posted at the AIDS Committee of 
Windsor. Please inquire onsite staff members at the ASO to direct you to the pamphlet, which 
will be available after October 2011.  Also, in fall 2011 summary of the results will be posted at  
http://www.uwindsor.ca/reb/study-results, and participants can find the study by searching for the 
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study title " Psychosocial Influences on HIV Treatment Adherence: Utility of the Theory of Self-
Determination".    
 
Date when results are available: _October 2011_________________ 
 
SUBSEQUENT USE OF DATA 
 
This data may be used in subsequent studies. 
 
 
RIGHTS OF RESEARCH SUBJECTS 
 
You may withdraw your consent at any time and discontinue participation without 
penalty. If you have questions regarding your rights as a research subject, contact: 
Research Ethics Coordinator, University of Windsor, Windsor, Ontario N9B 3P4; 
Telephone: 519-253-3000, ext. 3948; e-mail:  ethics@uwindsor.ca 
 
SIGNATURE OF RESEARCH SUBJECT/LEGAL REPRESENTATIVE 
 
I understand the information provided for the study Patient Perceptions of Factors that 
Influence HIV Treatment as described herein.  My questions have been answered to my 
satisfaction, and I agree to participate in this study.  I have been given a copy of this form. 
 
 
______________________________________ 
Initials of Participant  
 
 
______________________________________  ___________________ 
Signature of Participant        Date 
 
 
SIGNATURE OF INVESTIGATOR 
 
These are the terms under which I will conduct research. 
 
 
_____________________________________  ____________________ 
Elena Ivanova        Date 
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APPENDIX I 
 
 
  
 
 
CONSENT FOR AUDIO TAPING 
 
  
 
 
 
Interviewee Name/Initials:  
 
Title of the Project: Patient Perceptions of Factors that Influence HIV Treatment. 
 
 
 
I consent to the audio-taping of the interview. 
 
I understand these are voluntary procedures and that I am free to 
withdraw at any time by requesting that the taping be stopped.  I also 
understand that my name will not be revealed to anyone and that taping 
will be kept confidential. Tapes are filed by number only and store in a 
locked cabinet. 
 
I understand that confidentiality will be respected and that the audio tape 
will be for professional use only. 
 
 
 
 
 
 
                (Research Participant) (Date) 
 
 Or 
 
 
 
 
                (Researchers) (Date) 
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VITA AUCTORIS 
 
Elena Ivanova was born in 1984 in Sofia, Bulgaria. Elena along with her parents and her 
older brother moved to Canada in 1996.  She graduated from Pope John Paul II 
Secondary School in 2002.  Following this, she pursued a Psychology Bachelor Degree 
from York University, and graduated with distinction from the Honours program in 2008.  
At present, Elena is a candidate for the Master‟s degree in Applied Social Psychology at 
the University of Windsor.  
 
